

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 618 926 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
01.03.2000 Bulletin 2000/09

(21) Application number: 92924993.6

(22) Date of filing: 01.12.1992

(51) Int. Cl.⁷: C07K 5/06, A61K 38/55,
C07K 5/04
// C07C279/12

(86) International application number:
PCT/SE92/00832

(87) International publication number:
WO 93/11152 (10.06.1993 Gazette 1993/14)

(54) NEW PEPTIDE DERIVATIVES

NEUARTIGE PEPTIDDERIVATE
NOUVEAUX DERIVES DE PEPTIDES

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE

(30) Priority: 04.12.1991 SE 9103612

(43) Date of publication of application:
12.10.1994 Bulletin 1994/41

(73) Proprietor: Astra Aktiebolag
151 85 Södertälje (SE)

(72) Inventors:
• TEGER-NILSSON, Ann-Catrine, Elisabet
S-431 69 Mölndal (SE)

• BYLUND, Ruth, Elvy
S-421 58 Västra Frölunda (SE)

(56) References cited:
EP-A- 0 074 787 EP-A- 0 192 135
EP-A- 0 235 692 WO-A-92/07869
GB-A- 2 085 444

• CHEMICAL ABSTRACTS, Volume 99, No. 25, 19
December 1983 (19.12.83), (Columbus, Ohio,
USA), BAJUSZ, SANDOR et al., "Inhibition of
thrombin with H- and Boc-D-Phe-Pro-Agm",
page 21, the Abstract No. 205609, Pept., Proc.
Eur. Pept. Symp. 17th 1983, 643-647, (e).

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 618 926 B1

Description

[0001] This invention relates to new competitive inhibitors of thrombin, their synthesis, pharmaceutical compositions containing the compounds as active ingredients, and the use of the compounds as anticoagulants for prophylaxis and treatment of thromboembolic diseases such as venous thrombosis, pulmonary embolism, arterial thrombosis, in particular myocardial infarction and cerebral thrombosis, general hypercoagulable states and local hypercoagulable states, e.g. following angioplasty and coronary bypass operations.

[0002] The invention also relates to novel use of a compound as a starting material in synthesis of a serine protease inhibitor. Furthermore the invention relates to a novel structural fragment in a serine protease inhibitor.

BACKGROUND

[0003] Blood coagulation is the key process involved in both haemostasis (i.e. prevention of blood loss from a damaged vessel) and thrombosis (i.e. the pathological occlusion of a blood vessel by a blood clot). Coagulation is the result of a complex series of enzymatic reactions, where one of the final steps is conversion of the proenzyme prothrombin to the active enzyme thrombin.

[0004] Thrombin plays a central role in coagulation. It activates platelets, it converts fibrinogen into fibrin monomers, which polymerise spontaneously into filaments, and it activates factor XIII, which in turn crosslinks the polymer to insoluble fibrin. Thrombin further activates factor V and factor VIII in a positive feedback reaction. Inhibitors of thrombin are therefore expected to be effective anticoagulants by inhibition of platelets, fibrin formation and fibrin stabilization. By inhibiting the positive feedback mechanism they are expected to exert inhibition early in the chain of events leading to coagulation and thrombosis.

PRIOR ART

[0005] Inhibitors of thrombin based on the amino acid sequence around the cleavage site for the fibrinogen A α chain were first reported by Blombäck et al in J. Clin. Lab. Invest. 24, suppl 107, 59, (1969), who suggested the sequence Phe-Val-Arg (P₉-P₂-P₁, herein referred to as the P₃-P₂-P₁ sequence) to be the best inhibitor.

[0006] In US 4,346,078 (Richter Gedeon Vegyeszeti Gyar R T, priority date 7.10.1980) and in Peptides 1983 by Walter de Gruyter & Co, Berlin, pp 643-647, S. Bajusz et al described the thrombin inhibitor H-DPhe-Pro-Agm, a dipeptidyl derivative with an aminoalkyl guanidine in the P₁-position.

[0007] S. Bajusz et. al. also reported in J. Med. Chem. 1990, 33, 1729-1735 and in EP-A2-0,185,390 (Richter Gedeon Vegyeszeti Gyar R T) (priority date 21.12.84) that replacing the agmatine with an arginine aldehyde gave a thrombin inhibitor which had much higher potency.

[0008] The reason for the increased activity of this thrombin inhibitor is thought possibly to be due to interaction of the aldehyde function with the Ser-OH in the active site of the enzyme forming a hemiacetal. It is not conceivable to have the same type of interaction in the dipeptide derivative H-DPhe-Pro-Agm since it does not have an amino acid derivative with a carbonyl group in the P₁-position.

[0009] In other work in the thrombin inhibitor field, inhibitors of serine proteases that are based on electrophilic ketones instead of aldehydes in the P₁-position include the following:

E. N. Shaw et al. (Research Corporation) US-4,318,904 (priority date 25.04.80) describing peptide chloro-methyl ketones e.g. H-DPhe-Pro-Arg-CH₂Cl.

M. Szelke and D.M. Jones in EP-A1-0,118,280, (priority date 4.3.83) describing compounds derived from the P₃ - P₂' pentapeptide sequence of the fibrinogen A α chain in which the scissile P₁ - P₁' peptide bond was replaced with the -CO-CH₂-moiety, forming a keto isostere to the corresponding peptides.

M. Kolb et. al. (Merrell-Dow) EP-A2-0,195,212 (Priority date 4.2.85) describing peptidyl α -keto esters and amides.

B. Imperiali and R.H. Abeles, Biochemistry 1986. 25. 3750 describing peptidyl fluoroalkyl ketones.

D. Schirlin et al. (Merrell-Dow) EP-A1-0,362,002 (priority date 1.9.88) describing fluoroalkylamide ketones.

P. Bey et al., (Merrell-Dow) EP-A2-0,364,344 (priority date 1.9.88) describing α,β,δ -triketo compounds.

Ueda et al., Biochem. J. 1990, 265, 539 also describing peptidyl fluoroalkyl ketones.


[0010] Inhibitors of thrombin based on C-terminal boronic acid derivatives of arginine and isothiuronium analogues thereof have been reported by A.D Kettner et al. (Du Pont) EP-A2-0,293,881 (priority dates 5.6.87 and 6.4.88).

[0011] An object of the present invention is to provide novel and potent thrombin inhibitors with competitive inhibitory activity towards their enzyme i.e. causing reversible inhibition. A further object is to obtain inhibitors which are orally bio-available and selective in inhibiting thrombin over other serine proteases. Stability, duration of action, and low toxicity at therapeutic dosages are still further objects of the invention.


DISCLOSURE OF THE INVENTION

Compounds

[0012] Compounds of the invention relate to the peptide sequence of human fibrinogen Act chain representing modified sub-sites P₉, P₂ and P₁:



[0013] According to the invention it has been found that compounds of the general Formula I, either as such or in the form of physiologically acceptable salts, and including stereoisomers, are potent inhibitors of thrombin:



Formula I

wherein:

A represents a methylene group, or

A represents an ethylene group and the resulting 5-membered ring may or may not carry one or two fluorine atoms, a hydroxy group or an oxo group in position 4, or may or may not be unsaturated, or

A represents -CH₂-O-, -CH₂-S-, -CH₂-SO-, with the heteroatom functionality in position 4, or

A represents a n-propylene group and the resulting 6-membered ring may or may not carry in position 5 one fluo-

rine atom, a hydroxy group or an oxo group, carry two fluorine atoms in one of positions 4 or 5 or be unsaturated in position 4 and 5, or carry in position 4 an alkyl group with 1 to 4 carbon atoms, or

A represents $-\text{CH}_2\text{-O-CH}_2-$, $-\text{CH}_2\text{-S-CH}_2-$, $-\text{CH}_2\text{-SO-CH}_2-$;

R^1 represents H, an alkyl group having 1 to 4 carbon atoms, a hydroxyalkyl group having 2-3 carbon atoms or $\text{R}^{11}\text{OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and R^{11} is H or an alkyl group having 1 to 4 carbon atoms or an alkylene group having 2-3 carbon atoms intramolecularly bound alpha to the carbonyl group in R^1 , or

R^1 represents $\text{R}^{12}\text{OOC-1,4-phenyl-CH}_2-$, where R^{12} is H or an alkyl group having 1 to 4 carbon atoms, or

R^1 represents $\text{R}^{13}\text{-NH-CO-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R^{13} is H or an alkyl group having 1 to 4 carbon atoms or $-\text{CH}_2\text{COOR}^{12}$ where R^{12} is as defined above, or

R^1 represents $\text{R}^{12}\text{OOC-CH}_2\text{-OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R^{12} is as defined above, or

R^1 represents CH_3SO_2- , or

R^1 represents $\text{R}^{12}\text{OCOCO-}$ where R^{12} is as defined above, or

R^1 represents $-\text{CH}_2\text{PO(OR}^{14})_2$, $-\text{CH}_2\text{SO}_3\text{H}$ or $-\text{CH}_2\text{-(5-(1H)-tetrazolyl)}$ where R^{14} is, individually at each occurrence, H, methyl or ethyl;

R^2 represents H or an alkyl group having 1 to 4 carbon atoms or $\text{R}^{21}\text{OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted in the position which is alpha to the carbonyl group, and the alpha substituent is a group $\text{R}^{22}\text{-(CH}_2\text{)}_p-$, wherein $p = 0-2$ and R^{22} is methyl, phenyl, OH, COOR^{21} , and R^{21} is H or an alkyl group having 1 to 4 carbon atoms;

m is 0, 1 or 2, R^3 represents a cyclohexyl group and R^4 represents H, or

m is 1 and R^3 represents a cyclohexyl or phenyl group and R^4 forms an ethylene bridge together with R^1 , or

m is 1 and R^3 and R^4 each represents a cyclohexyl or phenyl group;

R^5 represents H or an alkyl group having 1 to 4 carbon atoms;

n is an integer 2 to 6; and

B represents $-\text{N(R}^6\text{)-C(NH)-NH}_2$, wherein R^6 is H or a methyl group, or

B represents $-\text{S-C(NH)-NH}_2$, or $-\text{C(NH)-NH}_2$.

[0014] An alkyl group may be straight or branched unless specified otherwise. Alkyl groups having 1 to 4 carbon atoms are methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl. When unsaturation is referred to, a carbon-carbon double bond is intended. Abbreviations are listed at the end of this specification.

[0015] According to a preferred embodiment the invention relates to compounds of Formula I, wherein R^1 represents $\text{R}^{11}\text{OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and R^{11} is H. Of those compounds, the compounds where A is ethylene and R^5 is H or an alkyl group having 1 to 4 carbon atoms, particularly those where R^5 is H are preferred.

[0016] Of the compound of Formula I, those compounds where R^3 is cyclohexyl, m is 1 or 2, particularly m is 1 and R^4 is H constitute another preferred subclass.

[0017] Another preferred group of compounds are the compounds where A is n-propylene and the resulting 6-membered ring may or may not carry in position 4 an alkyl group with 1 to 4 carbon atoms, and R^5 is H or an alkyl group having 1 to 4 carbon atoms, particularly those where R^5 is H.

[0018] According to another preferred embodiment n is 3.

[0019] Compounds of Formula I having S-configuration on the α -amino acid in the P2-position are preferred ones, of

those compounds also having R-konfiguration on the α -amino acid in the P3-position are particularly preferred ones.

[0020] Preferred compounds of the invention are:

	<u>Example No.</u>	<u>Compound</u>
5	1	H-(R) Cha-Pro-Agm
	2	Me-(R) Cha-Pro-Agm
10	3	HO-(CH ₂) ₃ -(R) Cha-Pro-Agm
	4	HOOC-CH ₂ -(R) Cha-Pro-Agm
	5	ⁱ PrOOC-CH ₂ -(R) Cha-Pro-Agm
	6	HOOC-CH ₂ -(Me) (R) Cha-Pro-Agm
15	7	HOOC-(R, S) CH (Me) - (R) Cha-Pro-Agm
	8	HOOC-(RorS) CH (Me) - (R) Cha-Pro-Agm/a
	9	HOOC-(RorS) CH (Me) - (R) Cha-Pro-Agm/b
20	10	HOOC-(RorS) CH (ⁿ Pr) - (R) Cha-Pro-Agm/a
	11	HOOC-(RorS) CH (ⁿ Pr) - (R) Cha-Pro-Agm/b
	12	HOOC-(RorS) CH (Ph) - (R) Cha-Pro-Agm/b
	13	HOOC-(R, S) CH (CH ₂ CH ₂ Ph) - (R) Cha-Pro-Agm
25	14	HOOC-(RorS) CH (CH ₂ CH ₂ Ph) - (R) Cha-Pro-Agm/a
	15	HOOC-CH ₂ -CH ₂ -(R) Cha-Pro-Agm
	16	EtOOC-CO-(R) Cha-Pro-Agm
30	17	(R, S) Bla-(R) Cha-Pro-Agm
	18	HOOC-(RorS) CH (CH ₂ CH ₂ Ph) - (R) Cha-Pro-Agm/b
	19	H-(R) Cha-Pro-Nag
	20	ⁿ Bu-(R) Cha-Pro-Nag
35	21	HO-(CH ₂) ₃ -(R) Cha-Pro-Nag
	22	HOOC-CH ₂ -(R) Cha-Pro-Nag
	23	EtOOC-CH ₂ -(R) Cha-Pro-Nag
	24	ⁿ PrOOC-CH ₂ -(R) Cha-Pro-Nag
40	25	^t BuOOC-CH ₂ -(R) Cha-Pro-Nag
	26	HOOC-CH ₂ -OOC-CH ₂ -(R) Cha-Pro-Nag
	27	H ₂ N-CO-CH ₂ -(R) Cha-Pro-Nag
45	28	HOOC-CH ₂ -NH-CO-CH ₂ -(R) Cha-Pro-Nag
	29	(HOOC-CH ₂) ₂ -(R) Cha-Pro-Nag
	30	HOOC-CH ₂ -(Me) (R) Cha-Pro-Nag
	31	HOOC-CH ₂ -(nBu) (R) Cha-Pro-Nag
50	32	HOOC-(R, S) CH (Me) - (R) Cha-Pro-Nag
	33	HOOC-(RorS) CH (Me) - (R) Cha-Pro-Nag/a
	34	HOOC-(RorS) CH (Me) - (R) Cha-Pro-Nag/b
55	35	EtOOC-(R, S) CH (Me) - (R) Cha-Pro-Nag

	36	HOOC-(RorS)CH(ⁿ Pr)-(R)Cha-Pro-Nag/a
	37	HOOC-(R)CH(CH ₂ -OH)-(R)Cha-Pro-Nag
5	38	HOOC-(R,S)CH(Ph)-(R)Cha-Pro-Nag
	39	HOOC-(S)CH(CH ₂ CH ₂ Ph)-(R)Cha-Pro-Nag
	40	HOOC-(R)CH(CH ₂ CH ₂ Ph)-(R)Cha-Pro-Nag
10	41	HOOC-CH ₂ -CH ₂ -(R)Cha-Pro-Nag
	42	EtOOC-CH ₂ -CH ₂ -(R)Cha-Pro-Nag
	43	HOOC-(CH ₂) ₃ -(R)Cha-Pro-Nag
	44	EtOOC-(CH ₂) ₃ -(R)Cha-Pro-Nag
15	45	HOOC-CO-(R)Cha-Pro-Nag
	46	MeOOC-CO-(R)Cha-Pro-Nag
	47	(R,S)Bla-(R)Cha-Pro-Nag
	48	HOOC-(R,S)CH(CH ₂ COOH)-(R)Cha-Pro-Nag
20	49	MeOOC-(R,S)CH(CH ₂ COOMe)-(R)Cha-Pro-Nag
	50	HOOC-Ph-4-CH ₂ -(R)Cha-Pro-Nag
	51	(HO) ₂ P(O)-CH ₂ -(R)Cha-Pro-Nag
25	52	EtO(HO)P(O)-CH ₂ -(R)Cha-Pro-Nag
	53	(EtO) ₂ P(O)-CH ₂ -(R)Cha-Pro-Nag
	54	HOOC-CH ₂ -(R)Cha-Pro-Mag
	55	H-(R,S)Pro(3-Ph)-Pro-Agm
30	56	H-(R,S)Pro(3-(trans)Ch)-Pro-Agm
	57	HOOC-CH ₂ -(R,S)Pro(3-(trans)Ph)-Pro-Agm
	58	HOOC-CH ₂ -(R,S)Pro(3-(trans)Ph)-Pro-Nag
	59	HOOC-CH ₂ -(R)Cha-Pic-Agm
35	60	HOOC-CH ₂ -(Me)(R)Cha-(R,S)Pic-Agm
	61	HOOC-(R,S)CH(Me)-(R)Cha-Pic-Agm
	62	HOOC-(RorS)CH(Me)-(R)Cha-Pic-Agm/a
40	63	HOOC-(RorS)CH(Me)-(R)Cha-Pic-Agm/b
	64	HOOC-CH ₂ -CH ₂ -(R)Cha-Pic-Agm
	65	H-(R)Cha-Pic-Nag
	66	Me-(R)Cha-(R,S)Pic-Nag
45	67	HOOC-CH ₂ -(R)Cha-Pic-Nag
	68	MeOOC-CH ₂ -(R)Cha-Pic-Nag
	69	ⁱ PrOOC-CH ₂ -(R)Cha-Pic-Nag
50	70	HOOC-CH ₂ -(Me)(R)Cha-(RorS)Pic-Nag/b
	71	HOOC-(R,S)CH(Me)-(R)Cha-(R,S)Pic-Nag
	72	HOOC-(RorS)CH(Me)-(R)Cha-(RorS)Pic-Nag/c

73	HOOC-(RorS)CH(Me)-(R)Cha-(RorS)Pic-Nag/d
74	HOOC-CH ₂ -CH ₂ -(R)Cha-Pic-Nag
5 75	HOOC-CH ₂ -(R)Cha-(R,S)Mor-Agm
76	HOOC-CH ₂ -(R)Cha-(RorS)Mor-Nag
77	H-(R)Cha-Aze-Nag
10 78	HOOC-CH ₂ -(R)Cha-Aze-Nag
79	H-(R)Cha-Pro(5-(S)Me)-Nag
80	HOOC-CH ₂ -(R)Cha-Pro(5-(S)Me)-Nag
15 81	HOOC-CH ₂ -(R)Cha-(RorS)Pic(4,5-dehydro)-Nag/b
82	HOOC-CH ₂ -(R)Cha-Pic(4-(S)Me)-Nag
83	HOOC-CH ₂ -(R)Cha-(R)Pic(4-(R)Me)-Nag
84	HOOC-CH ₂ -(R)Cgl-Pic-Nag
20 85	H-(R)Hoc-Pro-Nag
86	HOOC-CH ₂ -(R)Hoc-Pro-Nag
87	HOOC-CH ₂ -(R)Hoc-Pic-Nag
25 88	HOOC-CH ₂ -(R)Dph-Pic-Nag
89	HOOC-CH ₂ -(R)Dch-Pic-Nag
90	HOOC-CH ₂ -(R)Cha-Pro(5-(R,S)Me)-Nag
30 91	H-(R)Cha-Pic(4-(R)Me)-Nag
92	HOOC-CH ₂ -(R)Cha-Pic(4-(R)Me)-Nag
93	HOOC-CH ₂ -(R)Cha-Pic(6-(S)Me)-Nag


35 Of those compounds, the compounds having Example Nos. 4, 6, 9, 22, 30, 34, 59, 63, 67, 73, 80 and 82 are particularly preferred, and of those the following compounds are most preferred:

30	HOOC-CH ₂ -(Me)(R)Cha-Pro-Nag
45 34	HOOC-(RorS)CH(Me)-(R)Cha-Pro-Nag/b
67	HOOC-CH ₂ -(R)Cha-Pic-Nag


50

[0021] In the above tables of compounds, the letters /a, /b, /c and /d refer to a substantially pure stereoisomer at the carbon atom denoted "RorS". The stereoisomer can be identified for each compound with reference to the experimental part herein. "R,S" refers to a mixture of stereoisomers.

55 [0022] In a further embodiment the invention relates to novel use of a compound of the formula:



as a starting material in synthesis of a serine protease inhibitor, and in particular in synthesis of a thrombin inhibitor. It can be used as such or having the guanidino group either mono protected at the δ -nitrogen or diprotected at the δ -nitrogens or the γ , δ -nitrogens, preferably with a protective group such as benzyloxy carbonyl. Protection of the noragmatine derivatives is carried out by methods known in the art for guanidino compounds. This compound is named "noragmatine" or "Nag" herein. The compound has been previously disclosed inter alia as a hair bleaching accelerator in GB 1,599,324 (Henkel, priority date 5.2.1977). The structural fragment of the formula



has however not been previously disclosed as a structural element in a pharmaceutically active compound. As such structural element the "noragmatine" fragment renders a serine protease inhibitor, and in particular a thrombin inhibitor valuable.

Medical and pharmaceutical use

[0023] In a further embodiment the invention relates to treatment, in a human or animal organism, of conditions where inhibition of thrombin is required. The compounds of the invention are expected to be useful in particular in animals including man in treatment or prophylaxis of thrombosis and hypercoagulability in blood and tissues. It is furthermore expected to be useful in situations where there is an undesirable excess of the thrombin without signs of hypercoagulability. Disease states in which the compounds have a potential utility, in treatment and/or prophylaxis, include venous thrombosis and pulmonary embolism, arterial thrombosis, such as in myocardial infarction, unstable angina, thrombosis-based stroke and peripheral arterial thrombosis. Further, the compounds have expected utility in prophylaxis of atherosclerotic diseases such as coronary arterial disease, cerebral arterial disease and peripheral arterial disease. Further, the compounds are expected to be useful together with thrombolytics in thrombotic diseases, in particular myocardial infarction. Further, the compounds have expected utility in prophylaxis for re-occlusion after thrombolysis, percutaneous trans-luminal angioplasty (PTCA) and coronary bypass operations. Further, the compounds have expected utility in prevention of re-thrombosis after microsurgery. Further, the compounds are expected to be useful in anticoagulant treatment in connection with artificial organs and cardiac valves. Further, the compounds have expected utility in anticoagulant treatment in haemodialysis and disseminated intravascular coagulation.

[0024] A further expected utility is in rinsing of catheters and mechanical devices used in patients *in vivo*, and as an anticoagulant for preservation of blood, plasma and other blood products *in vitro*.

Pharmaceutical preparations

[0025] The compounds of the Formula I will normally be administered by the oral, rectal, dermal, nasal or parenteral route in the form of pharmaceutical preparations comprising the active ingredient either as a free base or a pharmaceutically acceptable non-toxic acid addition salt, e.g. the hydrochloride, hydrobromide, lactate, acetate, citrate, p-toluenesulfonate, trifluoroacetate and the like in a pharmaceutically acceptable dosage form.


[0026] The dosage form may be a solid, semisolid or liquid preparation prepared by *per se* known techniques. Usually the active substance will constitute between 0.1 and 99 % by weight of the preparation, more specifically between 0.1 and 50 % by weight for preparations intended for parenteral administration and between 0.2 and 75 % by weight for preparations suitable for oral administration.

[0027] Suitable daily doses of the compounds of the invention in therapeutical treatment of humans are about 0.001-

100 mg/kg body weight at peroral administration and 0.001-50 mg/kg body weight at parenteral administration.

Preparation

[0028] A further objective of the invention is the mode of preparation of the compounds. The compounds of Formula I may be prepared by coupling of an N-terminally protected amino acid or dipeptide or a preformed, N-terminally alkylated protected dipeptide to a compound




wherein n is as defined with Formula I and X is an unprotected or protected guanidino group or a protected amino group, or a group transferable into an amino group, where the amino group is subsequently transferred into a guanidino group.

[0029] The coupling is accordingly done by one of the following methods:

Method I

[0030] Coupling of an N-terminally protected dipeptide, prepared by standard peptide coupling, with either a protected- or unprotected amino guanidine or a straight chain alkylamine carrying a protected or masked amino group at the terminal end of the alkyl chain, using standard peptide coupling, shown in the formula




wherein R^3 , R^4 , R^5 , n, m and A are as defined in Formula I, R^6 is H or alkyl, W_1 is an amino protecting group such as tertiarybutoxy carbonyl and benzyloxy carbonyl and X is $-\text{NH}-\text{C}(\text{NH})\text{NH}_2$, $-\text{NH}-\text{C}(\text{NH})\text{NH}-\text{W}_2$, $-\text{N}(\text{W}_2)-\text{C}(\text{NH})\text{NH}-\text{W}_2$, $-\text{NH}-\text{C}(\text{NW}_2)\text{NH}-\text{W}_2$ or $-\text{NH}-\text{W}_2$, where W_2 is an amine protecting group such as tertiarybutoxy carbonyl or benzyloxy carbonyl, or X is a masked amino group such as azide, giving the protected peptide. The final compounds can be made

in any of the following ways, depending on the nature of the X- group used: Removal of the protecting group(s) (when X= -NH-C(NH)NH₂, -N(W₂)-C(NH)NH-W₂, -NH-C(NW₂)NH-W₂ or -NH-C(NH)NH-W₂), or a selective deprotection of the W₁- group (e.g when X= -NH-C(NH)NH-W₂, -N(W₂)-C(NH)NH-W₂, -NH-C(NW₂)NH-W₂, W₂ in this case must be orthogonal to W₁) followed by alkylation of the N-terminal nitrogen and deprotection or a selective deprotection/unmasking of the terminal alkylamino function (X= NH-W₂, W₂ in this case must be orthogonal to W₁ or X= a masked aminogroup, such as azide) followed by a guanidation reaction, using standard methods, of the free amine and deprotection of the W₁-group.

Method II

[0031] Coupling of an N-terminally protected amino acid, prepared by standard methods, with either a protected- or unprotected amino guanidine or a straight chain alkylamine carrying a protected or masked amino group at the terminal end of the alkyl chain, using standard peptide coupling, shown in the formula




wherein W₁, A, R⁵ and X are as defined above followed by deprotection of the W₁-group and coupling with the N-terminal amino acid, in a protected form, leading to the protected peptide described in Method I or III, depending on the choice of the substitution pattern on the nitrogen of the N-terminal amino acid used in the coupling. The synthesis is then continued according to Method I or Method III to give the final peptides.

Method III

[0032] Coupling of a preformed N-terminally alkylated and protected dipeptide, prepared by standard peptide coupling, with either a protected or unprotected amino guanidine or a straight chain alkylamine carrying a protected or

masked aminogroup at the terminal end of the alkyl chain, using standard peptide coupling, shown in the formula



wherein R^2 , R^3 , R^4 , R^5 , n , m , A and X are defined as above provided that R^2 is other than H and W_3 is an acyl protecting group such as trifluoroacetyl.

[0033] The final compounds can be made in any of the following ways depending on the nature of the X-group used: Removal of protecting groups (when $X = NH-C(NH)NH_2$, $NH-C(NH)NH-W_2$, $N(W_2)-C(NH)NH-W_2$, $NH-C(NW_2)NH-W_2$ or $NH-W_2$) or a selective deprotection/unmasking of the terminal alkylamino function ($X = NH-W_2$, W_2 in this case must be orthogonal to W_3 or X = a masked amino group such as azide) followed by a guanidation deprotection of the W_3 group.

DETAILED DESCRIPTION OF THE INVENTION

[0034] The following description is illustrative of aspects of the invention.

EXPERIMENTAL PART

[0035] Synthesis of the compounds of the invention is illustrated in Schemes I to VI appended hereto.

General Experimental Procedures.

[0036] The 1H NMR and ^{13}C NMR measurements were performed on BRUKER AC-P 300 and BRUKER AM 500 spectrometers, the former operating at a 1H frequency of 500.14 MHz and a ^{13}C frequency of 125.76 MHz and the latter

at ^1H and ^{13}C frequency of 300.13 MHz and 75.46 MHz respectively.

[0037] The samples were 10-50 mg dissolved in 0.6 ml of either of the following solvents; CDCl_3 (isotopic purity > 99.8%, Dr. Glaser AG Basel), CD_3OD (isotopic purity > 99.95%, Dr. Glaser AG Basel) or D_2O (isotopic purity > 99.98%, Dr. Glaser AG Basel).

[0038] The ^1H and ^{13}C chemical shift values in CDCl_3 and CD_3OD are relative to tetramethylsilane as an external standard. The ^1H chemical shifts in D_2O are relative to the sodium salt of 3-(trimethylsilyl)- d_4 -propanoic acid and the ^{13}C chemical shifts in D_2O are referenced relative to 1,4-dioxane (67.3 ppm), both as external standard. Calibrating with an external standard may in some cases cause minor shift differences compared to an internal standard, however, the difference in ^1H chemical shift is less than 0.02 ppm and in ^{13}C less than 0.1 ppm.

[0039] The ^1H NMR spectrum of peptide sequences containing a proline residue frequently exhibits two sets of resonances. This corresponds to the existence of two contributing conformers with respect to the rotation around the amide bond, where proline is the N-part of the amide bond. The conformers are named *cis* and *trans*. In our compounds the sequences (R)Cha-Pro- and -(R)Cha-Pic- often give rise to a cis-trans equilibrium with one conformer as the preponderant conformer (>90%). In those cases only the ^1H chemical shifts of the major rotamer is reported.

[0040] Thin-Layer Chromatography was carried out on commercial Merck Silicagel 60F₂₅₄ coated glass or aluminium plates. Visualization was by a combination of UV-light, followed by spraying with a solution prepared by mixing 372 ml of EtOH(95%), 13.8 ml of concentrated H_2SO_4 , 4.2 ml of concentrated acetic acid and 10.2 ml of p-methoxy benzaldehyde or phosphomolybdic acid reagent (5-10 w.t % in EtOH(95%)) and heating.

[0041] Flash chromatography was carried out on Merck Silicagel 60 (0.040 - 0.063 mm) under pressure of N_2 .

[0042] Reversed phase high-performance liquid chromatography (in the Examples referred to as RPLC) was performed on a Waters M-590 instrument equipped with three reverse phase Kromasil 100,C8 columns (Eka-Nobel) having different dimensions for analytical (4.6 mm x 250 mm), semipreparative (25.4 mm x 250 mm) [(1" x 250 mm)] and preparative (50.8 mm x 500 mm) [(2" x 500 mm)] chromatography detecting at 226 nm.

[0043] Freeze-drying was done on a Leybold-Heraeus, model Lyovac GT 2, apparatus.

Protection Procedures

Boc-(R)Cha-OH

[0044] To a solution of H-(R)Cha-OH, 21.55 g (125.8 mmol), in 130 ml 1 M NaOH and 65 ml THF was added 30 g (137.5 mmol) of $(\text{Boc})_2\text{O}$ and the mixture was stirred for 4.5 h at room temperature. The THF was evaporated and an additional 150 ml of water was added. The alkaline aqueous phase was washed twice with EtOAc, then acidified with 2 M KHSO_4 and extracted with 3 x 150 ml of EtOAc. The combined organic phase was washed with water, brine and dried (Na_2SO_4). Evaporation of the solvent afforded 30.9 g (90.5 %) of the title compound as a white solid.

Z-(R)Cha-OH

[0045] The same procedure as described in Bodanszky M. and Bodanszky A. "The Practice of Peptide Synthesis", Springer-Verlag, 1984, p. 12, was used starting from H-(R)Cha-OH.

Boc-(Me)Phe-OH

[0046] Prepared in the same way as Boc-(R)Cha-OH from Me-(R)Phe-OH.

Boc-(R,S)Pro(3-(trans)Ph)-OH

[0047] To a well stirred solution of 2.0 g (8.8 mmol, 1 eq.) H-(R,S)Pro(3-(trans)Ph)-OH x HCl (Prepared as described in J. Org. Chem., 55, p. 270-75, 1990 and J. Org. Chem., 39, 1710-1716, 1974), in 17.6 ml of 1 N NaOH, 12 ml of H_2O and 12 ml of THF at +5 °C was added 2.33 g ($(\text{Boc})_2\text{O}$) (10.7 mmol, 1.2 eq.). The reaction was allowed to reach room temperature and the stirring was continued for an additional 18 h. The organic solvent was evaporated and 50 ml of H_2O was added to the residue. The basic water phase was washed with 2x50 ml of EtOAc and acidified with 2 M KHSO_4 (pH about 1). The acidic water phase was extracted with 4x75 ml of EtOAc and the combined organic phase was washed with 1x40 ml of H_2O , 1x40 ml of brine and dried (MgSO_4). Evaporation of the solvent gave 2.0 g (78 %) of pure product as a white solid.

[0048] ^1H -NMR (CDCl_3 , 500 MHz, mixture of two rotamers): δ 1.4 and 1.5 (2s, 9H), 2.0-2.1 (m, 1H), 2.3-2.4 (m, 1H), 3.45-3.88 (m, 3H), 4.3 and 4.45 (2d, 1H), 7.2-7.4 (m, 5H).

Boc-(R,S)Pro(3-Ph)-OH

[0049] Prepared as above starting from a cis/trans mixture of H-(R,S)Pro(3-Ph)-OH.

5 **Boc-(R)Dph-OH**

[0050] Prepared according to the method described by K. Hsich et.al. in J. Med. Chem., 32, p. 898 (1989) from H-(R)Dph-OH.

10 **Boc-(R)Hop-OH**

[0051] Prepared by the same procedure as described for Boc-(R)Cha-OH starting from H-(R)Hop-OH.

[0052] ¹H-NMR (300 MHz, CDCl₃): δ 1.45 (s, 9H), 2.00 (m, 1H), 2.22 (m, 1H), 2.75 (bt, 2H), 4.36 (bs, 1H), 5.05 (bs, 1H), 7.15-7.33 (m, 5H).

15

Deprotection Procedures.

[0053]

20 (a) The protected peptide was dissolved in EtOH (95%) and hydrogenated over 5 % Pd/C at atmospheric pressure in the presence of an excess of TFA or HOAc (> 2 eq.) for about 1-4 h. The catalyst was filtered off, the solvent evaporated and the final peptide (TFA or HOAc salt) was isolated as a white powder after freeze drying (H₂O)

(b) The same as in (a) except that EtOH/H₂O (ca:5/1) was used as solvent.

25

(c) The same procedure as in (a) but MeOH was used as solvent.

(d) The same procedure as in (a) but 2 M HCl was used as acid to give the HCl-salt.

30 (e) Hydrolysis of esters, an illustrative example:

EtOOC-CH₂-(R)Cha-Pro-Nag x 2 HOAc (0.4 mmol) was dissolved in 1.5 ml of MeOH and 1.2 ml (1.2 mmol) of 1M NaOH was added at room temperature. After 3 h the methanol was evaporated and an excess HOAc was added to the residue and the mixture was freeze dried and purified by RPLC (CH₃CN/0.1 M NH₄OAc (70/30)). The pure product was obtained as a powder in 73 % yield after freeze drying from water.

35

(f) Cleavage of t-butyl esters, an illustrative example:

The t-butyl ester was dissolved in an excess of TFA. After stirring for 2 h at room temperature the TFA was evaporated. Purification by treatment with activated charcoal in water-ethanol was followed by freeze drying from water giving the desired compounds.

40

Preparation of Starting Materials.**H-Pic-OEt x HCl**

45 [0054] L-Pipecolinic acid, 4.0 g (0.031 mol), was slurried in 100 ml of abs. ethanol and HCl (g) was briefly bubbled through until a clear solution was obtained. It was cooled in an ice bath and 17 ml of thionyl chloride was added dropwise over 15 min.

[0055] The ice bath was removed and the mixture was refluxed for 2.5 h. The solvent was evaporated and the product was obtained as its hydrochloride salt in a quantitative yield.

50 [0056] ¹H-NMR (300 MHz, D₂O): δ 1.33 (t, 3H), 1.8-2.1 (m, 5H), 2.3-2.5 (m, 1H), 3.1-3.3 (m, 1H), 3.5-3.7 (m, 1H), 4.14 (dd, 1H), 4.44 (q, 2H).

H-Pic-OMe x HCl

55 [0057] Prepared in the same way as described for H-Pic-OEt x HCl by replacing EtOH with MeOH.

H-Aze-OEt x HCl

[0058] Prepared in the same way as described for H-Pic-OEt x HCl from H-Aze-OH.

5 **H-Pic(4-(S)Me)-OEt x HCl**

[0059] Prepared in the same way as described for H-Pic-OEt x HCl from H-Pic(4-(S)Me)-OH (purchased from Synthelec, Lund, Sweden).

10 **H-(R)Pic(4-(R)Me)-OEt x HCl**

[0060] Prepared in the same way as described for H-Pic-OEt x HCl from H-(R)Pic(4-(R)Me)OH (purchased from Synthelec, Lund, Sweden).

15 **H-(R)Dph-OH**

[0061] Prepared by the general method given by A. Evans et. al. in JACS, 112, 4011 (1990).

H-(R,S)Pic(4,5-dehydro)-OEt

20

[0062] H-(R,S)Pic(4,5-dehydro)-OH, 3.05 g (18.1 mmol) (Prepared according to the procedure by Burgstahler et. al. J. Org. Chem, 25, 4, p. 489-92 (1960), was dissolved in 75 ml EtOH/HCl (saturated) and the mixture was refluxed for 5 hours. The solvent was evaporated and the remaining residue was dissolved in water, made alkaline with sodium hydroxide (aq) and extracted three times with ethylacetate. Drying (Na₂SO₄) and careful evaporation gave 2.05g (71%) of the

25

title compound.
[0063] ¹H-NMR (CDCl₃): δ 1.28 (t, 3H), 1.88 (bs, NH) 2.2-2.4 (m, 2H), 3.45 (bs, 2H), 3.57 (dd, 1H), 4.21 (q, 2H), 5.68-5.82 (m, 2H).

Boc-(R)Cgl-OH

30

[0064] Boc-(R)Pgl-OH was hydrogenated over 5% Rh/Al₂O₃ in MeOH at 5 Mpa. Filtration and evaporation of the solvent gave the title compound which was used without further purification.

[0065] ¹H-NMR (300 MHz, CDCl₃): δ 0.9-1.7 (m, 20H), 4.0-4.2 (m, 1H), 5.2 (d, 1H).

35 **Boc-(R)Dch-OH**

[0066] Boc-(R)Dph-OH, 0.75 g (2.2 mmol), was dissolved in 25 ml of MeOH and a catalytic amount of 5% Rh/Al₂O₃ was added. The mixture was hydrogenated at 5 Mpa, 50°C for 40 h, filtered and evaporated to give 0.72 g (93%) of the title compound.

40

[0067] ¹H-NMR (CDCl₃): δ 0.9-2.0 (m, 32H), thereof 1.45 (bs, 9H), 4.55 (bd) and 4.9 (bd); two rotamers integrating for a total of 1H, 5.7-6.1 (broad, NH).

H-(R)Pro(5-(S)Me)-OMe

45 [0068] Prepared according to the procedure given by B. Gopalan et.al. in J. Org. Chem., 51, 2405, (1986).

H-Mor-OH

[0069] Prepared according to the method of K. Nakajima. et al. Bull. Chem. Soc. Jpn., 51 (5), 1577-78, 1978 and ibid 60, 2963-2965, 1987.

50

H-Mor-OEt x HCl

[0070] Prepared in the same way as H-Pic-OEt x HCl from H-Mor-OH.

55

Boc-(R)Cha-OSu

[0071] Boc-(R)Cha-OH (1 eq.), HOSu (1.1 eq) and DCC or CME-CDI (1.1 eq) were dissolved in acetonitrile (about

2.5 ml/mmol acid) and stirred at room temperature over night. The precipitate formed during the reaction was filtered off, the solvent evaporated and the product dried in vacuo. (When CME-CDI was used in the reaction the residue, after evaporation of the CH₃CN, was dissolved in EtOAc and the organic phase washed with water and dried. Evaporation of the solvent gave the title compound).

[0072] ¹H-NMR (500 MHz, CDCl₃, 2 rotamers ca: 1:1 ratio) δ 0.85-1.1 (m, 2H), 1.1-1.48 (m, 4H), 1.5-1.98 (m, 16H; thereof 1.55 (bs, 9H)), 2.82 (bs, 4H), 4.72 (bs, 1H, major rotamer), 4.85 (bs, 1H, minor).

Boc-(Me)(R)Cha-OSu

(i) Boc-(Me)(R)Cha-OH

[0073] A solution of 11.9 g (42.6 mmol) Boc-(Me)(R)Phe-OH in 150 ml MeOH was hydrogenated over 5% Rh/Al₂O₃ at 0.28 Mpa for 24 h. Filtration of the catalyst and evaporation of the solvent gave the product as a white solid (95 % yield) which was used in the next step without further purification.

[0074] ¹H-NMR (500 MHz, CDCl₃, mixture of two rotamers ca: 1/1). δ 0.8-1.1 (m, 2H), 1.1-1.9 (m, 20H, thereof 1.47 and 1.45 (s, 9H)), 2.82 and 2.79 (s, total 3H), 4.88 and 4.67 (m, total 1H).

(ii) Boc-(Me)(R)Cha-OSu

[0075] Prepared in the same way as described for Boc-(R)Cha-OSu- from Boc-(Me)(R)Cha-OH.

Boc-(R)Cha-Pro-OSu

(i) Boc-(R)Cha-Pro-OH

[0076] H-(S)Pro-OH (680 mmol) was dissolved in 0.87M sodium hydroxide (750 ml). Boc-(R)Cha-OSu (170 mmol) dissolved in DMF (375 ml) was added dropwise during 20 min. The reaction mixture was stirred at room temperature for 20 h. The mixture was acidified (2M KHSO₄) and extracted three times with ethyl acetate. The organic layers were combined and washed three times with water and once with brine. After drying over sodium sulphate and evaporation of the solvent, the syrupy oil was dissolved in diethyl ether, the solvent evaporated and finally the product dried in vacuo to yield Boc-(R)Cha-Pro-OH as a white powder in almost quantitative yield.

[0077] ¹H-NMR (500 MHz, CDCl₃, minor rotamer 10%) δ 0.8-1.05 (m, 2H), 1.05-1.55 (m, 15H; thereof 1.5 (bs, 9H)), 1.55-1.8 (m, 5H), 1.8-2.15 (m, 3H), 2.47 (m, 1H), 3.48 (m, 1H), 3.89 (m, 1H), 4.55 (m, 2H), 5.06 (m, 1H); minor rotamer signals 2.27 (m, 1H), 3.58 (m, 1H), 4.33 (m, 1H), 5.0 (m, 1H)

(ii) Boc-(R)Cha-Pro-OSu

[0078] Prepared in the same way as described for Boc-(R)Cha-OSu- from Boc-(R)Cha-Pro-OH.

[0079] ¹H-NMR (500 MHz, CDCl₃, 2 rotamers, 5:1 ratio) δ 0.78-1.05 (m, 2H), 1.05-1.83 (m, 20H; thereof 1.43 (bs, 9H)), 1.83-2.26 (m, 3H), 2.32 (m, 1H), 2.72-2.9 (m, 4H), 3.2 (m, 1H, minor rotamer), 3.52 (m, 1H, major), 3.68 (m, 1H, minor rotamer), 3.89 (m, 1H, major), 4.31 (bq, 1H, minor rotamer), 4.56 (bq, 1H, major), 4.71 (bt, 1H, major rotamer), 4.93 (bt, 1H, minor), 5.22 (bd, 1H, major rotamer), 5.44 (bd, 1H, minor).

Z-(R)Cha-Pro-OSu

[0080] Prepared in the same way as Boc-(R)Cha-Pro-OSu from Z-(R)Cha-OH.

Boc-(R)Cha-Pic-OSu

(i) Boc-(R)Cha-Pic-OEt

[0081] Boc-(R)Cha-OH, 6.3 g (0.023 mol), was dissolved in 150 ml of CH₂Cl₂. The solution was cooled in an ice bath and 6.3 g (0.047 mol) of N-hydroxybenzotriazole and 11.2 g (0.0265 mol) of CME-CDI were added. The ice bath was removed after 15 min and the reaction mixture was stirred for 4 h at room temperature. The solvent was evaporated and the residue dissolved in 150 ml of DMF and cooled in an ice bath. H-Pic-OEt·HCl, 4.1 g (0.021 mol) was added and the pH adjusted to approximately 9 by addition of N-methylmorpholine. The ice bath was removed after 15 min and the reaction mixture was stirred for 3 days. The solvent was evaporated and the residue was dissolved in ethyl acetate and washed with dilute KHSO₄ (aq), NaHCO₃ (aq) and water. The organic layer was dried (Na₂SO₄) and evaporated to give

7.7 g (89 %) of Boc-(R)Cha-Pic-OEt which was used without further purification.

[0082] ¹H-NMR (500 MHz, CDCl₃, 2 rotamers, 3:1 ratio) δ 0.7-1.0 (m, 2H), 1.1-1.9 (m, 29H; thereof 1.28 (t, 3H)), 1.45 (bs, 9H), 2.01 (bd, 1H, major rotamer), 2.31 (bd, 1H), 2.88 (bt, 1H, minor), 3.30 (bt, 1H, major), 3.80 (bd, 1H, major), 4.15-4.3 (m, 2H), 4.5-4.7 (m, 2H, minor), 4.77 (bq, 1H, major), 4.90 (bd, 1H, minor), 5.28 (bd, 1H, major), 5.33 (bd, 1H, major).

(ii) Boc-(R)Cha-Pic-OH

[0083] Boc-(R)Cha-Pic-OEt, 5.6 g (0.014 mol), was mixed with 100 ml of THF, 100 ml of water and 7 g of LiOH. The mixture was stirred at room temperature overnight. The THF was evaporated and the aqueous solution was acidified with KHSO₄ (aq) and extracted three times with ethyl acetate. The combined organic phase was washed with water, dried (Na₂SO₄) and evaporated to give 4.9 g (94 %) of Boc-(R)Cha-Pic-OH which was used without further purification. The compound can be crystallized from diisopropyl ether/hexane.

[0084] ¹H-NMR (500 MHz, CDCl₃, 2 rotamers, 3.5:1 ratio) δ 0.8-1.1 (m, 2H), 1.1-2.1 (m, 27H; thereof 1.43 (s, 9H, major rotamer), 1.46 (s, 9H, minor)), 2.33 (bd, 1H), 2.80 (bt, 1H, minor), 3.33 (bt, 1H, major), 3.85 (bd, 1H, major), 4.57 (bd, 1H, minor), 4.68 (m, 1H, minor), 4.77 (bq, 1H, major), 5.03 (bs, 1H, minor), 5.33 (bd, 1H, major), 5.56 (m, 1H, major).

(iii) Boc-(R)Cha-Pic-OSu

[0085] Boc-(R)Cha-Pic-OH (1 g, 2.6 mmol) was dissolved in DMF (15 ml) at room temperature and then cooled to -18°C, a temperature which was maintained during the additions of the reactants. Hydroxy succinimid (0.60 g, 5.2 mmol) was added and the reaction mixture was stirred for a few minutes until the crystals were dissolved. Dicyclohexyl carbodiimid (0.56 g, 2.7 mmol) dissolved in DMF (10 ml) and precooled was added dropwise to the reaction mixture. After a few minutes at -18°C the reaction mixture was put into a water bath at 20°C for 2 h under stirring. The solvent was evaporated, ethyl acetate (40 ml) was added and the precipitated urea was filtered off.

[0086] The organic phase was washed once with water, twice with 0.3 M KHSO₄, twice with diluted NaHCO₃, once with water, once with brine and dried (Na₂SO₄). The solvent was evaporated and the product dried in vacuo to yield 1.16 g (93%) of the product. According to ¹H-NMR the product contained two diastereoisomers (epimers in Pic, S/R) in a ratio of 95/5.

[0087] ¹H-NMR (300 MHz, CDCl₃, major diastereomer) δ 0.7-2.0 (m, 27H; thereof 1.46 (bs, 9H)), 2.29 (bd, 1H), 2.85 (bs, 4H), 3.40 (m, 1H), 4.5-4.8 (m, 1H), 5.1-5.4 (m, 1H), 5.70 (bd, 1H, major).

Boc-(R)Cha-Mor-OSu

[0088] Prepared in the same way as Boc-(R)Cha-Pic-OSu from H-Mor-OEt x HCl except that CH₃CN was used as solvent instead of DMF in the formation of the OSu-ester.

Boc-(Me)(R)Cha-Pro-OSu

[0089] Prepared in the same way as Boc-(R)Cha-Pro-OSu from Boc-(Me)-(R)Cha-OH.

Boc-(Me)(R)Cha-Pic-OSu

[0090] Prepared in the same way as Boc-(R)Cha-Pic-OSu from Boc-(Me)(R)Cha-OH.

Boc-(R,S)Pro(3-Ph)-Pro-OSu

[0091] Prepared in the same way as Boc-(R)Cha-Pro-OSu from Boc-(R,S)Pro(3-Ph)-OH.

Boc-(R,S)Pro(3-(trans)Ph)-Pro-OSu

(i) Boc-(R,S)Pro(3-(trans)Ph)-Pro-OBn

[0092] To a slurry of 1.0 g of Boc-(R,S)Pro(3-(trans)Ph)-OH (3.43 mmol, 1 eq.), 1.04 g of H-Pro-OBn x HCl (4.29 mmol, 1.25 eq.), 0.04 g of HOBT (0.24 mmol, 0.07 eq.) in 15 ml DMF was added 1.83 g of CME-CDI (4.29 mmol, 1.25 eq.) and 0.525 ml of NMM (4.73 mmol, 1.38 eq.) at room temperature. After stirring an additional 4 days the solvent was evaporated and the residue taken up in 200 ml EtOAc. The organic phase was washed with 2x40 ml of H₂O, 2x25

ml of 1M KHSO₄, 2x25 ml of 1M NaOH, 2x25 ml of H₂O and dried (MgSO₄). Evaporation of the solvent and flash chromatography (CH₂Cl₂/MeOH, 97/3) gave the pure product (44% yield) as a ca: 1:1 mixture of diastereomers.

(ii) Boc-(R,S)Pro(3-(trans)Ph)-Pro-OH

[0093] The benzyl ester from the previous step was removed by hydrogenation over 5 % Pd/C in EtOH at atmospheric pressure for 4 h. Filtration and evaporation gave the pure product as a ca: 1:1 mixture of diastereomers in quantitative yield.

[0094] ¹H-NMR (CDCl₃, 500 MHz, two diastereomers each consisting of two rotamers): δ 1.3-2.4 (m + 4s from the Boc groups, total 14H), 2.5-2.9 (m, total 1H), 3.2-3.9 (m, total 5H), 4.3-4.65 (m, total 2H), 7.2-7.5 (m, 5H).

(iii) Boc-(R,S)Pro(3-(trans)Ph)-Pro-OSu

[0095] Prepared according to the procedure described for Boc-(R)Cha-OSu from Boc-(R,S)Pro(3-(trans)Ph)-Pro-OH.

Boc-(R,S)Pro(3-(trans)Ch)-Pro-OSu

(i) Boc-(R,S)Pro(3-(trans)Ch)-Pro-OH

[0096] Boc-(R,S)Pro(3-(trans)Ph)-Pro-OH was hydrogenated over 5 % Rh/Al₂O₃ in methanol together with a small amount of HOAc for 7 days at 0,34 Mpa. Filtration of the catalyst, evaporation of the solvent and flash chromatography (CH₂Cl₂/MeOH, 94/6 gave the pure product as a white solid (mixture of two diastereomers).

(ii) Boc-(R,S)Pro(3-(trans)Ch)-Pro-OSu

[0097] Prepared according to the procedure described for Boc-(R)Cha-OSu from Boc-(R,S)Pro(3-(trans)Ch)-Pro-OH.

Boc-(R)Hoc-Pro-OH

(i) Boc-(R)Hoc-OH

[0098] Boc-(R)Hop-OH, 3.2 g (11.46 mmol) was dissolved in methanol (75 ml). Rhodium on activated aluminium oxide (Rh/Al₂O₃), 0,5 g was added and the mixture stirred in hydrogen atmosphere at 0.41 MPa for 18 h. The catalyst was filtered off through celite and the solvent evaporated giving the product in almost quantitative yield.

[0099] ¹H-NMR (500 MHz, CDCl₃): δ 0.90 (m, 2H), 1.08-1.33 (m, 6H), 1.43 (s, 9H), 1.60-1.74 (m, 6H), 1.88 (bs, 1H), 4.27 (bs, 1H).

(ii) Boc-(R)Hoc-OSu

[0100] Prepared in the same way as described for Boc-(R)Cha-OSu from Boc-(R)Hoc-OH.

(iii) Boc-(R)Hoc-Pro-OH

[0101] Prepared in the same way as described for Boc-(R)Cha-Pro-OH from Boc-(R)Hoc-OSu.

[0102] ¹H-NMR (500 MHz, CDCl₃): δ 0.80-0.94 (m, 2H), 1.05-1.36 (m, 7H), 1.36-1.48 (bs, 9H), 1.48-1.78 (m, 7H), 1.98-2.14 (m, 2H), 2.34 (m, 1H), 3.48 (m, 1H), 3.85 (m, 1H), 4.43 (m, 1H), 4.52 (bd, 1H), 5.26 (bd, 1H), signals of a minor rotamer appears at: δ 1.92, 2.25, 3.58, 4.20 and 4.93.

Boc-(R)Hoc-Pic-OH

(i) Boc-(R)Hoc-Pic-OMe

[0103] Prepared the same way as described for Boc-(R)Cha-Pic-OEt from Boc-(R)Hoc-OH and H-Pic-OMe x HCl.

(ii) Boc-(R)Hoc-Pic-OH

[0104] Prepared in the same way as described for Boc-(R)Cha-Pic-OH from Boc-(R)Hoc-Pic-OMe.

[0105] ¹H-NMR (500 MHz, CDCl₃): δ 0.82-0.97 (m, 2H), 1.10-1.36 (m, 7H), 1.36-1.50 (bs, 9H), 1.50-1.82 (m, 11H),

2.35 (bd, 1H) 3.28 (bt, 1H), 3.85 (bd, 1H) 4.63 (m, 1H), 5.33 (bs, 1H), 5.44 (bd, 1H), signals of a minor rotamer appears at: δ 1.88, 2.80, 4.25, 4.55 and 4.97.

Boc-(R)Cha-Aze-OH

[0106] Prepared in the same way as described for Boc-(R)Cha-Pic-OH from H-Aze-OEt x HCL.

Boc-(R)Cha-Pic(4-(S)Me)-OH

[0107] Prepared in the same way as described for Boc-(R)Cha-Pic-OH from H-Pic(4-(S)Me)-OEt x HCl except that CH_2Cl_2 was used as solvent.

Boc-(R)Cha-(R)Pic(4-(R)Me)-OSu

(i) Boc-(R)Cha-(R)Pic(4-(R)Me)-OEt

[0108] Prepared in the same way as described for Boc-(R)Cha-Pic-OEt from H-(R)Pic(4-(R)Me)-OEt x HCl.

(ii) Boc-(R)Cha-(R)Pic(4-(R)Me)-OH

[0109] Prepared by using the deprotection (e) on the product (i) above.

(iii) Boc-(R)Cha-(R)Pic(4-(R)Me)OSu

[0110] Prepared in the same way as described for Boc-(R)Cha-Pic-OSu from Boc-(R)Cha-(R)Pic(4-(R)Me)-OH.

Boc-(R)Cha-(R,S)Pic(4,5-dehydro)-OH

[0111] Prepared according to the procedure described for Boc-(R)Cha-Pic-OH from H-(R,S)Pic(4,5-dehydro)-OEt.

Boc-(R)Cgl-Pic-OH

(i) Boc-(R)Cgl-Pic-OMe

[0112] Pivaloyl chloride (1.000 mL, 8.1 mmol) was added to a solution of Boc-(R)Cgl-OH (2.086 g, 8.1 mmol) and triethyl amine (1.13 mL, 8.1 mmol) in toluene (25 mL) and DMF (5 mL). A mixture of H-Pic-OMe x HCl (1.46 g, 8.1 mmol) and triethyl amine (1.13 mL, 8.1 mmol) in DMF (20 mL) was subsequently added at ice bath temperature. The reaction mixture was slowly allowed to warm up to room temperature and after 24 h it was diluted with water and extracted with toluene. After washing with 0.3 M KHSO_4 , 10% Na_2CO_3 and brine the solvent was removed in vacuo to give 2.52 g (81%) of colorless oil which was used without further purification.

[0113] $^1\text{H-NMR}$ (500 MHz, CDCl_3 , 2 rotamers, 5:1 ratio) δ 0.8-1.8 (m, 25H), 2.25 (d, 1H), 2.75 (t, 1H, minor rotamer), 3.3 (t, 1H), 3.7 (s, 3H), 3.85 (d, 1H), 4.3 (t, 1H, minor rotamer), 4.5-4.6 (m, 1H), 5.25 (d, 1H), 5.30 (d, 1H).

(ii) Boc-(R)Cgl-Pic-OH

[0114] Prepared according to the procedure for hydrolysis of Boc-(R)Cha-Pic-OEt using the product from (i) above. The product was crystallized from di-isopropyl ether and hexane.

[0115] $^1\text{H-NMR}$ (500 MHz, CDCl_3 , 2 rotamers, 5:1 ratio) δ 0.8-1.8 (m, 25H), 2.3 (d, 1H), 2.8 (t, 1H, minor rotamer), 3.3 (t, 1H), 3.9 (d, 1H), 4.4 (t, 1H, minor), 4.5-4.6 (m, 1H), 5.1 (s, 1H, minor rotamer), 5.3 (d, 1H), 5.40 (d, 1H).

Boc-(R)Dph-Pic-OH

[0116] Prepared in the same way as described for Boc-(R)Cha-Pic-OH from Boc-(R)Dph-OH.

Boc-(R)Dch-Pic-OH

[0117] Prepared in the same way as described for Boc-(R)Cha-Pic-OH from Boc-(R)Dch-OH.

Boc-(R)Cha-Pro(5-(S)Me)-OH

[0118] Prepared in the same way as described for Boc-(R)Cha-Pic-OH from H-Pro(5-(S)Me)-OMe.

5 **Boc-Nag(Z)**

(i) N-Benzyloxycarbonyl-O-methyl isourea

[0119] To a stirred solution of concentrated aqueous NaOH (2.8 L, 50% w/w, 19.1 M, 53 mol) and water (32 L) at 180°
 10 C was added in two portions O-methylisourea hemisulphate (1.7 kg, 94%, 13.0 mol) and O-methylisourea hydrogensulphate (1.57 kg, 99%, 9.0 mol). The reaction mixture was cooled to 3-5° C. Benzyl chloroformate (3.88 kg, 92%, 20.9 mol) was added over a 20 minutes period under cooling and vigorous stirring. The reaction temperature went from 3 to 8° C during the addition of Z-Cl. The addition funnel was rinsed with 5 litres of water which was added to the reactor. The reaction mixture was stirred at 0-3° C for 18 h, filtered and the crystals were washed with cooled (3° C) water (10
 15 L). Vacuum drying 25° C, 10-20 mbar) for 48 h gave 3.37 kg (89%) of the title compound as a white crystalline powder.

(ii) Boc-Nag(Z)

[0120] To a stirred solution Boc-NH-(CH₂)₃-NH₂ x HCl (prepared according to Mattingly P.G., Synthesis, 367 (1990))
 20 (3.9 kg, 18.5 mol) in iso-propanol (24 kg) at 60-70° C was added in portions over a 30 minutes period KHCO₃ (4.2 kg, 42 mol). A slow evolution of CO₂ (g) occurs. The mixture was stirred for another 30 minutes followed by addition in portions over a 30 minutes period N-benzyloxycarbonyl-O-methyl isourea (3.74 kg, 18.0 mol). The reaction mixture was stirred at 65-70° C for 16 h, cooled to 20° C and filtered. The precipitate was washed with iso-propanol (10 + 5 L). The combined filtrates were concentrated at reduced pressure keeping the heating mantle not warmer than 65-70° C. Then
 25 approximately 45 litres was distilled off EtOAc (90 L) was added. The reaction mixture was cooled to 20-25° C, washed with water (10 and 5 L) and brine (5 L), and dried with Na₂SO₄ (2 kg). After stirring the reaction mixture was filtered and the filter cake was washed with EtOAc (11 and 7 L). The combined filtrates were concentrated at reduced pressure keeping the heating mantle not warmer than 40-50° C. When approximately 90 litres of EtOAc was distilled off, toluene (25 L) was added and the evaporation continued. After
 30 collection of approximately another 18 litres of distillate, toluene (20 L) was added under vigorous stirring and the resulting mixture was cooled to -1 to 0° C and gently stirred over night (17 h). The crystal slurry was filtered and the product was washed with cooled toluene (10 and 5 L). Vacuum drying (10-20 mbar, 40° C) for 24 h gave 4.83 kg (13.8 mol, 76%) of Boc-Nag(Z).

[0121] ¹H-NMR (300 MHz, CDCl₃): δ 1.41 (s, 9H), 1.6-1.7 (m, 2H), 3.0-3.3 (m, 4H), 4.8-5.0 (bs, 1H), 5.10 (s, 2H), 7.2-
 35 7.4 (m, 5H).

Boc-Agm(Z)

(i) Boc-Agm

40 [0122] To a slurry of 14.95 g (65.5 mmol, 1 eq.) of agmatine sulphate (Aldrich), 13.7 ml of Et₃N (98.25 mmol, 1.5 eq.), 165 ml of H₂O and 165 ml of THF was added 21.5 g (93.25 mmol, 1.5 eq.) of (Boc)₂O during 5 minutes at room temperature. The mixture was stirred vigorously over night, evaporated to dryness and the residue was washed with 2x100 ml of Et₂O to give Boc-Agm as a white powder which was used without further purification in the next step.

45 (ii) Boc-Agm(Z)

[0123] To a cold (+5°C) slurry of the crude Boc-Agm from the previous step (ca: 65.5 mmol) in 180 ml of 4N NaOH and 165 ml of THF was added 24 ml (169 mmol, 2.5 eq) of benzyl chloroformate during 10 minutes. After stirring at
 50 room temperature for 4 h methanol (150 ml) was added and the stirring was continued for an additional 20 h at room temperature. The organic solvent was evaporated and 200 ml of H₂O was added to the residue. The basic water phase was extracted with 1x300 ml and 2x200 ml of EtOAc. The combined organic phases were washed with H₂O (2x100ml), brine (1x100 ml) and dried (MgSO₄). Evaporation of the solvent and flash chromatography (CH₂Cl₂/MeOH, a stepwise gradient of 97/3, 95/5 and 9/1 was used) gave 14.63 g (58%) of pure Boc-Agm(Z) as a white powder.

55 [0124] ¹H-NMR (CDCl₃, 500 MHz): δ 1.35-1.40 (m, 2H), 1.45 (s, 9H), 1.5-1.6 (m, 2H), 3.0-3.2 (m, 4H), 4.65 (bs, 1H), 5.1 (s, 2H), 7.23-7.40 (m, 5H).

[0125] ¹³C-NMR (CDCl₃, 75.5 MHz): δ 25.44, 27.36, 28.21, 65.83, 79.15, 127.47, 127.66, 128.14, 137.29, 156.47, 161.48, 163.30.

Boc-NH-(CH₂)₃-N₃

[0126] Prepared according to the method described by Mattingly P. G., in *Synthesis* 1990, 367.

Z-NH-(CH₂)₂-NH₂

[0127] To a cold solution of 6 g ethylene diamine (0.1 mol) and 22 ml triethyl amine in 20 ml of chloroform was added 2.5 g of Z-OSu dissolved in 5 ml of chloroform. The mixture was allowed to reach room temperature and left over night under stirring. Filtration, evaporation of the solvent and flash chromatography (CH₂Cl₂/MeOH(NH₃-saturated), 95/5) gave 0.9 g (46 %) of the title compound.

[0128] ¹H-NMR (300 MHz, CDCl₃): δ 1.27 (s, 2H), 2.85 (t, 2H), 3.24 (g, 2H), 5.14 (s, 2H), 7.22-7.40 (m, 5H).

Agm x HCl

[0129] Prepared from Agm x H₂SO₄ (Aldrich) by exchanging the hydrogen sulphate ion for chloride on an ion exchange column.

H-Nag(Z) x 2 HCl

[0130] Prepared by bubbling HCl(e) into a solution of Boc-Nag(Z) in EtOAc followed by evaporation of the solvent.

BnOOC-CH₂-NH-CO-CH₂-Br

[0131] To a solution of p-TsOH x H-Gly-OBn (5 mmol) and triethyl amine (5 mmol) in 10 ml of CH₂Cl₂ was added 2-bromoacetic acid (5 mmol) dissolved in 10 ml of CH₂Cl₂ and dicyclohexyl carbodiimide (5 mmol). The mixture was stirred at room temperature over night and filtered. The organic phase was washed twice with 0.2 M KHSO₄, 0.2 M NaOH, brine and dried. Evaporation and flash chromatography (CH₂Cl₂/MeOH, 95/5) gave a quantitative yield of the desired compound.

[0132] ¹H-NMR (300 MHz, CDCl₃): δ = 3.89 (s, 2H), 4.05-4.11 (d, 2H), 5.19 (s, 2H), 7.06 (bs, 1H), 7.3-7.4 (m, 5H).

BnOOC-CH₂-OCO-CH₂-Br

[0133] A mixture of 2.8 g (0.020 mmol) bromoacetic acid, 4.2 g (0.020 mmol) of benzyl bromoacetate and 2.0 g (0.020 mmol) of triethylamine in 25 ml of EtOAc was refluxed for 3 h. It was diluted with more EtOAc and cooled. The solution was washed with dilute HCl and thereafter with NaHCO₃ (aq) and finally with water. Drying (Na₂SO₄) and evaporation followed by flash chromatography (heptane/ethylacetate, 75/25) gave the title compound in 26 % yield.

[0134] ¹H-NMR (500 MHz, CDCl₃): δ 3.95 (s, 2H), 4.75 (s, 2H), 5.23 (s, 2H), 7.35-7.45 (m, 5H).

BnO-(CH₂)₃-OTf

[0135] Propanediol monobenzyl ether (0.83 g, 5 mmol) was dissolved in dry pyridine (0.6 g, 7 mmol) and dichloromethane (20 ml) and cooled to -15°C. Triflic anhydride, precooled to -15°C, was added and the reaction mixture stirred for 45 min under which the temperature was allowed to rise to 15°C. The solvent was evaporated and the product dissolved in hexane/ethyl acetate 4:1 (10 ml) and filtered through silica.

[0136] Finally the solvent was evaporated and the product dried in vacuo to yield 0.95 g (64%) of 1-benzyloxy 3-trifluoromethanesulfonylpropane which was used directly (see Example 21).

[0137] ¹H-NMR (500 MHz, CDCl₃): δ 2.12 (m, 2H), 3.6 (t, 2H), 4.51 (s, 2H), 4.72 (t, 2H), 7.22-7.42 (m, 5H).

BnO-(CH₂)₂-CHO

[0138] Prepared by Swern oxidation (described by D. Swern et al., *J. Org. Chem.*, 1973, 2430-82) of BnO-(CH₂)₃-OH.

[0139] ¹H-NMR (300 MHz, CDCl₃): δ 2.63 (dt, 2H), 3.80 (t, 2H), 4.51 (s, 2H), 7.30 (m, 5H), 9.76 (bt, 1H).

Br-(S)CH(CH₂OBn)-COOBn

(i) Br-(S)CH(CH₂OBn)-COOH

[0140] O-Benzylserine (3.9 g, 19 mmol) in water (10 ml) was added to a solution of sodium bromide (11 g, 107 mmol)

in water (20 ml) and sulphuric acid (2 g, 20 mmol). The reaction mixture was cooled to -10°C and NaNO₂ (1.73 g, 25 mmol) was added under vigorous stirring. Another portion of water was added to the thick mixture followed, after a few minutes, by H₂SO₄ (1 g, 10 mmol). The mixture was stirred at ambient temperature over night after which it was extracted twice with EtOAc (100ml). The combined organic phase was washed twice with water and once with brine and dried (Na₂SO₄). Evaporation of the solvent gave 3.7 g (75%) of the title compound as a yellow oil which was pure enough to use directly in the next step.

(ii) Br-(S)CH(CH₂OBn)-COOBn

[0141] To a solution of the crude product from (i) above (2.6 g, 10 mmol) in dry benzene (25 ml) was added oxalyl chloride (2.6 g, 20.5 mmol) and molecular sieves (4 Å, 1 g). The mixture was stirred at ambient temperature under an atmosphere of Argon for 18 h. The molecular sieves was removed by filtration and the solvent evaporated. The slightly yellow residue was dissolved in CH₃CN (10 ml) and benzyl alcohol (1 g, 9.2 mmol) was added. The mixture was stirred at ambient temperature for 5 h. The solvent was evaporated and the residue dissolved in Et₂O and washed once with 1 M NaOH, water, brine and dried (Na₂SO₄). Evaporation of the solvent followed by flash chromatography (CH₂Cl₂/MeOH, 95/5) gave 1.8 g (67 %) of the desired compound.

[0142] ¹H-NMR (500 MHz, CDCl₃): δ 3.82 (dd, 1H), 3.99 (dd, 1H), 4.38 (dd, 1H), 4.56 (s, 2H), 5.23 (s, 2H), 7.23-7.46 (m, 5H).

Working Examples

Example 1

H-(R)Cha-Pro-Agm x 2 HOAc

(i) Boc-(R)Cha-Pro-Agm x HOAc

[0143] Boc-(R)Cha-Pro-OSu (1.7 mmol) and agmatine dihydrochloride (2.0 mmol, 1.18 eq) was dissolved in DMF/H₂O 95:5 (35 ml). Triethylamine was added to adjust the pH to about 10 and the solution was stirred at room temperature for 2 days. The solution was evaporated (5 mm Hg/ 60 °C) until dryness and the crude product was purified by RPLC (CH₃CN/NH₄OAc (0.1 M), 38:62). The desired compound was obtained as a white powder after freeze-drying.

[0144] ¹H NMR (500 MHz, CDCl₃/DMSO-d₆ 5:2, Two rotamers, 9:1 δ (major rotamer) : 0.75-0.90 (m, 2H), 1.1-2.05 (m, 19H), 1.35 (s, 9H) 2.98-3.14 (m, 4H), 3.37 (q, 1H), 3.76 (m, 1H), 4.20 (m, 1H), 4.33 (dd, 1H), 6.30 (d, 1H), 7.05-7.80 (broad m, 5H), 8.67 (broad d, 1H).

[0145] Exchange broadened signals of the minor rotamer are unambiguously observed at δ 3.44 (m, 1H), 3.62 (m, 1H), 4.10 (m, 1H), 4.64 (m, 1H), 5.56 (d, 1H), 9.08 (m, 1H).

(ii) H-(R)Cha-Pro-Agm x 2 HOAc

[0146] A solution of Boc-(R)Cha-Pro-Agm (0.2 mmol) in TFA (2ml) was stirred at room temperature for 4.5 h. The solvent was evaporated and the remaining oil was subjected to RPLC (CH₃CN/NH₄OAc (0.1 M), 25:75). The diacetate salt was obtained as a white powder after repeated freeze-drying.

[0147] ¹H NMR (500.13 MHz, D₂O): δ 0.80-0.95 (m, 2H), 1.00-1.21 (m, 3H), 1.32 (m, 1H), 1.40-1.78 (m, 12H), 1.83-2.00 (m, 2H), 1.90 (s, acetate), 2.20 (m, 1H), 3.06-3.14 (m, 4H), 3.50 (m, 1H), 3.67 (m, 1H), 4.20-4.30 (m, 2H).

[0148] ¹³C NMR (75.6 MHz, D₂O): guanidine: δ 157.4; carbonyl carbons: δ 169.9, 174.5.

Example 2

Me-(R)Cha-Pro-Agm x 2 HOAc

(i) Boc-(Me)(R)Cha-Pro-Agm

[0149] To a solution of 479.6 mg (1 mmol, 1 eq.) of Boc-(Me)(R)Cha-Pro-OSu and 500 ml of NMM in 16 ml DMF/H₂O (15/1) was added 166.5 mg (1.2 mmol, 1.2 eq.) of Agm x HCl at room temperature. The reaction was stirred an additional 70 h and the solvent was evaporated to give a crude product as an oil. This was used without purification in the next step.

(ii) Me-(R)Cha-Pro-Agm x 2 HOAc

[0150] The crude oil from the previous step was dissolved in 10 ml TFA/CH₂Cl₂ (1:4) at room temperature. After stirring for 2 h 25 min the solvent was evaporated and the crude product was purified with RPLC (CH₃CN/NH₄OAc(0.1M), 35/65) to give the desired product as a white powder after freeze-drying.

[0151] ¹H-NMR (500 MHz, D₂O): δ 0.93-1.05 (m, 2H), 1.10-1.29 (m, 3H), 1.33-1.43 (m, 1H), 1.50-1.80 (m, 12H), 1.88-2.10 (m, 2H), 1.92 (s, acetate), 2.27-2.36 (m, 1H), 2.68 (s, 3H), 3.15-3.23 (m, 3H), 3.24-3.31 (m, 1H), 3.57-3.66 (m, 1H), 3.76-3.83 (m, 1H), 4.28 (t, 1H), 4.39 (dd, 1H).

[0152] ¹³C-NMR (125.76 MHz, D₂O): guanidine: δ 157.24; carbonyl carbons: δ 174.03, 168.24.

Example 3HO-(CH₂)₃-(R)Cha-Pro-Agm x 2 HCl

(i) Boc-(R)-Cha-Pro-Agm(Z)

[0153] Boc-Agm(Z) (1 eq) was dissolved in TFA/CH₂Cl₂ (1:4, ca: 6 ml/mmol) and stirred at room temperature for ca: 2 h. The solvent was evaporated and the product dissolved together with Boc-(R)Cha-Pro-OSu (1 eq) in DMF (ca: 1 ml/mmol), the pH was adjusted with NMM to ca: 9 and the mixture was stirred at room temperature for 20 h. The solvent was evaporated in vacuo, the crude product dissolved in CH₂Cl₂ and washed three times with water and once with brine. After drying (sodium sulphate) the solvent was evaporated and the product flash chromatographed (CH₂Cl₂/MeOH) affording Boc-(R)Cha-Pro-Agm(Z) as a white powder.

(ii) H-(R)Cha-Pro-Agm(Z)

[0154] Boc-(R)Cha-Pro-Agm(Z) was dissolved in TFA/CH₂Cl₂ (1:4, ca: 6 ml/mmol) and stirred at room temperature for 2 h. The solvent was evaporated, the product dissolved in 0.2M NaOH (20 ml/mmol) and extracted twice with dichloromethane. The organic layers were combined and washed with brine, dried (sodium sulphate) and the solvent evaporated to yield H-(R)Cha-Pro-Agm(Z) as a white powder.

(iii) BnO-(CH₂)₃-(R)Cha-Pro-Agm(Z)

[0155] H-(R)Cha-Pro-Agm(Z) (1 mmol) was dissolved in methanol (10 ml). Triethylammonium hydrochloride (1mmol), sodium cyanoborohydride (0.7 mmol) and thereafter BnO-(CH₂)₂-CHO (1.05 mmol) were added and the reaction mixture stirred at room temperature over night. The solvent was evaporated and the crude product was dissolved in ethyl acetate, washed twice with water, once with brine and dried over sodium sulphate. The solvent was evaporated and the crude product was purified by flash chromatography (EtOAc/MeOH).

(iv) HO-(CH₂)₃-(R)Cha-Pro-Agm x 2 HCl

[0156] Prepared by using deprotection procedure (d) on the product (iii) above.

[0157] ¹H-NMR (500 MHz, D₂O): δ 0.72 (m, minor rotamer), 0.84 (m, minor rotamer), 0.87-1.03 (m, 2H), 1.03-1.26 (m, 3H), 1.28-1.40 (bs, 1H), 1.44-1.80 (m, 11H), 1.80-1.95 (bs, 3H), 1.95-2.10 (bs, 2H), 2.28 (m, 1H), 3.04 (m, 1H), 3.08-3.27 (m, 5H), 3.58 (bs, 1H), 3.67 (bs, 2H), 3.78 (m, 1H), 4.12 (bd, minor rotamer), 4.30 (m, 1H), 4.37 (m, 1H).

[0158] ¹³C-NMR (125 MHz, D₂O): guanidine: δ 157.26; carbonyl carbons: δ 174.06, 168.36.

Example 4HOOC-CH₂-(R)Cha-Pro-Agm x HOAc

General Procedure for the alkylation of the N-terminal.

[0159] This procedure is described in more general terms and will be referred to in the Examples below together with the alkylating agent used in each specific Example.

[0160] The peptide to be alkylated (1 eq) and the alkylating agent (1.1-1.2 eq) were dissolved in acetonitrile (ca 10 ml/mmol). Potassium carbonate (2.0-2.2 eq) was added and the reaction mixture stirred at 50-60°C until the starting material was consumed (TLC, usually 1-5 h). Filtration, evaporation of the solvent and flash chromatography (CH₂Cl₂/MeOH, CH₂Cl₂/MeOH(NH₃-saturated) or EtOAc/MeOH, ca 9/1) gave the alkylated product after evaporation

of the solvent.

(i) $\text{BnOOC-CH}_2\text{-(R)Cha-Pro-Agm(Z)}$

5 [0161] Prepared from $\text{H-(R)Cha-Pro-Agm(Z)}$ (See Example 3) and $\text{Br-CH}_2\text{COOBn}$ according to the procedure described above.

(ii) $\text{HOOC-CH}_2\text{-(R)Cha-Pro-Agm x HOAc}$

10 [0162] Prepared by using the deprotection procedure (b) on the product (i) above.

[0163] $^1\text{H-NMR}$ (300 MHz, MeOD): δ 0.9-1.1 (m, 2H), 1.1-2.3 (m, 19H) 1.95 (s, acetate), 3.1-3.2 (m, 4H), 3.2-3.65 (m, 3H), 3.85 (m, 1H), 4.0 (bt, 1H), 4.35 (dd, 1H).

[0164] $^{13}\text{C-NMR}$ (75 MHz, D_2O): guanidine: δ 157.55; carbonyl carbons: δ 168.71, 171.37 and 174.3.

15 Example 5

$^i\text{Pr-OOC-CH}_2\text{-(R)Cha-Pro-Agm x HOAc}$

[0165] Alkylation as in Example 4 using $\text{H-(R)Cha-Pro-Agm(Z)}$ (See Example 3) and $\text{Br-CH}_2\text{COO}^i\text{Pr}$ followed by deprotection procedure (b) gave the title compound.

[0166] $^1\text{H-NMR}$ (500 MHz, MeOD): δ 0.85-1.05 (m, 2H), 1.1-1.35 (m, 9H; thereof 1.23 (d, 3H), 1.25 (d, 3H)), 1.35-2.02 (m, 14H) 1.92 (s, acetate), 2.03 (m, 1H), 2.2 (m, 1H), 3.07-3.45 (m, 6H), 3.55 (m, 1H), 3.7-3.8 (m, 2H), 4.3 (dd, 1H), 5.05 (m, 1H).

[0167] $^{13}\text{C-NMR}$ (125 MHz, D_2O): guanidine: δ 157.39; carbonyl carbons: δ 171.10, 172.76 and 174.44.

25

Example 6

$\text{HOOC-CH}_2\text{-(Me)(R)Cha-Pro-Agm x 2 TFA}$

30 (i) $\text{Me-(R)Cha-Pro-Agm(Z)}$

[0168] Prepared from $\text{Boc-(Me)(R)Cha-Pro-OSu}$ in the same way as described for $\text{H-(R)Cha-Pro-Agm(Z)}$ in Example 3.

35 (ii) $\text{HOOC-CH}_2\text{-(Me)(R)Cha-Pro-Agm x 2 TFA}$

[0169] Alkylation as in Example 4 using $\text{Me-(R)Cha-Pro-Agm(Z)}$ and $\text{Br-CH}_2\text{COOBn}$ followed by deprotection procedure (b) gave the title compound.

[0170] $^1\text{H-NMR}$ (300 MHz, D_2O): δ 0.9-1.35 (m, 6H), 1.5-2.2 (m, 14H), 2.25-2.45 (m, 1H), 3.12 (s, 3H), 3.15-3.35 (m, 4H), 3.6-3.75 (m, 1H), 3.8-3.95 (m, 1H), 4.22 (apparent bs, 2H), 4.45 (m, 1H), 4.6 (bt, 1H).

[0171] $^{13}\text{C-NMR}$ (75.47 MHz, D_2O): guanidine: δ 157.52; carbonyl carbons: δ 173.86, 168.79, 167.38.

Example 7

45 $\text{HOOC-(R,S)CH(Me)-(R)Cha-Pro-Agm x HOAc}$

[0172] Alkylation as in Example 4 using $\text{H-(R)Cha-Pro-Agm(Z)}$ (See Example 3) and Br-CH(Me)COOBn followed by deprotection procedure (a) gave the title compound as a mixture of two diastereomers.

50 Example 8

$\text{HOOC-(RorS)CH(Me)-(R)Cha-Pro-Agm/a x HOAc}$

[0173] Obtained by separating the diastereomers formed in Example 7 using RPLC ($\text{CH}_3\text{CN}/\text{NH}_4\text{OAc}$ (0.1M), 1/4). This diastereomer came out first of the two from the column.

[0174] $^1\text{H-NMR}$ (500 MHz, D_2O ; 2 rotamers ca: 5:1 ratio): δ 0.74 (m, minor rotamer), 1.01 (m, 2H), 1.10-1.33 (m, 3H), 1.48-1.88 (m, 15H; thereof 1.51 (d, 3H)), 1.92-2.12 (m, 3H) 1.96 (s, acetate), 2.30 (m, 1H), 3.20 (m, 3H), 3.38 (m, 1H), 3.47 (q, minor rotamer), 3.53-3.68 (m, 2H), 3.73 (m, 1H), 4.20 (d, minor rotamer), 4.33 (m, 1H), 4.38 (m, 1H), 4.51 (d,

minor rotamer).

[0175] ^{13}C -NMR (125 MHz, D_2O): guanidine: δ 157.38; carbonyl carbons: δ 174.11, 173.45, 168.64.

Example 9

HOOC-(RorS)CH(Me)-(R)Cha-Pro-Agm/b x HOAc

[0176] The diastereomer that came out after the first one from the column in the separation in Example 8 is the title compound above.

[0177] ^1H -NMR (500 MHz, D_2O , 2 rotamers ca 9:1 ratio): δ 0.88 (m, minor rotamer), 1.05 (m, 2H), 1.12-1.33 (m, 3H), 1.42 (bs, 1H), 1.50-1.88 (m, 15H; thereof 1.55 (d, 3H)), 1.93- 2.13 (m, 3H) 1.95 (s, acetate), 2.30 (m, 1H), 2.40 (m, minor rotamer), 3.22 (t, 2H), 3.28 (t, 2H), 3.64 (m, 1H), 3.70 (q, 1H), 3.98 (t, minor rotamer), 4.35 (t, 1H), 4.41 (dd, 1H).

Example 10

HOOC-(RorS)CH(^nPr)-(R)Cha-Pro-Agm/a x HOAc

[0178] Alkylation as in Example 4 using H-(R)Cha-Pro-Agm(Z) (See Example 3) and Br-CH(^nPr)COOEt and deprotection procedure (e) followed by deprotection procedure (b) gave HOOC-(R,S)CH(^nPr)-(R)Cha-Pro-Agm. The title compound was obtained by separating the diastereomers by RPLC ($\text{CH}_3\text{CN}/\text{NH}_4\text{OAc}$ (0.1 M), 1/4) and freeze drying (H_2O) after evaporation of the solvent. This diastereomer came out first of the two from the column.

[0179] ^1H -NMR (300 MHz, MeOD): δ 0.8-1.1 (m, 5H; thereof 0.92 (t, 3H)), 1.1-2.1 (m, 22H) 1.95 (s, acetate), 2.2 (m, 1H), 3.1-3.35 (m, 5H), 3.48 (m, 1H), 3.88 (m, 1H), 4.0 (m, 1H), 4.4 (dd, 1H).

[0180] ^{13}C -NMR (75 MHz, D_2O): guanidine: δ 157.50; carbonyl carbons: δ 168.55 and 174.16.

Example 11

HOOC-(RorS)CH(^nPr)-(R)Cha-Pro-Agm/b x HOAc

[0181] The other diastereomer from the separation in Example 10 which came out after the first one from the column is the title compound above.

[0182] ^1H -NMR (500 MHz, MeOD): δ 0.85-1.05 (m, 5H; thereof 0.95 (t, 3H)) 1.1-2.08 (m, 22H) 1.9 (s, acetate), 2.14 (m, 1H), 3.1-3.4 (m, 5H), 3.45 (m, 1H), 3.62 (m, 1H), 3.80 (m, 1H), 4.34 (dd, 1H).

[0183] ^{13}C -NMR (75 MHz, D_2O): guanidine: δ 157.53; carbonyl carbons: δ 169.01 and 174.27.

Example 12

HOOC-(RorS)CH(Ph)-(R)Cha-Pro-Agm/b x HOAc

(i) $^t\text{BuOOC}$ -(RorS)CH(Ph)-(R)Cha-Pro-Agm(Z)

[0184] A mixture of H-(R)Cha-Pro-Agm(Z) (See Example 3) (0.55 mmol), tert.butyl-(R,S)phenyl bromoacetate (0.66 mmol), K_2CO_3 (1.4 mmol) in CH_3CN (10 ml) was stirred at room temperature for 28 h and an additional 5 h at 60°C . The diastereomeric mixture (ca: 3:1, according to NMR) was filtered and evaporated. The remaining oil was twice subjected to flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 92/8), which resulted in a complete separation of the two diastereomers ($R_f=0.36$ (minor isomer) and 0.27 (major isomer), respectively).

[0185] ^1H NMR of major isomer (500.13 MHz, CDCl_3): δ 0.79 (quart, 1H), 0.90 (quart, 1H), 1.06-1.70 (m, H), 1.37 (s, 9H), 1.85-2.03 (m, 3H), 2.20 (m, 1H), 3.10-3.24 (m, 3H), 3.25-3.38 (m, 2H), 3.42 (m, 1H), 3.53 (m, 1H), 4.30 (s, 1H), 4.49 (dd, 1H), 5.08 (s, 2H), 7.19-7.40 (m, 10H); broad NH signals are observed in the region 6.7-8.6.

(ii) HOOC-(RorS)CH(Ph)-(R)Cha-Pro-Agm/b x HOAc

[0186] The major isomer (50 mmol) and thioanisole (0.5 mmol) dissolved in TFA was kept at room temperature for 8 h. After evaporation (0.1 mm Hg) for 5 h, the remaining oil was purified on RPLC ($\text{CH}_3\text{CN}/\text{NH}_4\text{OAc}$ (0.1 M), 2:3) to give the title compound after evaporation of the solvent and freeze-drying.

[0187] ^1H NMR (500.13 MHz, MeOD): δ 0.85-1.01 (m, 2H), 1.13-1.38 (m, 4H), 1.53-2.05 (m, 14H), 1.92 (s, acetate) 2.18 (m, 1H), 3.08-3.26 (m, 3H), 3.32-3.45 (m, 2H), 3.64 (m, 1H), 3.93 (t, 1H), 4.37 (dd, 1H), 4.43 (s, 1H), 7.28-7.50 (m, 5H).

[0188] ^{13}C NMR (125.6 MHz, MeOD): guanidine: δ 158.7; carbonyl carbons: δ 173.8, 174.7, 177.0.

Example 13

5 HOOC-(R,S)CH(CH₂CH₂Ph)-(R)Cha-Pro-Agm x HOAc

[0189] Alkylation as in Example 4 using H-(R)Cha-Pro-Agm(Z) (See Example 3) and Br-CH(CH₂-CH₂-Ph)COOEt and deprotection procedure (a) followed by deprotection procedure (e) gave HOOC-(R,S)CH(CH₂-CH₂-Ph)-(R)Cha-Pro-Agm.

10 Example 14

HOOC-(RorS)CH(CH₂CH₂Ph)-(R)Cha-Pro-Agm/a x 2 TFA

15 [0190] The title compound was obtained by separating the diastereomers obtained in Example 13 by RPLC (CH₃CN/NH₄OAc (0.1 M), 2/3) and freeze drying (H₂O/TFA) after evaporation of the solvent. This diastereomer came out first of the two from the column is the title compound above.

[0191] ^1H -NMR (500 MHz, MeOD): δ 0.93-1.11 (m, 2H), 1.24 (m, 1H), 1.29-1.40 (m, 2H), 1.52-1.85 (m, 11H), 1.89-2.11 (m, 4H), 2.14-2.32 (m, 3H), 2.83 (t, 2H), 3.14 (t, 2H), 3.24 (t, 2H), 3.50 (q, 1H), 3.70 (m, 1H), 4.00 (t, 1H), 4.36-4.42 (m, 2H), 7.17-7.31 (m, 5H).

20 [0192] ^{13}C -NMR (125 MHz, MeOD): guanidine: δ 158.66; carbonyl carbons: δ 168.08, 171.53, 174.16.

Example 15

25 HOOC-CH₂-CH₂-(R)Cha-Pro-Agm x HOAc

(i) BnOOC-CH₂-CH₂-(R)Cha-Pro-Agm(Z)

30 [0193] Benzyl acrylate (1.1 eq) and H-(R)Cha-Pro-Agm(Z) (See Example 3) (1 eq) were dissolved in ethanol (20 ml/mmol) and stirred at room temperature for 20 h. The solvent was evaporated and the crude product purified by flash chromatography (CH₂Cl₂/MeOH(NH₃-saturated), 95/5). Finally the solvent was evaporated and the product dried in vacuo.

[0194] ^1H -NMR (500 MHz, CDCl₃): δ 0.7-0.95 (m, 2H), 1.0-1.5 (m, 10H), 1.5-1.75 (m, 5H), 1.75-1.92 (m, 2H), 2.0 (m, 1H), 2.17 (bs, 1H), 2.45 (m, 2H), 2.63 (m, 1H), 2.79 (m, 1H), 2.97-3.25 (m, 4H), 3.33 (m, 2H), 3.52 (bt, 1H), 4.45 (bd, 35 1H), 4.95-5.12 (m, 4H), 7.13-7.4 (m, 10H).

(ii) HOOC-CH₂-CH₂-(R)Cha-Pro-Agm x HOAc

[0195] Prepared by using the deprotection procedure (a) on the product (i) above.

40 [0196] ^1H -NMR (500 MHz, D₂O): δ 0.88 (m, 2H), 1.00-1.23 (m, 3H), 1.33 (bs, 1H), 1.42-1.72 (m, 11H), 1.78-2.00 (m, 3H), 1.94 (s, acetate), 2.18 (m, 1H), 2.52 (m, 2H), 3.03-3.20 (m, 6H), 3.50 (m, 1H), 3.72 (m, 1H), 4.23 (m, 1H), 4.30 (m, 1H).

[0197] ^{13}C -NMR (125 MHz, D₂O): guanidine: δ 157.25; carbonyl carbons: δ 178.07, 173.96, 168.24.

45 Example 16

EtOOC-CO-(R)Cha-Pro-Agm x HOAc

(i) EtOOC-CO-(R)Cha-Pro-Agm(Z)

50 [0198] To a cold (-10° C) solution of H-(R)Cha-Pro-Agm(Z) (See Example 3) (0.46 g, 0.89 mmol) and NMM (199 mg, 1.97 mmol) in 10 ml of THF was added Cl-COCOOEt (134 mg, 0.98 mmol) dissolved in 3 ml of THF. The mixture was kept at -10° C for one hour after which it was stirred at room temperature for another hour. The solvent was evaporated and the residue was dissolved in ethyl acetate. The organic phase was washed twice with water and dried (Na₂SO₄).
55 Evaporation of the solvent and crystallization from EtOAc gave 0.275 g (50%) of the title compound as white crystals.

(ii) EtOOC-CO-(R)Cha-Pro-Agm x HOAc

[0199] Prepared by using the deprotection procedure (b) on the product (i) above.

[0200] ¹H-NMR (300 MHz, MeOD): δ 0.9-2.25 (m, 24H; thereof 1.17 (t, 3H)) 1.90 (s, acetate), 3.1-3.25 (m, 4H), 3.5-3.65 (m, 3H; thereof 3.59 (q, 2H)), 3.88 (m, 1H), 4.35 (m, 1H), 4.69 (dd, 1H).

[0201] ¹³C-NMR (75.5 MHz, MeOD): guanidine: δ 157.56 and carbonyl carbons: δ 159.21, 160.74, 172.81, 174.56.

Example 17

(R,S)Bla-(R)Cha-Pro-Agm x 2 TFA

[0202] Alkylation as in Example 4 using H-(R)Cha-Pro-Agm(Z) (See Example 3) and α-bromo butyrolacton followed by deprotection procedure (a) gave the title compound as a mixture of two diastereomers.

[0203] ¹H-NMR (500 MHz, D₂O, mixture of diastereomers ca: 1/1): δ 0.93-1.06 (m, 2H), 1.09-1.30 (m, 3H), 1.37-1.49 (m, 1H), 1.50-1.87 (m, 11H), 1.89-2.10 (m, 3H), 2.24-2.36 (m, 1H), 2.44-2.56 (m, 1H), 2.72-2.85 (m, 1H), 3.10-3.30 (m, 4H), 3.56-3.65 (m, 1H), 3.75-3.84 (m, 1H), 4.2-5.0 (m, 5H, partially hidden by the H-O-D signal).

[0204] ¹³C-NMR (125.76 MHz, D₂O) guanidine: δ 157.34 (peaks overlapping); carbonyl carbons: δ 174.34, 173.90, 173.62, 167.88, 167.58 (two peaks are overlapping).

Example 18

HOOC-(RorS)CH(CH₂CH₂Ph)-(R)Cha-Pro-Agm/b x 2 TFA

[0205] The title compound was obtained by treating the diastereomer in Example 13 by the same way as described in Example 14. This diastereomer came out after the first one from the column.

[0206] ¹H-NMR (500 MHz, MeOD): δ 0.95-1.06 (m, 2H), 1.14-1.40 (m, 4H), 1.48-1.84 (m, 11H), 1.87-2.30 (m, 6H), 2.72-2.90 (m, 2H), 3.12-3.32 (m, 4H), 3.52 (m, 1H), 3.72 (m, 1H), 4.04 (dd, 1H), 4.27 (t, 1H), 4.37 (dd, 1H), 7.17-7.32 (m, 5H).

[0207] ¹³C-NMR (125 MHz, MeOD): guanidine: δ 158.68; carbonyl carbons: δ 168.14, 171.46, 174.03.

Example 19

H-(R)Cha-Pro-Nag x 2 HOAc

(i) Z-(R)Cha-Pro-NH-(CH₂)₃-NH(Boc)

[0208] To a solution of Z-(R)Cha-Pro-OSu (1 mmol) in 1 ml of DMF at 0 °C was added H₂N-(CH₂)₃-NH(Boc) (See Preparation of starting material) dissolved in 1 ml of DMF and the pH was adjusted to ca: 9 with NMM. The reaction was stirred at room temperature for 3 days after which it was poured out on water. The aqueous phase was extracted four times with EtOAc. The combined organic phase was washed twice with 0.3 M KHSO₄, 0.2 M NaOH, brine and dried. Evaporation and flash chromatography (EtOAc/ petroleum ether, 4/1) gave the title compound in 59 % yield.

(ii) Z-(R)Cha-Pro-NH-(CH₂)₃-NH₂

[0209] Z-(R)Cha-Pro-NH-(CH₂)₃-NH(Boc) (0.6 mmol) was dissolved in CH₂Cl₂ (8 ml). TFA (2 ml) was added and the reaction mixture was stirred for 1 h. The solvent was evaporated and the residue was dissolved in CH₂Cl₂, washed twice with 0.2 M NaOH and dried (Na₂SO₄). Evaporation of the solvent gave the amine in 93 % yield.

[0210] ¹H-NMR (500 MHz, CDCl₃): δ 0.79-1.03 (m, 2H), 1.05-1.75 (m, 15H), 1.84-2.08 (m, 4H), 2.36 (m, 1H), 2.66 (m, 2H), 3.25 (m, 2H), 3.43 (q, 1H), 3.85 (m, 1H), 4.45 (m, 1H), 4.56 (d, 1H) 5.09 (m, 2H), 5.35 (d, 1H), 7.30-7.45 (m, 5H).

(iii) Z-(R)Cha-Pro-Nag x HOAc

[0211] Z-(R)Cha-Pro-NH-(CH₂)₃-NH₂ (0.55 mmol, 1 eq) was dissolved in DMF (2 ml) and the pH adjusted with triethylamine to 8-9. 3,5-Dimethyl-1-pyrazolylformamidine nitrate (0.55 mmol, 1 eq) dissolved in DMF (1 ml) was added and the reaction mixture stirred at room temperature for three days. The solvent was evaporated, the crude product freeze-dried (H₂O) and purified with RPLC (CH₃CN/NH₄OAc (0.1M), 4/6) to give the title compound in 93 % yield after evaporation of the solvent and freeze-drying (H₂O).

(iv) H-(R)Cha-Pro-Nag x 2 HOAc

[0212] Prepared by using the deprotection procedure (a) on the product (iii) above.

[0213] ¹H-NMR (500 MHz, D₂O): δ 0.82-1.03 (m, 2H), 1.03-1.28 (m, 3H), 1.35 (m, 1H), 1.53-1.82 (m, 9H), 1.82-2.05 (m, 3H), 1.89 (s, acetate), 2.24 (m, 1H), 3.15 (t, 2H), 3.23 (q, 2H), 3.55 (m, 1H), 3.72 (m, 1H), 4.27-4.34 (m, 2H).

[0214] ¹³C-NMR (125 MHz, D₂O): guanidine: δ 157.37; carbonyl carbons: δ 169.81, 174.52.

Example 20

ⁿBu-(R)Cha-Pro-Nag x 2 HOAc

(i) H-(R)Cha-Pro-Nag(Z)

[0215] Prepared from Boc-(R)Cha-Pro-OSu and Boc-Nag(Z) in the same way as described for H-(R)Cha-Pro-Agm(Z) in Example 3.

[0216] ¹H-NMR (500 MHz, CDCl₃): δ 0.8-1.03 (m, 2H), 1.10-1.50 (m, 6H), 1.60-1.83 (m, 8H), 1.87-2.20 (m, 3H), 3.15 (m, 1H), 3.25 (m, 2H), 3.42 (m, 2H), 3.63 (dd, 1H), 3.70 (m, 1H), 4.36 (bs, 1H), 5.07 (s, 2H), 7.22-7.43 (m, 5H).

(ii) ⁿBu-(R)Cha-Pro-Nag(Z)

[0217] H-(R)Cha-Pro-Nag(Z) (0.5 g, 1 mmol) was dissolved in methanol (10 ml). Triethylammonium hydrochloride (0.1 g, 1 mmol), sodium cyanoborohydride (44 mg, 0.7 mmol) and thereafter butyric aldehyde (76 mg, 1.05 mmol) were added and the reaction mixture stirred at room temperature for 20 h. The solvent was evaporated and the crude product was dissolved in ethyl acetate, washed twice with water, once with brine and dried over sodium sulphate. The solvent was evaporated and the crude product was purified by flash chromatography (EtOAc/EtOH/Et₃N, 88/10/2). Finally the solvent was evaporated and the product dried in vacuo to yield 0.22 g (40 %) of ⁿBu-(R)Cha-Pro-Nag(Z).

[0218] ¹H-NMR (500 MHz, CDCl₃): δ 0.82-1.0 (m, 5H; thereof 0.88 (t, 3H)), 1.08-1.49 (m, 10H), 1.58-1.8 (m, 7H), 1.88-2.22 (m, 3H), 2.4 (m, 1H), 2.5 (m, 1H), 3.05 (bs, 1H), 3.3 (m, 1H), 3.4-3.53 (m, 3H), 3.73 (m, 1H), 4.42 (bs, 1H), 5.1 (s, 2H), 7.25-7.43 (m, 5H).

(iii) ⁿBu-(R)Cha-Pro-Nag x 2 HOAc

[0219] Prepared by using the deprotection procedure (a) on the product (ii) above.

[0220] ¹H-NMR (300 MHz, D₂O): δ 0.94 (t, 2H), 1.10-1.31 (m, 3H), 1.38 (m, 3H), 1.53-1.88 (m, 11H), 1.88-2.15 (m, 3H), 1.95 (s, acetate), 2.34 (m, 1H), 2.95 (m, 1H), 3.08 (m, 1H), 3.24 (t, 2H), 3.30 (m, 2H), 3.66 (m, 1H), 3.82 (m, 1H), 4.32 (t, 1H), 4.41 (dd, 1H).

[0221] ¹³C-NMR (125 MHz, D₂O): guanidine: δ 157.40; carbonyl carbons: δ 180.39, 174.28, 168.55.

Example 21

HO-(CH₂)₃-(R)Cha-Pro-Nag x 2 TFA

(i) BnO-(CH₂)₃-(R)Cha-Pro-Nag(Z)

[0222] 1-Benzyloxy 3-trifluoromethanesulfonylpropane (See Prep. of Starting Materials) (0.5 g, 1 mmol) and H-(R)Cha-Pro-Nag(Z) (See Example 20) were dissolved in tetrahydrofuran (10 ml). Potassium carbonate (0.28 g, 2 mmol) was added and the reaction mixture was stirred at room temperature for two hours. The solvent was evaporated and the crude product extracted with ethyl acetate/water. The organic phase was washed once with aqueous sodium hydrogen carbonate, once with water and once with brine. After drying over sodium sulphate the solvent was evaporated and the crude product flash chromatographed (CH₂CH₂/MeOH(NH₃-saturated), 95:5). Finally the solvent was evaporated and the product dried in vacuo to yield 0.29 g (45%) of the title compound.

[0223] ¹H-NMR (500 MHz, CDCl₃): δ 0.77-1.03 (m, 2H), 1.03-2.18 (m, 19H), 2.52 (m, 1H), 2.64 (m, 1H), 3.03 (bs, 1H), 3.1-3.6 (m, 7H), 3.66 (m, 1H), 4.41 (bs, 1H), 4.46 (s, 2H), 5.08 (s, 2H), 7.2-7.4 (m, 5H), 7.55 (m, 1H).

(ii) HO-(CH₂)₃-(R)Cha-Pro-Nag x 2 TFA

[0224] Prepared by using the deprotection procedure (a) on the product (i) above.

[0225] ¹H-NMR (500 MHz, D₂O): δ 1.00 (bs, 2H), 1.10-1.32 (m, 3H), 1.40 (bs, 1H), 1.55-2.15 (m, 14H), 2.30 (m, 1H),

3.05-3.35 (m, 6H), 3.57-3.75 (m, 3H), 3.81 (bs, 1H), 4.35 (bs, 1H), 4.42 (bs, 1H).

Example 22

5 HOOC-CH₂-(R)Cha-Pro-Nag x HOAc

(i) H-(R)Cha-Pro-NH-(CH₂)₃-N₃

[0226] Prepared in the same way as H-(R)Cha-Pro-Agm(Z) (See Example 3) starting from Boc-(R)Cha-Pro-OSu and
10 Boc-NH-(CH₂)₃-N₃ (replacing Boc-Agm(Z)).

(ii) EtOOC-CH₂-(R)Cha-Pro-NH-(CH₂)₃-NH₂ x HOAc

[0227] Alkylation as in Example 4 using H-(R)Cha-Pro-NH-(CH₂)₃-N₃ and EtOOC-CH₂-Br followed by deprotection
15 procedure (a) to reduce the azide gave the title compound.

(iii) EtOOC-CH₂-(R)Cha-Pro-Nag x HOAc

[0228] The same procedure as described in Example 19 (iii) for Z-(R)Cha-Pro-Nag was used to accomplish the gua-
20 nidation of the amine from (ii) above. The title compound was obtained in a pure form after RPLC (CH₃CN/NH₄OAc
(0.1M), 3/7) evaporation of the solvent and freeze drying (H₂O).

(iv) HOOC-CH₂-(R)Cha-Pro-Nag x HOAc

25 [0229] Prepared by using the deprotection procedure (e) on the product (iii) above.

[0230] ¹H-NMR (500 MHz, D₂O): δ 0.99 (m, 2H), 1.09-1.30 (m, 3H), 1.44 (m, 1H), 1.59-2.09 (m, 12H) 1.92 (s, ace-
tate), 2.29 (m, 1H), 3.20 (t, 2H), 3.28 (m, 2H), 3.52-3.63 (m, 3H), 3.76 (m, 1H), 4.38 (dd, 1H), 4.42 (t, 1H).

[0231] ¹³C-NMR (125 MHz, D₂O): guanidine: δ 157.43; carbonyl carbons: δ 168.72, 171.36, 174.35.

30 Example 23

EtOOC-CH₂-(R)Cha-Pro-Nag x HOAc

[0232] Prepared according to example 22 (iii).

35 [0233] ¹H-NMR (300 MHz, D₂O): δ 1.07 (m, 2H), 1.17-1.59 (m, 7H; thereof 1.38 (t, 3H)), 1.60-2.24 (m, 12H) 2.04 (s, acetate), 2.39 (m, 1H), 3.31 (t, 2H), 3.39 (t, 2H), 3.63-3.90 (m, 4H), 4.12 (t, 1H), 4.36 (q, 2H), 4.46 (dd, 1H).

[0234] ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.37; carbonyl carbons: δ 173.73, 175.09, 175.70.

Example 24

40

ⁱPrOOC-CH₂-(R)Cha-Pro-Nag x HOAc

[0235] Alkylation as in Example 4 using H-(R)Cha-Pro-Nag(Z) (See Example 20) and Br-CH₂COOⁱPr followed by
deprotection procedure (b) gave the title compound.

45 [0236] ¹H-NMR (500 MHz, MeOD): δ 0.85-1.05 (m, 2H), 1.1-2.15 (m, 22H; thereof 1.23 (d, 3H), 1.25 (d, 3H), 1.92 (s, acetate), 2.2 (m, 1H), 3.10-3.35 (m, 5H), 3.4 (m, 1H), 3.55 (m, 1H), 3.65-3.8 (m, 2H), 4.28 (dd, 1H), 5.03 (m, 1H).

[0237] ¹³C-NMR (125 MHz, D₂O): guanidine: δ 157.39; carbonyl carbons: δ 170.40, 172.00 and 174.50.

Example 25

50

^tBuOOC-CH₂-(R)Cha-Pro-Nag x 2 TFA

[0238] Alkylation as in Example 4 using H-(R)Cha-Pro-Nag(Z) (See Example 20) and Br-CH₂COO^tBu followed by
deprotection procedure (b) gave the title compound.

55 [0239] ¹H-NMR (300 MHz, MeOD): δ 0.9-1.15 (m, 2H), 1.15-2.15 (m, 25H; thereof 1.55 (bs, 9H)), 2.3 (m, 1H), 3.15-3.45 (m, 4H), 3.55 (m, 1H), 3.7-3.95 (m, 3H), 4.3- 4.4 (m, 2H).

[0240] ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.55; carbonyl carbons: δ 166.55, 168.13 and 174.33.

Example 26HOOC-CH₂-OOC-CH₂-(R)Cha-Pro-Nag x HOAc5 (i) BnOOC-CH₂-OOC-CH₂-(R)Cha-Pro-Nag(Z)

[0241] H-(R)Cha-Pro-Nag(Z) (See Example 20), 0.20 g (0.40 mmol), was mixed with 0.115 g (0.40 mmol) of benzyloxycarbonylmethyl bromoacetate, 55 mg of K₂CO₃ (0.40 mmol) and 5 ml of CH₃CN. The mixture was stirred at room temperature for 6 h. The solvent was evaporated and the crude product chromatographed (CH₂Cl₂/MeOH, 9/1) to give
 10 0.20 g (71%) of the desired compound after evaporation of the solvent.

(ii) HOOC-CH₂-OOC-CH₂-(R)Cha-Pro-Nag x HOAc

[0242] Prepared by using the deprotection procedure (a) on the product (i) above.

15 [0243] ¹H-NMR (500 MHz, MeOD): δ 0.85-1.1 (m, 2H), 1.1-1.6 (m, 8H), 1.6-2.15 (m, 10H) 1.99 (s, acetate), 2.23 (m, 1H), 3.1-3.4 (m, 4H), 3.45-3.65 (m, 4H), 3.7-3.9 (m, 3H), 4.34 (m, 1H), 4.48 (dd, 2H).

[0244] ¹³C-NMR (125 MHz, MeOD), guanidine: δ 158.8; carbonyl carbons: δ 176.1, 175.2, 174.9, 173.1.Example 27

20

H₂N-CO-CH₂-(R)Cha-Pro-Nag x HOAc[0245] Alkylation as in Example 4 using H-(R)Cha-Pro-Nag(Z) (See Example 20) and Cl-CH₂CONH₂, in the presence of a catalytic (10 mol%) amount of KI in the reaction, followed by deprotection procedure (a) gave the title compound.

25 [0246] ¹H-NMR (500 MHz, D₂O): δ 1.02 (m, 2H), 1.12-1.34 (m, 3H), 1.46 (m, 1H), 1.61-2.13 (m, 9H) 1.99 (s, acetate), 2.34 (m, 1H), 3.25 (t, 2H), 3.33 (t, 2H), 3.60-3.82 (m, 4H), 4.22 (t, 1H), 4.41 (dd, 1H).

[0247] ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.5; carbonyl carbons: δ 168.94, 169.40, 174.43.Example 28

30

HOOC-CH₂-NH-CO-CH₂-(R)Cha-Pro-Nag x 2 TFA[0248] Alkylation as in Example 4 using H-(R)Cha-Pro-Nag(Z) (See Example 20) and Br-CH₂CONHCH₂COOBn (See Prep. of starting materials) followed by deprotection procedure (a) gave the title compound.

35 [0249] ¹H-NMR (500 MHz, MeOD): δ 1.01 (m, 2H), 1.15-1.38 (m, 3H), 1.47 (m, 1H), 1.64-2.13 (m, 12H), 2.27 (m, 1H), 3.17-3.26 (m, 3H), 3.37 (m, 1H), 3.51 (m, 1H), 3.83 (m, 1H), 3.88 (s, 2H), 3.93-4.06 (m, 2H), 4.35-4.45 (m, 2H).

[0250] ¹³C-NMR (75 MHz, MeOD): guanidine: δ 158.71; carbonyl carbons: δ 166.94, 168.35, 172.44, 174.17.Example 29

40

(HOOC-CH₂)₂-(R)Cha-Pro-Nag x HOAc(i) (EtOOC-CH₂)₂-(R)Cha-Pro-NH-(CH₂)₃-NH₂ x HOAc

45 [0251] Alkylation as in Example 4 using H-(R)Cha-Pro-NH-(CH₂)₃-N₃ (See Example 22) and Br-CH₂COOEt (10 eq. was used to accomplish the dialkylation) followed by deprotection procedure (a) gave the title compound.

(ii) (EtOOC-CH₂)₂-(R)Cha-Pro-Nag x HOAc

50 [0252] The same procedure as described in Example 19 (iii) for Z-(R)Cha-Pro-Nag was used to accomplish the guanidination of the amine above. Purification of the compound was made with RPLC (CH₃CN/NH₄OAc (0.1M), 4:6)

(iii) (HOOC-CH₂)₂-(R)Cha-Pro-Nag x HOAc

55 [0253] The hydrolysis of the ester groups was made according to deprotection procedure (e) using a double amount of NaOH. The final compound was obtained pur after RPLC (CH₃CN/NH₄OAc (0.1M), 2:8), evaporation of the solvent and freeze drying (H₂O).

[0254] ¹H-NMR (300 MHz, D₂O): δ 0.92-1.49 (m, 6H), 1.60-2.54 (m, 10H) 2.05 (s, acetate), 3.25-3.50 (m, 4H), 3.65-

4.03 (m, 6H; thereof 3.95 (s, 4H)), 4.49 (m, 1H), 4.71 (m, 1H; partly hidden by the H-O-D peak).

[0255] ^{13}C -NMR (75 MHz, D_2O): guanidine: δ 157.64; carbonyl carbons: δ 168.62, 171.39, 174.30.

Example 30

HOOC-CH₂-(Me)(R)Cha-Pro-Nag x 2 TFA

(i) Me-(R)Cha-Pro-Nag(Z)

[0256] Prepared from Boc-(Me)(R)Cha-Pro-OSu and Boc-Nag(Z) in the same way as described for H-(R)Cha-Pro-Agm(Z) in Example 3.

(ii) HOOC-CH₂-(Me)(R)Cha-Pro-Nag x 2 TFA

[0257] Alkylation as in Example 4 using Me-(R)Cha-Pro-Nag(Z) and Br-CH₂COOBn followed by deprotection procedure (b) gave the title compound.

[0258] ^1H -NMR (500 MHz, D_2O): δ 0.8-1.06 (m, 2H), 1.08-1.27 (m, 4H), 1.55-2.10 (m, 12H), 2.30 (m, 1H), 3.04 (s, 3H), 3.14-3.33 (m, 4H), 3.63 (m, 1H), 3.81 (m, 1H), 4.13 (apparent bs, 2H), 4.38 (br.dd, 1H), 4.56 (bt, 1H).

[0259] ^{13}C -NMR (125.76 MHz, D_2O): guanidine: δ 157.40; carbonyl carbons: δ 174.05, 168.83, 167.44.

Example 31

HOOC-CH₂-(ⁿBu)(R)Cha-Pro-Nag x 2 TFA

[0260] Alkylation as in Example 4 using ⁿBu-(R)Cha-Pro-Nag(Z) (See Example 20) and Br-CH₂COOBn followed by deprotection procedure (a) gave the title compound.

[0261] ^1H -NMR (500 MHz, D_2O): δ 0.78-0.88 (m, 3H), 0.88-1.02 (m, 2H), 1.02-1.23 (m, 4H), 1.23-1.38 (m, 2H), 1.45-1.84 (m, 11H), 1.84-2.10 (m, 3H), 2.24 (m, 1H), 3.05-3.18 (m, 3H), 3.18-3.38 (m, 3H), 3.57 (m, 1H), 3.77 (m, 1H), 4.05-4.25 (m, 2H), 4.32 (m, 1H), 4.50 (m, 1H).

[0262] ^{13}C -NMR (125 MHz, D_2O): guanidine: δ 159.17; carbonyl carbons: δ 175.66, 171.13, 169.31.

Example 32

HOOC-(R,S)CH(Me)-(R)Cha-Pro-Nag x HOAc

[0263] Alkylation as in Example 4 using H-(R)Cha-Pro-Nag(Z) (See Example 20) and Br-CH(Me)COOBn followed by deprotection procedure (a) gave the title compound as a mixture of two diastereomers.

Example 33

HOOC-(RorS)CH(Me)-(R)Cha-Pro-Nag/a x HOAc

[0264] Obtained by separating the diastereomers formed in Example 32 using RPLC ($\text{CH}_3\text{CN}/\text{NH}_4\text{OAc}$ (0.1M), 1/4) followed by evaporation of the solvent. This diastereomer came out first of the two from the column.

[0265] ^1H -NMR (300 MHz, D_2O , 2 rotamers ca: 9:1 ratio): δ 0.78 (m, minor rotamer), 1.07 (m, 2H), 1.17-1.42 (m, 3H), 1.48-1.64 (m, 4H; thereof 1.56 (d, 3H)), 1.64-1.95 (m, 9H), 1.95-2.20 (m, 3H) 2.00 (s, acetate), 2.37 (m, 1H), 3.28 (t, 2H), 3.38 (t, 2H), 3.53 (m, minor rotamer), 3.63 (m, 2H), 3.77 (m, 1H), 4.24 (d, minor rotamer), 4.35-4.50 (m, 2H), 4.60 (d, minor rotamer).

Example 34

HOOC-(RorS)CH(Me)-(R)Cha-Pro-Nag/b x HOAc

[0266] The title compound was obtained by using the same procedure as described in Example 33 on the compound formed in Example 32. This diastereomer came out after the first one from the column.

[0267] ^1H -NMR (300 MHz, D_2O , 2 rotamers ca: 9:1 ratio): δ 0.95 (m, minor rotamer), 1.12 (m, 2H), 1.22-1.40 (m, 3H), 1.40-1.67 (m, 4H; thereof 1.60 (d, 3H)), 1.67-2.00 (m, 9H), 2.00-2.25 (m, 3H) 2.03 (s, acetate), 2.40 (m, 1H), 3.25-3.48 (m, 4H), 3.66-3.84 (m, 2H), 3.93 (m, 1H), 4.38 (m, 1H), 4.50 (m, 1H), 4.93 (m, minor rotamer).

[0268] ^{13}C -NMR (75.5 MHz, D_2O): δ 157.42; carbonyl carbons: δ 168.05, 171.99, 174.04.

Example 35

5 EtOOC-(R,S)CH(Me)-(R)Cha-Pro-Nag x 2 TFA

[0269] Prepared in the same way as described for Example 22 using EtOOC-CH(Me)-Br instead of Br-CH₂-COOEt in the alkylation.

[0270] ^1H -NMR (500 MHz, MeOD, 2 diastereomers ca: 2.5:1 ratio and 4 rotamers): δ 0.88-2.43 (m, 25H), 3.1-4.55 (m, 11H).

[0271] ^{13}C -NMR (75 MHz, MeOD): guanidine: δ 158.65; carbonyl carbons: δ 174.33, 170.66, 168.20.

Example 36

15 HOOC-(RorS)CH(nPr)-(R)Cha-Pro-Nag/a x HOAc

[0272] Alkylation as in Example 4 using H-(R)Cha-Pro-Nag(Z) (See Example 20) and Br-CH(^nPr)COOEt and deprotection procedure (e) followed by deprotection procedure (b) gave HOOC-(R,S)CH(^nPr)-(R)Cha-Pro-Agm. The title compound was obtained by separating the diastereomers (this diastereomer came out first of the two from the column) by RPLC ($\text{CH}_3\text{CN}/\text{NH}_4\text{OAc}$ (0.1 M), 1/4) and freeze drying (H_2O) after evaporation of the solvent.

[0273] ^1H -NMR (500 MHz, MeOD): δ 0.85-1.05 (m, 5H; thereof 0.95 (t, 3H)), 1.1-2.05 (m, 20H) 1.95 (s, acetate), 2.18 (m, 1H), 3.15-3.3 (m, 4H), 3.35 (m, 1H), 3.46 (m, 1H), 3.85 (m, 1H), 4.04 (m, 1H), 4.38 (dd, 1H).

[0274] ^{13}C -NMR (125 MHz, MeOD): guanidine: δ 158.73; carbonyl carbons: δ 171.63, 174.43 and 176.78.

25 Example 37

HOOC-(R)CH(CH₂-OH)-(R)Cha-Pro-Nag x 2 TFA

[0275] Alkylation as in Example 4 using H-(R)Cha-Pro-Nag(Z) (See Example 20) and Br-(S)CH(CH₂-OBn)-COOBn followed by deprotection procedure (a) gave the title compound.

[0276] ^1H -NMR (300 MHz, D_2O): δ 0.75-1.56 (m, 7H), 1.56-2.30 (m, 11H), 2.40 (m, 1H), 3.15-3.55 (m, 4H), 3.55-4.60 (m, 7H).

Example 38

35 HOOC-(R,S)CH(Ph)-(R)Cha-Pro-Nag x 2 TFA

[0277] Alkylation as in Example 4 using H-(R)Cha-Pro-Nag(Z) (See Example 20) and Br-CH(Ph)COO^tBu and deprotection procedure (a) followed by (f) gave the title compound as a mixture of two diastereomers.

[0278] ^1H -NMR (300 MHz, MeOD): δ 0.8-1.1 (m, 2H), 1.1-2.18 (m, 16H), 2.26 (m, 1H), 3.04-3.35 (m, 5H), 3.45 (m, 1H), 3.7 (m, 1H), 4.35 (m, 1H), 4.85 (s, 1H, one isomer), 5.05 (s, 1H, the other isomer), 7.4-7.6 (m, 5H), 7.75 (bt, 1H).

[0279] ^{13}C -NMR (75 MHz, D_2O): guanidine: δ 158.68; carbonyl carbons: δ 174.39, 174.15 and 170.5, 170.06 and 168.32, 167.78.

45 Example 39

HOOC-(S)CH(CH₂CH₂Ph)-(R)Cha-Pro-Nag x HOAc

[0280] Alkylation as in Example 21 using H-(R)Cha-Pro-Nag(Z) (See Example 20) and TfO-(R)CH(CH₂CH₂Ph)-COOEt and deprotection procedure (e) followed by (a) gave the title compound.

[0281] ^1H -NMR (300 MHz, MeOD): δ 0.77-1.05 (m, 2H), 1.05-1.35 (m, 5H), 1.35-2.16 (m, 14H) 1.88 (s, acetate), 2.71 (t, 2H), 3.07-3.53 (m, 7H), 3.73 (m, 1H), 4.32 (m, 1H), 7.03-7.25 (m, 5H).

[0282] ^{13}C -NMR (75 MHz, MeOD): guanidine: δ 158.71; carbonyl carbons: δ 174.15, 177.31, 182.61.

55

Example 40**HOOC-(R)CH(CH₂CH₂Ph)-(R)Cha-Pro-Nag x HOAc**

5 [0283] Alkylation as in Example 4 using H-(R)Cha-Pro-Nag(Z) (See Example 20) and Br-CH(CH₂CH₂Ph)COOEt followed by deprotection procedure (a) and (e) gave HOOC-(R,S)CH(CH₂-CH₂-Ph)-(R)Cha-Pro-Nag. The title compound was obtained, by separating the two diastereomers with RPLC (CH₃CN/NH₄OAc (0.1 M), 2/3) and freeze drying (H₂O) after evaporation of the solvent.

10 [0284] ¹H-NMR (300 MHz, MeOD): δ 0.97 (m, 2H), 1.10-1.41 (m, 3H), 1.43-2.30 (m, 16H) 1.96 (s, acetate), 2.70 (m, 2H), 3.06-3.26 (m, 3H), 3.28-3.66 (m, 3H), 3.84 (m, 1H), 4.14 (bt, 1H), 4.39 (dd, 1H), 7.11-7.28 (m, 5H).

[0285] ¹³C-NMR (75 MHz, MeOD): guanidine: δ 158.66

Example 4115 **HOOC-CH₂-CH₂-(R)Cha-Pro-Nag x HOAc**

(i) EtOOC-CH₂-CH₂-(R)Cha-Pro-NH-(CH₂)₃-NH₂

20 [0286] Alkylation as described in Example 15 using H-(R)Cha-Pro-NH-(CH₂)₃-N₃ instead of H-(R)Cha-Pro-Agm(Z) followed by deprotection procedure (a) gave the title compound.

(ii) Et-OOC-CH₂-CH₂-(R)Cha-Pro-Nag x HOAc

25 [0287] Guanidination of the amine above in the same way as described in Example 19 for Z-(R)Cha-Pro-Nag gave the title compound (ii).

(iii) HOOC-CH₂-CH₂-(R)Cha-Pro-Nag x HOAc

[0288] Prepared by using the deprotection procedure (e) on the product (ii) above.

30 [0289] ¹H-NMR (500 MHz, D₂O): δ 1.12 (m, 2H), 1.22-1.48 (m, 3H), 1.54 (bs, 1H), 1.70-2.37 (m, 12H) 2.14 (s, acetate), 2.53 (m, 1H), 2.70 (bs, 2H), 3.15 (t, 1H), 3.25-3.55 (m, 5H), 3.75 (m, 1H), 3.93 (m, 1H), 4.43 (t, 1H), 4.52 (m, 1H).

Example 4235 **EtOOC-CH₂-CH₂-(R)Cha-Pro-Nag x HOAc**

[0290] Prepared according to Example 41 (ii).

40 [0291] ¹H-NMR (500 MHz, D₂O): δ 0.97 (m, 2H), 1.11-1.39 (m, 7H; thereof 1.30 (t, 3H)), 1.50 (t, 2H), 1.62-1.76 (m, 5H), 1.76-2.14 (m, 5H) 1.93 (s, acetate), 2.29 (m, 1H), 2.62 (t, 2H), 2.77-2.94 (m, 2H), 3.23 (t, 2H), 3.32 (t, 2H), 3.60-3.87 (m, 3H), 4.20 (q, 2H), 4.36 (dd, 1H).

[0292] ¹³C-NMR (125 MHz, D₂O): guanidine: δ 157.39; carbonyl carbons: δ 182.05, 175.13, 175.02.

Example 4345 **HOOC-(CH₂)₃-(R)Cha-Pro-Nag x 2 HOAc**

(i) Et-OOC-CH=CH-CH₂-(R)Cha-Pro-Nag(Z)

50 [0293] H-(R)Cha-Pro-Nag(Z) (See Example 20) (1 eq) and ethyl 3-bromocrotonate (1.1 eq) were dissolved in acetonitrile (15 ml/mmol). Potassium carbonate was added and the reaction mixture stirred at room temperature for 2 h. After filtration and evaporation of the solvent, the crude product was purified by flash chromatography (CH₂Cl₂/MeOH). Finally the solvent was evaporated and product dried in vacuo.

55 [0294] ¹H-NMR (500 MHz, CDCl₃): δ 0.73-1.0 (m, 2H), 1.0-1.4 (m, 8H; thereof 1.33 (t, 3H)), 1.43-2.15 (m, 12H), 2.96 (bs, 1H), 3.12 (dd, 1H), 3.16-3.48 (m, 6H), 3.56 (m, 1H), 4.15 (q, 2H), 4.35 (bs, 1H), 5.03 (s, 1H), 6.0 (d, 1H), 6.85 (dt, 1H), 7.05 (bs, 1H), 7.17-7.37 (m, 5H), 7.5 (bs, 1H).

(ii) EtOOC-(CH₂)₃-(R)Cha-Pro-Nag x 2 TFA

[0295] Prepared by using the deprotection procedure (a) on the product (i) above.

5 (iii) HOOC-(CH₂)₃-(R)Cha-Pro-Nag x 2 HOAc

[0296] Prepared by using the deprotection procedure (e) on the product (ii) above.

[0297] ¹H-NMR (500 MHz, D₂O): δ 1.02 (bs, 2H), 1.08-1.32 (m, 3H), 1.42 (bs, 1H), 1.55-2.15 (m, 14H) 1.92 (s, acetate), 2.33 (bs, 3H), 3.00 (bs, 1H), 3.07 (bs, 1H), 3.18-3.40 (m, 4H), 3.62 (bs, 1H), 3.82 (bs, 1H), 4.33 (bs, 1H), 4.40 (bs, 1H).

[0298] ¹³C-NMR (125 MHz, D₂O): guanidine: δ 157.42; carbonyl carbons: δ 181.87, 174.34, 168.64.

Example 44

15 EtOOC-(CH₂)₃-(R)Cha-Pro-Nag x 2 TFA

[0299] Prepared according to Example 43 (ii).

[0300] ¹H-NMR (300 MHz, MeOD/D₂O): δ 0.63-1.30 (m, 9H; thereof 1.02 (t, 3H)), 1.30-1.97 (m, 14H), 2.06 (bs, 1H), 2.28 (m, 2H), 2.72-3.20 (m, 6H), 3.36 (m, 1H), 3.60 (m, 1H), 3.94 (m, 2H), 4.06 (m, 1H), 4.17 (m, 1H).

20 [0301] ¹³C-NMR (75 MHz, MeOD/D₂O): guanidine: δ 158.10; carbonyl carbons: δ 175.40, 174.23, 168.54.

Example 45

HOOC-CO-(R)Cha-Pro-Nag x HOAc

25

(i) EtOOC-CO-(R)Cha-Pro-Nag(Z)

[0302] H-(R)Cha-Pro-Nag(Z), 0.50 g (0.97 mmol) was dissolved in 0.54 ml triethyl amine and 8 ml of CH₂Cl₂. Ethyl oxalylchloride, 0.146 g (1.07 mmol) dissolved in 2 ml of CH₂Cl₂ was added while the temperature rose from 22-28°C and the reaction was stirred at room temperature for 2 h. The organic phase was washed twice with water, dried (Na₂SO₄) and flash chromatographed (EtOAc/EtOH(99%), 9/1) to give 92 mg (15 %) of the title compound.

(ii) HOOC-CO-(R)Cha-Pro-Nag x HOAc

35 [0303] Using the deprotection procedure (b) followed by (e) gave the title compound.

[0304] ¹H-NMR (300 MHz, MeOD): δ 0.88-1.14 (m, 2H), 1.15-1.5 (m, 4H), 1.5-2.3 (m, 13H) 1.9 (s, acetate), 3.1-3.43 (m, 4H), 3.6 (m, 1H), 4.05 (m, 1H), 4.43 (dd, 1H), 4.5 (m, 1H).

[0305] ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.57; carbonyl carbons: δ 165.94, 173.95, 174.85 and 181.22.

40 Example 46

MeOOC-CO-(R)Cha-Pro-Nag x HOAc

(i) MeOOC-CO-(R)Cha-Pro-Nag(Z)

45

[0306] The methyl ester was obtained by transesterification of EtOOC-CO-(R)Cha-Pro-Nag(Z) (See Example 45) on the column during flash chromatography when EtOAc/MeOH(9:1) was used as eluent. Yield 55%.

(ii) MeOOC-CO-(R)Cha-Pro-Nag x HOAc

50

[0307] Prepared by using the deprotection procedure (b) on the product (i) above.

[0308] ¹H-NMR (300 MHz, MeOD): δ 0.9-1.1 (m, 2H), 1.1-2.3 (m, 17H) 1.9 (s, acetate), 3.12-3.4 (m, 4H), 3.52-3.67 (m, 2H), 3.9 (s, 3H), 4.35 (m, 1H), 4.65 (m, 1H).

[0309] ¹³C-NMR (75MHz, D₂O): guanidine: δ 157.52; carbonyl carbons: δ 159.11, 161.20 173.17 and 174.90.

55

Example 47**(R,S)Bla-(R)Cha-Pro-Nag x 2 TFA**

[0310] Alkylation as in Example 4 using H-(R)Cha-Pro-Nag(Z) (See Example 20) and α -bromo butyrolacton followed by deprotection procedure (a) gave the title compound as a mixture of two diastereomers.

[0311] $^1\text{H-NMR}$ (300 MHz, D_2O , mixture of diastereomers): δ 1.0-1.43 (m, 5H), 1.45-1.60 (br.s, 1H), 1.64-2.28 (m, 12H), 2.31-2.50 (m, 1H), 2.80-2.98 (m, 1H), 3.23-3.46 (m, 4H), 3.66-3.79 (m, 1H), 3.82-3.96 (m, 1H), 4.33-5.08 (m, 5H, partially hidden by the H-O-D signal).

Example 48 **$\text{HOOC-(R,S)CH(CH}_2\text{COOH)-(R)Cha-Pro-Nag x HOAc}$**

(i) $\text{BnOOC-(R,S)CH(CH}_2\text{COOBn)-(R)Cha-Pro-Nag(Z)}$

[0312] H-(R)Cha-Pro-Nag(Z) (See Example 20), 0.21 g (0.42 mmol), and 0.12 g (0.42 mmol) of dibenzyl maleate were dissolved in 10 ml of CH_3CN . The mixture was refluxed over night, evaporated and flash chromatographed ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 94/6). Evaporation of the solvent gave the desired compound in 22 % yield.

(ii) $\text{HOOC-(R,S)CH(CH}_2\text{COOH)-(R)Cha-Pro-Nag x HOAc}$

[0313] Prepared by using the deprotection procedure (a) on the product (i) above.

[0314] $^1\text{H-NMR}$ (500 MHz, MeOD): δ 0.9-2.4 (m, 19H), 2.00 (s, acetate) 2.7-3.0 (m, 2H), 3.1-3.6 (m, 5H), 3.75-3.9 (m, 2H), 4.2-4.5 (m, 2H).

Example 49 **$\text{MeOOC-(R,S)CH(CH}_2\text{COOMe)-(R)Cha-Pro-Nag x HOAc}$**

(i) $\text{MeOOC-(R,S)CH(CH}_2\text{COOMe)-(R)Cha-Pro-Nag(Z)}$

[0315] H-(R)Cha-Pro-Nag(Z) (See Example 20), 0.21 g (0.42 mmol), and 0.24 g (1.7 mmol) of dimethyl maleate were dissolved in 15 ml of MeOH. The mixture was refluxed over night, evaporated and flash chromatographed ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9/1). Evaporation of the solvent gave the desired compound in 45% yield.

(ii) $\text{MeOOC-(R,S)CH(CH}_2\text{COOMe)-(R)Cha-Pro-Nag x HOAc}$

[0316] Prepared by using the deprotection procedure (c) on the product (i) above.

[0317] $^1\text{H-NMR}$ (500 MHz, MeOD): δ 0.85-1.1 (m, 2H), 1.15-2.3 (m, 17H), 1.91 (s, acetate), 2.6-2.8 (m, 2H), 3.1-3.5 (m, 5H), 3.5-3.8 (m, 10H; thereof 4 singlets 3.66, 3.68, 3.71, 3.73), 4.29 (m, 1H).

Example 50 **$\text{HOOC-Ph-4-CH}_2\text{-(R)Cha-Pro-Nag x 2 TFA}$**

(i) $^t\text{BuOOC-Ph-4-CH}_2\text{-(R)Cha-Pro-NH-(CH}_2\text{)}_3\text{-N}_3$

[0318] H-(R)Cha-Pro-NH-(CH_2)₃-N₃ (See Example 22), 0.39 g (1.1 mmol) and 0.33 g (1.2 mmol) of tertiarybutyl p-bromomethylbenzoate were dissolved in 10 ml of CH_3CN and 0.19 g (2.4 mmol) of K_2CO_3 was added. The mixture was refluxed over night and evaporated. The crude product was flash chromatographed ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 92:5) to give 0.50 g (84%) of the title compound.

(ii) $^t\text{BuOOC-Ph-4-CH}_2\text{-(R)Cha-Pro-NH-(CH}_2\text{)}_3\text{-NH}_2$

[0319] To a solution of 0.60 g (1.8 mmol) of bis-phenylthio stannane, 0.20 g (1.8 mmol) of thiophenol and 0.18 g (1.8 mmol) of triethyl amine in 50 ml of CH_2Cl_2 at 0°C was added 0.50 g (0.92 mmol) of $^t\text{BuOOC-Ph-4-CH}_2\text{-(R)Cha-Pro-NH-(CH}_2\text{)}_3\text{-N}_3$. The mixture was stirred at 0°C for 30 min. and at room temperature for 4 h. It was then diluted with CH_2Cl_2

and washed with aqueous sodium bicarbonate and subsequently 3 times with 2% H₂O₂. The organic layer was extracted with dilute HCl. The combined acidic water phase was washed with EtOAc and subsequently made alkaline with NaOH(aq). The aqueous layer was extracted twice with ethyl acetate. The combined organic layer was dried (Na₂SO₄) and evaporated. Flash chromatography (CH₂Cl₂/MeOH(NH₃-saturated), 8:2) gave 0.12g (26%) of the title compound.

(iii) HOOC-Ph-4-CH₂-(R)Cha-Pro-Nag x 2 TFA

[0320] Guanidination of the amine above in the same way as described in Example 19 for Z-(R)Cha-Pro-Nag followed by deprotection procedure (f) gave the title compound.

[0321] ¹H-NMR (500 MHz, MeOD): δ 0.9-1.5 (m, 7H), 1.4-1.9 (m, 9H), 1.95-2.1 (m, 2H), 2.16 (m, 1H), 2.32 (m, 1H), 3.2-3.3 (m, 3H), 3.41 (pentet, 1H), 3.53 (m, 1H), 3.77 (m, 1H), 4.2-4.3 (m, 3H), 4.42 (dd, 1H), 7.15 (d, 2H), 8.10 (d, 2H).

[0322] ¹³C-NMR (125 MHz, MeOD), guanidine: δ 160.8; carbonyl carbons: δ 174.3, 168.9, 168.2.

Example 51

(HO)₂P(O)-CH₂-(R)Cha-Pro-Nag x HOAc

[0323] (EtO)₂PO-CH₂-(R)Cha-Pro-Nag(Z) (See Example 53), 60 mg (92 mmol), was dissolved in 3 ml of CH₃CN. Trimethylsilyl bromide, 0.15 ml, was added and the mixture was left at room temperature for 21 h. After evaporation and NMR analysis it was found that some ester remained. The crude material was again dissolved in 3 ml of CH₃CN and 0.15 ml of trimethylsilyl bromide was added. After 5 h the mixture was evaporated and purified with RPLC (CH₃CN/NH₄OAc (0.1M), 30:70) to give the final compound after filtration, evaporation and freeze drying in 8 % yield.

[0324] ¹H-NMR (500 MHz, MeOD): δ 0.8-1.1 (m, 2H), 1.15-1.4 (m, 4H), 1.5-1.9 (m, 10H), 1.9-2.1 (m, 4H) 1.96 (s, acetate), 2.20 (m, 1H), 2.95 (m, 1H), 3.0-3.2 (m, 3H), 3.4-3.5 (m, 2H), 4.09 (m, 1H), 4.39 (bd, 1H), 4.59 (m, 1H).

[0325] ¹³C-NMR (125 MHz, MeOD): guanidine: δ 158.6; carbonyl carbons: δ 174.2, 170.6

Example 52

EtO(HO)P(O)-CH₂-(R)Cha-Pro-Nag x 2 HOAc

(i) (EtO)(HO)PO-CH₂-(R)Cha-Pro-Nag(Z).

[0326] (EtO)₂PO-CH₂-(R)Cha-Pro-Nag(Z) (See Example 53), 50 mg (77 mmol) was dissolved in 2 ml of EtOH and 2 ml 2 M NaOH. The mixture was stirred over night and evaporated. The crude material was purified with RPLC (CH₃CN/NH₄OAc (0.1M), 30:70) to give the title compound after filtration and evaporation of the solvent.

(ii) (EtO)(HO)PO-CH₂-(R)Cha-Pro-Nag x 2 HOAc

[0327] Prepared by using deprotection procedure (c) on the product (i) above.

[0328] ¹H-NMR (500 MHz, MeOD): δ 0.9-1.1 (m, 2H), 1.15-1.35 (m, 6H; thereof 1.28 (t, 3H)), 1.35-1.5 (m, 2H), 1.5-1.6 (m, 1H), 1.65-1.8 (m, 6H), 1.9-2.1 (m, 3H) 1.95 (s, acetate), 2.19 (m, 1H), 2.8-3.0 (m, 2H), 3.1-3.25 (m, 2H), 3.27 (m, 1H), 3.36 (m, 1H), 3.48 (m, 1H), 3.9-4.05 (m, 4H), 4.36 (bd, 1H).

[0329] ¹³C-NMR (125 MHz, MeOD): guanidine: δ 158.6; carbonyl carbons: δ 175.0, 174.7

Example 53

(EtO)₂P(O)-CH₂-(R)Cha-Pro-Nag x HOAc

(i) (EtO)₂PO-CH₂-(R)Cha-Pro-Nag(Z).

[0330] H-(R)Cha-Pro-Nag(Z) (See Example 20), 0.2 g (0.40 mmol), was dissolved in 5 ml of THF and 0.11 g (0.80 mmol) of potassium carbonate and 0.12 g (0.40 mmol) diethyl triflylmethylphosphonate were added. The mixture was stirred at room temperature for 2 h. The reaction was worked up with water and extraction of the aqueous layer three times with EtOAc. The combined organic layer was dried (Na₂SO₄) and evaporated to yield 0.14 g (53%) of the title compound.

(ii) $(\text{EtO})_2\text{PO-CH}_2\text{-(R)Cha-Pro-Nag x HOAc}$

[0331] Prepared by using the deprotection procedure (c) on the product (i) above.

[0332] $^1\text{H-NMR}$ (500 MHz, MeOD): δ 0.85-1.05 (m, 2H), 1.15-1.3 (m, 5H), 1.34 (t, 6H), 1.5-1.85 (m, 8H), 1.9-2.05 (m, 3H), 1.91 (s, acetate), 2.10 (m, 1H), 2.22 (m, 1H), 2.90 (dd, 1H), 3.05 (dd, 1H), 3.1-3.3 (m, 3H), 3.42 (m, 1H), 3.53 (m, 1H), 3.71 (dd, 1H), 3.82 (m, 1H), 4.1-4.2 (m, 4H), 4.28 (dd, 1H).

[0333] $^{13}\text{C-NMR}$ (125 MHz, MeOD), guanidine: δ 158.7; carbonyl carbons: δ 176.1, 175.1.

Example 54

HOOC-CH₂-(R)Cha-Pro-Mag x HOAc

(i) H-(R) Cha-Pro-NH-(CH₂)₂-NH(Z)

[0334] Prepared from Boc-(R)Cha-Pro-OSu and H₂N-(CH₂)₂-NH(Z) in the same way as described for H-(R)Cha-Pro-Agm(Z) in Example 3.

(ii) EtOOC-CH₂-(R)Cha-Pro-NH-(CH₂)₂-NH₂ x HOAc

[0335] Alkylation as in Example 4 followed by deprotection procedure (a) gave the title compound.

(iii) HOOC-CH₂-(R)Cha-Pro-Mag x HOAc

[0336] Guanidation of the amine above in the same way as described in Example 19 for Z-(R)Cha-Pro-Nag followed by deprotection procedure (e) gave the title compound after purification by RPLC (CH₃CN/NH₄OAc (0.1M), 1/4) and freeze drying (H₂O).

[0337] $^1\text{H-NMR}$ (300 MHz, D₂O): δ 0.90-1.18 (m, 2H), 1.19-1.43 (m, 3H), 1.52 (m, 1H), 1.63-2.20 (m, 10H), 2.06 (s, acetate), 2.31-2.47 (m, 1H), 3.44 (m, 2H), 3.50 (m, 2H), 3.60-3.75 (m, 3H), 3.85 (m, 1H), 4.46-4.54 (m, 2H).

[0338] $^{13}\text{C-NMR}$ (75 MHz, D₂O): guanidine: δ 157.82; carbonyl carbons: δ 168.80, 171.41, 174.81.

Example 55

H-(R,S)Pro(3-Ph)-Pro-Agm x 2 TFA

[0339] Prepared from Boc-(R,S)Pro(3-Ph)-Pro-OSu (See Prep. of starting materials) in the same way as described for H-(R)Cha-Pro-Agm(Z) in Example 3 followed by deprotection procedure (b).

[0340] $^1\text{H-NMR}$ (500 MHz, D₂O, mixture of two diastereomers with unknown relative stereochemistry): δ 1.0-1.8 (m, 7H), 2.0-2.5 (m, 3H), 2.8-4.3 (m, 10H), 4.56 (d, 1H, major), 4.90 (d, 1H, major), 7.2-7.5 (m, 5H).

[0341] $^{13}\text{C-NMR}$ (125.76 MHz, D₂O): guanidine: δ 157.36 (minor and major); carbonyl carbons: δ 174.1 (major), 174.0 (minor), 167.8 (major), 167.0 (minor).

Example 56

H-(R,S)Pro(3-(trans)Ch)-Pro-Agm x 2 TFA

[0342] Prepared from Boc-(R,S)Pro(3-(trans)Ch)-Pro-OSu (See Prep. of starting materials) in the same way as described for H-(R)Cha-Pro-Agm(Z) in Example 3 followed by deprotection procedure (b).

[0343] $^1\text{H-NMR}$ (500 MHz, D₂O, mixture of two diastereomers, ratio 1.8/1): δ 0.95-1.32 (m, 5H), 1.35-1.46 (m, 1H), 1.50-1.92 (m, 10H), 1.93-2.15 (m, 4H), 2.23-2.43 (m, 2H), 3.15-3.30 (m, 4H), 3.35-3.50 (m, 2H), 3.57-3.68 (m, 1H), 3.74-3.82 (m, 1H), 4.34-4.41 (m, 1H), 4.51 (d, 1H, minor), 4.48 (d, 1H, major).

[0344] $^{13}\text{C-NMR}$ (125.76 MHz, D₂O): guanidine: δ 157.36 (minor and major); carbonyl carbons: δ 174.34 (major), 174.07 (minor), 168.94 (minor and major).

Example 57**HOOC-CH₂-(R,S)Pro(3-(trans)Ph)-Pro-Agm x 2 TFA**

5 (i) H-(R,S)Pro(3-(trans)Ph)-Pro-Agm(Z)

[0345] Prepared from Boc-(R,S)Pro(3-(trans)Ph)-Pro-OSu (See Prep. of starting materials) in the same way as described for H-(R)Cha-Pro-Agm(Z) in Example 3.

10 (ii) HOOC-CH₂-(R,S)Pro(3-(trans)Ph)-Pro-Agm x 2 TFA

[0346] Alkylation as in Example 4 using Br-CH₂COOBn followed by deprotection procedure (b) gave the title compound as a mixture of two diastereomers.

[0347] ¹H-NMR (500 MHz, MeOD, mixture of two diastereomers, ratio ca: 1.1/1): δ 1.40-1.80 (m, 6H), 1.85-2.05 (m, 1H), 2.10-2.30 (m, 1H), 2.50-2.65 (m, 2H), 3.10-3.40 (m, 6H), 3.50-3.70 (m, 2H), 3.9-4.40 (m, 4H), 4.63 (d, 1H, major), 4.67 (d, 1H, minor), 7.30-7.60 (m, 5H).

[0348] ¹³C-NMR (125.76 MHz, D₂O): guanidine: δ 157.52 (both isomers); carbonyl carbons: δ 173.87, 173.73, 169.12, 168.94, 167.21, 167.00.

20 Example 58

HOOC-CH₂-(R,S)Pro(3-(trans)Ph)-Pro-Nag x 2 TFA

25 (i) H-(R,S)Pro(3-(trans)Ph)-Pro-Nag(Z)

[0349] Prepared from Boc-(R,S)Pro(3-(trans)Ph)-Pro-OSu (See Prep. of starting materials) and Boc-Nag(Z) in the same way as described for H-(R)Cha-Pro-Agm(Z) in Example 3.

30 (ii) HOOC-CH₂-(R,S)Pro(3-(trans)Ph)-Pro-Nag x 2 TFA

[0350] Alkylation as in Example 4 using Br-CH₂COOBn followed by deprotection procedure (b) gave the title compound as a mixture of two diastereomers.

[0351] ¹H-NMR (500 MHz, MeOD, mixture of two diastereomers, ratio ca: 1.5/1): δ 1.40-1.85 (m, 4H), 1.90-2.00 (m, 1H), 2.10-2.38 (m, 1H), 2.45-2.70 (m, 2H), 3.08-3.46 (m, 6H), 3.57-3.70 (m, 2H), 3.90-4.0 (m, 1H), 4.32-4.40 (m, 1H), 4.04 and 4.29 (AB-quartet, 2H, major), 4.16 and 4.37 (AB-quartet, 2H, minor), 4.60 (d, 1H, major), 4.64 (d, 1H, minor), 7.3-7.6 (m, 5H).

[0352] ¹³C-NMR (125.76 MHz, D₂O): guanidine: δ 157.48 (both isomers); carbonyl carbons: δ 173.90, 173.71, 169.01, 168.94, 167.07 (both isomers).

40 Example 59

HOOC-CH₂-(R)Cha-Pic-Agm x 2 TFA

45 (i) H-(R)Cha-Pic-Agm(Z)

[0353] Prepared from Boc-(R)Cha-Pic-OSu (See Prep. of starting materials) in the same way as described for H-(R)Cha-Pro-Agm(Z) in Example 3.

50 (ii) HOOC-CH₂-(R)Cha-Pic-Agm x 2 TFA

[0354] Alkylation as in Example 4 using Br-CH₂COOBn followed by deprotection procedure (a) gave the title compound.

[0355] ¹H-NMR (300 MHz, MeOD): δ 1.02 (m, 2H), 1.13-2.00 (m, 20H), 2.24 (bd, 1H), 3.12-3.45 (m, 5H), 3.71 (bd, 1H), 3.87 (s, 2H), 4.65 (bt, 1H), 5.06 (m, 1H).

55 [0356] ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.47; carbonyl carbons: δ 169.42, 170.03, 172.71.

Example 60**HOOC-CH₂-(Me)(R)Cha-(R,S)Pic-Agm x HOAc**

(i) Me-(R)Cha-(R,S)Pic-Agm(Z)

[0357] Prepared from Boc-(Me)(R)Cha-Pic-OSu in the same way as described for H-(R)Cha-Pro-Agm(Z) in Example 3.(ii) HOOC-CH₂-(Me)(R)Cha-(R,S)Pic-Agm x HOAc**[0358]** Alkylation as in Example 4 using Br-CH₂COOBn followed by deprotection procedure (b) gave the title compound.**[0359]** Comment: An epimerization of Pic occurred somewhere during the synthesis.**[0360]** The ¹H-NMR spectrum is complex consisting of two diastereomers ca: 1:1 ratio and rotamers thereof.**[0361]** ¹H-NMR (500 MHz, MeOD): δ 0.75-2.15 (several m, 20H) 1.95 (bs, acetate), 2.2-2.7 (6H, two distinct sets of signals are observed in the ratio of ca: 1:1; thereof 2.35 and 2.55 (s, 3H)), 3.0-3.5 (m, 6H), 3.9-4.17 (m, 2H; thereof 4.14 (dd)), 4.4-4.5 (m, 1H), 4.97-5.15 (two bdd, 1H).**[0362]** ¹³C-NMR (75MHz, D₂O): guanidine: δ 157.50; carbonyl carbons: δ 169.65, 170.01, 170.54, 172.67, 172.89.Example 61**HOOC-(R,S)CH(Me)-(R)Cha-Pic-Agm x TFA****[0363]** Alkylation as in Example 4 using H-(R)Cha-Pic-Agm(Z) (See Example 59) and Br-CH(Me)COOBn followed by deprotection procedure (a) gave the title compound as a mixture of two diastereomers.Example 62**HOOC-(RorS)CH(Me)-(R)Cha-Pic-Agm/a x 2 TFA****[0364]** Obtained by separating the diastereomers formed in Example 61 using RPLC (CH₂CN/NH₄OAc (0.1M), 1/3) followed by evaporation of the solvent and freeze-drying from H₂O/TFA. This diastereomer came out first of the two from the column.**[0365]** ¹H-NMR (300 MHz, D₂O, 2 rotamers ca: 5:1 ratio): δ 0.70 (m, minor rotamer), 0.75-1.0 (m, 2H), 1.0-1.28 (m, 3H), 1.28-1.83 (m, 20H; thereof 1.57 (d, 3H)), 2.14 (bd, 1H), 2.92 (t, minor rotamer), 3.03-3.32 (m, 5H), 3.59 (bd, 1H), 3.85 (q, minor rotamer), 3.98 (q, 1H), 4.30-4.50 (m, minor rotamer), 4.54 (m, 1H), 4.95 (s, 1H).**[0366]** ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.39; carbonyl carbons: δ 172.26 (2 carbons), 169.92.Example 63**HOOC-(RorS)CH(Me)-(R)Cha-Pic-Agm/b x 2 TFA****[0367]** The title compound was obtained by using the same procedure as described in Example 62 on the compound formed in Example 61. This diastereomer came out after the first one from the column.**[0368]** ¹H-NMR (500 MHz, D₂O, 2 rotamers ca: 5:1 ratio): δ 0.72 (m, minor rotamer), 0.82 (m, minor rotamer), 0.97 (m, 2H), 1.0-1.23 (m, 3H), 1.23-1.40 (m, 2H), 1.40-1.83 (m, 18H; thereof 1.63 (d, 3H)), 2.11 (d, 1H), 2.17 (d, minor rotamer), 2.92 (t, minor rotamer), 3.05-3.25 (m, 4H), 3.29 (t, 1H), 3.74 (d, 1H), 4.02 (q, 1H), 4.34 (d, minor rotamer), 4.41 (dd, minor rotamer), 4.52 (t, 1H), 4.95 (s, 1H).**[0369]** ¹³C-NMR (125 MHz, D₂O): guanidine: δ 154.68; carbonyl carbons: δ 169.81, 169.60, 167.36.Example 64**HOOC-CH₂-CH₂-(R)Cha-Pic-Agm x 2 TFA****[0370]** Prepared from H-(R)Cha-Pic-Agm(Z) (See Example 59) in the same way as described for HOOC-CH₂-CH₂-(R)Cha-Pro-Agm in Example 15 using 1.2 eq. of benzylacrylate instead of 1.1 eq.**[0371]** ¹H-NMR (500 MHz, D₂O, 2 rotamers ca: 4:1 ratio): δ 0.70-0.90 (m, minor rotamer), 0.90-1.0 (m, 2H), 1.05-1.25

(m, 3H), 1.30-1.45 (m, 2H), 1.45-1.85 (m, 15H), 2.1 (bd, 1H), 2.2 (bd, minor rotamer), 2.75 (t, 2H), 2.95 (t, minor rotamer), 3.1-3.4 (m, 7H), 3.75 (bd, 1H), 4.55 (t, 1H), 4.95 (m, 1H).

[0372] ^{13}C -NMR (75 MHz, D_2O): guanidine: δ 157.48; carbonyl carbons: δ 170.10, 172.58, 174.75.

5 Example 65

H-(R)Cha-Pic-Nag x 2 TFA

(i) Boc-(R)Cha-Pic-Nag(Z)

10

(ia) Prepared by starting from Boc-(R)Cha-Pic-OSu by using the same procedure as described for Boc-(R)Cha-Pro-Agm(Z) in Example 3.

(ib) Prepared by starting from Boc-(R)Cha-Pic-OH

15

[0373] Diphenylphosphoryl azide (0.432 ml, 2 mmol) was added to a stirred solution of Boc-(R)Cha-Pic-OH (765 mg, 2 mmol) in 5 ml DMF at -10°C . After 10 minutes H-Nag(Z) x 2 HCl (600 mg, 2.1 mmol, see Preparation of Starting Materials) in 5 ml DMF and triethylamine (615 mg, 4.4 mmol) was added. The reaction mixture was kept in an ice bath for 3 h and then at room temperature for 12 h after which it was poured out in water. Extraction of the water phase with EtOAc followed by drying (MgSO_4) of the organic phase and evaporation of the solvent in vacuo gave 1.18 g (96 %) of the product as a mixture of diastereomers (Epimers in Pic) in a ratio of 97:3 (RS/RR).

20

(ic) Starting from Boc-(R)Cha-Pic-OH

25

[0374] EDC hydrochloride (4.2 g, 21.9 mmol) was added at -15°C to a stirred solution of Boc-(R)Cha-Pic-OH (8 g, 20.9 mmol), DMAP (10.6 g, 88 mmol) and H-Nag-(Z) x 2 HCl (6.3 g, 19.5 mmol, see Preparation of Starting Materials) in acetonitrile. The reaction mixture was allowed to warm up to $+15^\circ\text{C}$ during 16 h. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate. Washing with water, 0.3 M KHSO_4 , 0.3 M NaHCO_3 , water and brine followed by drying (Na_2SO_4) and evaporation of the solvent gave 11.9 g (92.5%) of the product as a mixture of diastereomers (Epimers in Pic) in a ratio of 98/2 (RS/RR).

30

[0375] ^1H -NMR (500 MHz, CDCl_3): δ 0.85-2.0 (m, 29H; thereof 1.40 (bs, 9H)), 2.46 (bd, 1H), 3.1-3.4 (m, 5H), 3.92 (bd, 1H), 4.53 (bq, 1H), 5.10 (s, 2H), 5.22 (bs, 1H), 5.29 (bd, 1H), 6.7-7.2 (b, 3H), 7.25-7.45 (m, 5H).

[0376] ^{13}C -NMR (125 MHz, CDCl_3): guanidine δ 156.9; carbonyl carbons: δ 173.6, 170.3, 163.7, 161.7.

35

(ii) H-(R)Cha-Pic-Nag(Z)

[0377] Prepared in the same way as described for H-(R)Cha-Pro-Agm(Z) in Example 3, starting from Boc-(R)Cha-Pic-Nag(Z).

40

[0378] ^1H -NMR (500 MHz, CDCl_3): δ 0.8-2.0 (m, 22H), 2.24 (bd, 1H), 3.1-3.4 (m, 5H), 3.72 (bd, 1H), 3.84 (bq, 1H), 5.05 (bd, 1H), 5.08 (s, 2H), 7.3-7.5 (m, 5H).

(iii) H-(R)Cha-Pic-Nag x 2 TFA

[0379] Prepared by using the deprotection procedure (a) on the product (ii) above.

45

[0380] ^1H -NMR (500 MHz, MeOD): δ 0.9-1.1 (m, 2H), 1.2-2.0 (m, 18H), 2.32 (bd, 1H), 3.20 (t, 2H), 3.30 (t, 2H), 3.36 (m, 1H), 3.69 (bd, 1H), 4.49 (dd, 1H), 5.05 (bd, 1H).

[0381] ^{13}C -NMR (125 MHz, MeOD): guanidine: δ 158.7; carbonyl carbons: δ 172.7, 171.4

Example 66

50

Me-(R)Cha-(R,S)Pic-Nag x 2 TFA

(i) Me-(R)Cha-(R,S)Pic-Nag(Z)

55

[0382] Prepared in the same way as described for H-(R)Cha-Pro-Agm(Z) in Example 3 starting from Boc-(Me)(R)Cha-Pic-OSu and Boc-Nag(Z). An epimerization of Pic occurred during the synthesis and the product was obtained as mixture of two diastereomers.

(ii) Me-(R)Cha-(R,S)Pic-Nag x 2 TFA

[0383] Prepared by using deprotection procedure (b).

[0384] The ^1H -NMR spectrum is complex consisting of two diastereomers ca: 4:1 ratio and rotamers thereof.

[0385] ^1H -NMR (500 MHz, MeOD): δ 0.8-1.08 (m, 2H), 1.15-2.4 (several m, 19H), 2.6-2.75 and 2.9-2.95 (several s, 3H) 3.1-3.6 (several m, 5H), 3.75-4.1 (several m, 1H) 4.4-4.7 (several m, 1H), 5.05-5.15 (two dd, 1H).

[0386] ^{13}C -NMR (125 MHz, D_2O): guanidine: δ 154.84; carbonyl carbons: δ 167.60 and 169.99.

Example 67

HOOC-CH₂-(R)Cha-Pic-Nag

(i) BnOOC-CH₂-(R)Cha-Pic-Nag(Z)

[0387] Alkylation as in Example 4 using H-(R)Cha-Pic-Nag(Z) (See Example 65) and Br-CH₂COOBn gave the title compound.

[0388] ^1H -NMR (500 MHz, CDCl_3): δ 0.8-1.0 (m, 2H), 1.1-1.7 (m, 19H), 1.79 (bd, 1H), 2.3-2.5 (m, 2H; thereof 2.38 (bd, 1H)), 3.00 (bt, 1H), 3.1-3.4 (m, 5H; thereof 3.38 (d, 1H)) 3.58 (d, 1H), 3.6-3.7 (m, 2H), 5.06 (dd, 2H), 5.07 (s, 2H), 5.16 (bs, 1H), 6.7-7.1 (b, 1H), 7.15 (bs, 1H), 7.2-7.4 (m, 10H).

[0389] ^{13}C -NMR (125 MHz, CDCl_3) guanidine and carbonyl carbons: δ 176.0, 173.6, 170.8, 163.8, 161.7.

(iia) HOOC-CH₂-(R)Cha-Pic-Nag x 2 HCl

[0390] Deprotection procedure (a) followed by purification with RPLC using $\text{CH}_3\text{CN}/0.1 \text{ M NH}_4\text{OAc}$, 1/3 as eluent, evaporation at 40-50° C and freeze drying gave the title compound as the acetate. Treatment with a 20-fold excess of hydrochloric acid, evaporation and renewed freeze drying gave the bis-hydrochloride of the desired compound.

[0391] ^1H -NMR (500MHz, D_2O , mixture of two rotamers) : δ 0.7-2.0 (m, 20H), 2.17 (bd, 1H), 2.95 (t, minor rotamer), 3.17 (t, 2H), 3.25-3.35 (m, 3H), 3.72 (bd, 1H), 3.86 (dd, minor rotamer), 3.90 (s, 2H), 4.72 (t, 1H), 4.99 (bs, 1H).

[0392] ^{13}C -NMR (75 MHz, D_2O): guanidine δ 157.4; carbonyl carbons δ 169.9, 170.2, 173.0.

(iib) HOOC-CH₂-(R)Cha-Pic-Nag x 2 HBr

[0393] BnOOC-CH₂-(R)Cha-Pic-Nag(Z) was dissolved in $^i\text{Pr-OH}/\text{H}_2\text{O}$ (95/5) and hydrogenated over 5% Pd/C at atmospheric pressure in the presence of HBr (2.2 eq.). The catalyst was filtered off and the solvent evaporated to give a yellow oil (Alternatively, the acid can be added after hydrogenation and filtration). Crystallisation from $^i\text{Pr-OH}$ (or EtOH)/EtOAc (1/1) gave the title compound as a white crystalline powder.

[0394] ^1H -NMR (500 MHz, D_2O , mixture of two rotamers): δ 1.15-2.0 (m, 20H), 2.30 (bd, 1H), 3.30 (m, 2H), 3.40-3.50 (m, 3H), 3.85-3.90 (m, 1H), 3.95 (apparent s, 2H), 4.75-4.85 (m, 1H, partially hidden by the H-O-D line), 5.10 (bs, 1H).

[0395] ^{13}C -NMR (125 MHz, D_2O): guanidine: δ 157.6; carbonyl carbons: δ 169.7, 170.2, 173.0.

Example 68

MeOOC-CH₂-(R)Cha-Pic-Nag x 2 TFA

[0396] The methyl ester MeOOC-CH₂-(R)Cha-Pic-Nag(Z) was obtained by trans esterification of $^i\text{PrOOC-CH}_2$ -(R)Cha-Pic-Nag(Z) (See Example 69) on the column during flash chromatography when $\text{CH}_2\text{Cl}_2/\text{MeOH}$ was used as eluent. The title compound was obtained by the deprotection procedure (a).

[0397] ^1H -NMR (500 MHz, MeOD): δ 0.95-1.15 (m, 2H), 1.2-1.6 (m, 6H), 1.65-2.0 (m, 13H), 2.25 (bd, 1H), 3.21 (t, 2H), 3.30 (t, 2H), 3.37 (m, 1H), 3.71 (m, 1H), 3.83 (s, 3H), 3.97 (dd, 2H), 4.67 (bt, 1H), 5.05 (bs, 1H).

[0398] ^{13}C -NMR (125 MHz, MeOD), guanidine: δ 158.0; carbonyl carbons: δ 173.0, 171.1, 168.3.

Example 69

$^i\text{PrOOC-CH}_2$ -(R)Cha-Pic-Nag x 2 TFA

[0399] Alkylation as described in Example 4 using H-(R)Cha-Pic-Nag(Z) (See Example 65) and Br-CH₂-COO ^iPr followed by deprotection procedure (a) gave the title compound.

[0400] ^1H -NMR (500 MHz, MeOD): δ 0.95-1.1 (m, 2H), 1.15-1.6 (m, 12H; thereof 1.25 (d, 3H), 1.28 (d, 3H)), 1.65-

1.95 (m, 12H), 2.28 (bd, 1H), 3.21 (t, 2H), 3.30 (t, 2H), 3.36 (m, 1H), 3.93 (dd, 2H), 4.67 (t, 1H), 5.04 (bs, 1H), 5.11 (pentet, 1H).

[0401] ¹³C-NMR (125 MHz, MeOD): guanidine: δ 157.9; carbonyl carbons: δ 173.1, 171.0, 168.3.

5 Example 70

HOOC-CH₂-(Me)(R)Cha-(RorS)Pic-Nag/b x 2 TFA

[0402] Alkylation as described in Example 4 using Me-(R)Cha-(R,S)Pic-Nag(Z) (See Example 66) and Br-CH₂-COOBn followed by deprotection procedure (b) gave HOOC-CH₂-(Me)(R)Cha-(R,S)Pic-Nag. The two diastereomers where separated by RPLC (CH₃CN/NH₄OAc, 1:3) followed by freeze-drying from H₂O/TFA. This diastereomer came out last of the two from the column.

[0403] ¹H-NMR (500 MHz, MeOD): δ 0.9-1.1 (m, 2H), 1.15-1.35 (m, 4H), 1.4-1.55 (m, 2H), 1.6-1.85 (m, 12H), 2.3 (m, 1H), 2.85 (s, 3H), 3.15-3.45 (m, 5H), 3.65 (bs, 2H), 4.0 (m, 1H), 4.65 (m, 1H), 5.08 (dd, 1H).

15 [0404] ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.65; carbonyl carbons: δ 169.86 and 172.48.

Example 71

HOOC-(R,S)CH(Me)-(R)Cha-(R,S)Pic-Nag x 2 TFA

20 [0405] Alkylation as described in Example 4 using H-(R)Cha-Pic-Nag(Z) (See Example 65) and Br-CH(Me)-COOBn followed by deprotection procedure (a) gave the title compound as a mixture of four diastereomers.

Example 72

25 HOOC-(RorS)CH(Me)-(R)Cha-(RorS)Pic-Nag/c x 2 TFA

[0406] Obtained by separating the diastereomers formed in Example 71 using RPLC (CH₃CN/NH₄OAc (0.1M), 1/4) followed by evaporation and freeze-drying from H₂O/TFA. This diastereomer came out as the third one of the four from the column.

30 [0407] ¹H-NMR (300 MHz, D₂O, 2 rotamers ca: 5:1 ratio): δ 0.88 (m, minor rotamer), 0.98-1.63 (m, 7H), 1.63-2.02 (m, 16H; thereof 1.68 (d, 3H), 2.28 (m, 1H), 3.10 (t, minor rotamer), 3.25-3.50 (m, 5H; thereof 3.33 (t, 2H) and 3.43 (t, 2H)), 3.82 (bd, 1H), 4.02 (q, 1H), 4.55 (d, minor rotamer), 4.65 (d, minor rotamer), 4.72 (m, 1H), 5.10 (m, 1H).

35 Example 73

HOOC-(RorS)CH(Me)-(R)Cha-(RorS)Pic-Nag/d x 2 TFA

40 [0408] Obtained by separating the diastereomers formed in Example 71 using RPLC (CH₃CN/NH₄OAc (0.1 M), 1:4) followed by evaporation and freeze-drying from H₂O/TFA. This diastereomer came out last of the four diastereomers from the column.

[0409] ¹H-NMR (500 MHz, D₂O, 2 rotamers ca: 5:1 ratio): δ 0.80 (m, minor rotamer), 0.90 (m, minor rotamer), 1.03 (m, 2H), 1.10-1.33 (m, 3H), 1.42 (m, 2H), 1.51-1.92 (m, 16H; thereof 1.57 (d, 3H)), 2.18 (d, 1H), 2.24 (d, minor rotamer), 2.98 (t, minor rotamer), 3.21 (t, 2H), 3.28-3.40 (m, 3H; thereof 3.44 (t, 2H)), 3.82 (d, 1H), 4.02 (q, 1H), 4.42 (d, minor rotamer), 4.50 (t, minor rotamer), 4.62 (t, 1H), 4.67 (s, minor rotamer), 5.03 (s, 1H).

Example 74

HOOC-CH₂-CH₂-(R)Cha-Pic-Nag x 2 TFA

50 [0410] Prepared from H-(R)Cha-Pic-Nag(Z) (See Example 65) in the same way as described for HOOC-CH₂-CH₂-(R)Cha-Pro-Agm in Example 15 using 1.2 eq. of benzylacrylate insted of 1.1 eq.

[0411] ¹H-NMR (500 MHz, D₂O, 2 rotamers ca: 4:1 ratio): δ 0.7-0.9 (m, minor rotamer), 0.9-1.0 (m, 2H), 1.05-1.3 (m, 3H), 1.3-1.45 (m, 2H), 1.5-1.8 (m, 13H), 2.10 (d, 1H), 2.20 (d, minor rotamer), 2.75 (t, 2H), 2.95 (t, minor rotamer), 3.15 (t, 2H), 3.2-3.35 (m, 5H), 3.75 (d, 1H), 4.55 (t, 1H), 4.95 (m, 1H).

55 [0412] ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.57; carbonyl carbons: δ 170.16, 172.82, 174.75.

Example 75HOOC-CH₂-(R)Cha-(R,S)Mor-Agm x 2 TFA

5 (i) H-(R)Cha-Mor-Agm(Z)

[0413] Prepared from Boc-(R)Cha-Mor-OSu (See Prep. of starting materials) in the same way as described for H-(R)Cha-Pro-Agm(Z) in Example 3.

10 (ii) HOOC-CH₂-(R)Cha-(R,S)Mor-Agm x 2 TFA

[0414] Alkylation as in Example 4 using Br-CH₂COOBn followed by deprotection procedure (b) gave the title compound. An epimerization of Mor had occurred somewhere during the synthesis and a mixture of about 9:1 of two diastereomers was observed in the final product.

15 [0415] ¹H-NMR (300 MHz, MeOD): δ 0.92-1.95 (m, 17 H), 3.12-3.39 (m, 4H), 3.44-4.05 (m, 7H), 4.37 (d, 1H), 4.63 (m, 1H), 4.79 (bd, 1H).

[0416] ¹³C-NMR (75.47 MHz, MeOD): guanidine: δ 158.63; carbonyl carbons: δ 170.87, 170.82, 169.08 others: δ 69.06, 67.01 (C-O-C).

20 Example 76HOOC-CH₂-(R)Cha-(RorS)Mor-Nag x 2 TFA

(i) H-(R)Cha-Mor-Nag(Z)

25

[0417] Prepared from Boc-(R)Cha-Mor-OSu (See Prep. of starting materials) and Boc-Nag(Z) in the same way as described for H-(R)Cha-Pro-Agm(Z) in Example 3.

(ii) HOOC-CH₂-(R)Cha-(RorS)Mor-Nag x 2 TFA

30

[0418] Alkylation as described in Example 4 using Br-CH₂COOBn followed by deprotection procedure (b) gave the title compound.

[0419] ¹H-NMR (300 MHz, MeOD): δ 0.92-1.13 (m, 2H), 1.15-1.42 (m, 3H), 1.50 (br.s, 1H), 1.62-1.95 (m, 9H), 3.14-3.40 (m, 4H), 3.46-4.13 (m, 7H), 4.41 (d, 1H), 4.63 (m, 1H), 4.80 (br.d, 1H).

35 [0420] ¹³C-NMR (75.47 MHz, MeOD): guanidine: δ 158.68; carbonyl carbons: δ 171.19, 170.90, 169.46. others: δ 68.81, 67.00 (C-O-C).

Example 77

40 H-(R)Cha-Aze-Nag x 2 HOAc

(i) Boc-(R)Cha-Aze-Nag(Z)

45 [0421] Prepared from Boc-(R)Cha-Aze-OH in the same way as described for Boc-(R)Cha-Pic-Nag(Z) according to Example 65 (ic).

(ii) H-(R)Cha-Aze-Nag(Z)

[0422] Prepared in the same way as described for H-(R)Cha-Pro-Agm(Z) (See Example 3).

50

(iii) H-(R)Cha-Aze-Nag x 2 HOAc

[0423] Prepared by using the deprotection procedure (a) on the product (ii) above.

55 [0424] ¹H-NMR (300 MHz, D₂O): δ 0.85-1.10 (m, 2H), 1.10-2.04 (m, 13H) 1.95 (s, acetate), 2.20-2.37 (m, 1H), 2.60-2.82 (m, 1H), 3.15-3.40 (m, 4H), 3.96-4.15 (m, 2H), 4.18-4.30 (m, 1H), 4.30-4.42 (m, 1H), signals of a minor rotamer appears at: δ 0.70, 3.90 and 5.10.

[0425] ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.39 and carbonyl carbons: δ 170.22 and 172.38.

Example 78**HOOC-CH₂-(R)Cha-Aze-Nag x HOAc**

(i) BnOOC-CH₂-(R)Cha-Aze-Nag(Z)

[0426] Prepared from H-(R)Cha-Aze-Nag(Z) (See Example 77) according to the procedure described in Example 4.

(ii) HOOC-CH₂-(R)Cha-Aze-Nag x HOAc

[0427] Prepared by using the deprotection (a) on the product (i) above.

[0428] ¹H-NMR (500 MHz, MeOD): δ 0.90-1.10 (m, 2H), 1.15-2.00 (m, 13H) 1.95 (s, acetate), 2.20-2.30 (m, 1H), 2.58-2.70 (m, 1H), 3.17-3.30 (m, 4H), 3.35-3.50 (m, 2H), 3.55-3.68 (m, 1H), 4.10-4.20 (m, 1H), 4.30-4.38 (m, 1H), 4.65-4.77 (m, 1H), signals of minor rotamer appears at: δ 3.75, 3.98, 4.03 and 5.08.

[0429] ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.40 and carbonyl carbons: δ 169.16, 171.92 and 172.13.

Example 79**H-(R)Cha-Pro(5-(S)Me)-Nag x 2 HCl**

(i) Boc-(R)Cha-Pro(5-(S)Me)-Nag(Z)

[0430] The same procedure as described for the coupling between Boc-(R)Cha-OH and H-Pic-OEt x HCl (See Preparation of Starting Materials) was used to accomplish the coupling between Boc-(R)Cha-Pro(5-(S)Me)-OH and H-Nag(Z) x 2 HCl.

(ii) H-(R)Cha-Pro(5-(S)Me)-Nag(Z)

[0431] The same procedure as described for the synthesis of H-(R)-Cgl-Pic-Nag(Z) (See Example 84 (ii) was used.

(iii) H-(R)Cha-Pro(5-(S)Me)-Nag x 2 HCl

[0432] Prepared by using the deprotection procedure (d) on the product (ii) above.

[0433] ¹H-NMR (300 MHz, D₂O): δ 1.0-2.3 (m, 21H); thereof 1.47 (d, 3H), 2.4-2.55 (m, 1H), 3.3-3.6 (m, 4H), 4.30 (bt, 1H), 4.38 (dd, 1H), 4.47 (bt, 1H).

[0434] ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.6 carbonyl carbons: δ 174.6, 169.6.

Example 80**HOOC-CH₂-(R)Cha-Pro(5-(S)Me)-Nag x HOAc**

[0435] Alkylation as in Example 4 using H-(R)Cha-Pro(5-(S)Me)-Nag(Z) (See Example 79) and Br-CH₂-COOBn followed by deprotection procedure (a) gave the title compound.

[0436] ¹H-NMR (300 MHz, D₂O): δ 0.9-1.9 (m, 19H); thereof 1.34 (bd, 3H), 1.93 (s, acetate), 2.0-2.2 (m, 3H), 2.34 (m, 1H), 3.1-3.5 (m, 7H), 3.97 (m, 1H), 4.20 (m, 1H), 4.31 (bt, 1H).

[0437] ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.4.

Example 81**HOOC-CH₂-(R)Cha-(RorS)Pic(4,5-dehydro)-Nag/b x HOAc**

(i) Boc-(R)Cha-(R,S)Pic(4,5-dehydro)-Nag(Z)

[0438] Prepared from Boc-(R)Cha-(R,S)Pic(4,5-dehydro)-OH in the same way as described for Boc-(R)Cha-Pic-Nag(Z) (See Example 65 (ic)).

(ii) H-(R)Cha-(R,S)Pic(4,5-dehydro)-Nag(Z)

[0439] Prepared in the same way as described for H-(R)Cha-Pro-Agm(Z) (See Example 3).

5 (iii) BnOOC-CH₂-(R)Cha-(R,S)Pic(4,5-dehydro)-Nag(Z)

[0440] Prepared from H-(R)Cha-(R,S)Pic(4,5-dehydro)-Nag(Z) according to the procedure described in Example 4.

(iv) HOOC-CH₂-(R)Cha-(RorS)Pic(4,5-dehydro)-Nag/b x HOAc

10

[0441] A mixture of 356 mg (0.539 mmol) of BnOOC-CH₂-(R)Cha-(R,S) Pic(4,5-dehydro)-Nag(Z), 10.8 mL trifluoroacetic acid and 3.4 ml toanisole was stirred at room temperature for 3.5 h. Water was added and the mixture was washed twice with CH₂Cl₂ evaporation of the solvent gave HOOC-CH₂-(R)Cha-(R,S)Pic(4,5-dehydro)-Nag. The title compound was obtained by separating the diastereomers by RPLC (CH₃CN/NH₄OAc (0.1 M), 3/7) and freeze drying (H₂O) after evaporation of the solvent. The diastereomer came out last of the two from the column.

15

[0442] ¹H-NMR (300 MHz, D₂O) δ 0.85-1.95 (m, 15H), 2.50-2.80 (m, 2H), 3.25 (t, 2H), 3.35 (t, 2H), 3.55 (bs, 2H), 3.85-4.6 (m, 3H), 4.92 (minor rotamer), 5.30 (d, 1H), 5.85-6.1 (m, 2H),

[0443] ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.59; carbonyl carbons: δ 171.46, 172.58, 173.03.

20 Example 82

HOOC-CH₂-(R)Cha-Pic(4-(S)Me)-Nag x 2 HCl

(i) Boc-(R)Cha-Pic(4-(S)Me)-Nag(Z)

25

[0444] Prepared from Boc-(R)Cha-Pic(4-(S)Me)-OH in the same way as described for Boc-(R)Cha-Pic-Nag(Z) according to method (ic) in Example 65.

(ii) H-(R)Cha-Pic(4-(S)Me)-Nag(Z)

30

[0445] Prepared in the same way as described for H-(R)Cha-Pro-Agm(Z) (See Example 3).

(iii) BnOOC-CH₂-(R)Cha-Pic(4-(S)Me)-Nag(Z)

35

[0446] Prepared from H-(R)Cha-Pic(4-(S)Me)-Nag(Z) according to the procedure described in Example 4.

(iv) HOOC-CH₂-(R)Cha-Pic(4-(9)Me)-Nag x 2 HCl

[0447] Prepared by using the deprotection procedure (d) on the product (iii) above.

40

[0448] ¹H-NMR (500 MHz, D₂O): δ 0.95-2.05 (m, 22H; thereof 1.05 (d, 3H)), 2.30-2.38 (bd, 1H), 3.28-3.36 (m, 2H) 3.36-3.50 (m, 3H), 3.85-3.95 (m, 1H), 3.98 (s, 2H), 4.70-4.90 (m, 1H; partly hidden behind the HOD signal), 5.22-5.27 (d, 1H), signal of a minor rotamer appears at δ 0.93, 3.13 and 4.57.

[0449] ¹³C-NMR (125 MHz, D₂O): guanidine: δ 157.58; carbonyl carbons: δ 170.12, 170.32 and 172.82.

45 Example 83

HOOC-CH₂-(R)Cha-(R)Pic(4-(R)Me)-Nag x 2 HCl

(i) Boc-(R)Cha-(R)Pic(4-(R)Me)-Nag(Z)

50

[0450] Prepared from Boc-(R)Cha-(R)Pic(4-(R)Me)-OSu and Boc-Nag(Z) in the same way as described for Boc-(R)Cha-Pro-Agm(Z) (See Example 3).

(ii) H-(R)Cha-(R)Pic(4-(R)Me)-Nag(Z)

55

[0451] Prepared in the same way as described for H-(R)Cha-Pro-Agm(Z) (See Example 3).

(iii) $\text{BnOOC-CH}_2\text{-(R)Cha-(R)Pic(4-(R)Me)-Nag(Z)}$

[0452] Prepared from $\text{H-(R)Cha-(R)Pic(4-(R)Me)-Nag(Z)}$ according to the procedure described in Example 4.

5 (iv) $\text{HOOC-CH}_2\text{-(R)Cha-(R)Pic(4-(R)Me)-Nag} \times 2 \text{ HCl}$

[0453] Prepared by using the deprotection procedure (d) on the product (iii) above.

[0454] $^1\text{H-NMR}$ (500 MHz, D_2O): δ 1.00-2.05 (m, 22H), 2.18-2.26 (bd, 1H), 3.28-3.36 (m, 2H), 3.36-3.55 (m, 3H), 3.85-4.05 (m, 3H), 4.70-4.90 (m, 1H; partly hidden behind the HOD signal), 5.25-5.30 (d, 1H), signals of minor rotamer appears at: δ 2.40, 2.90, 4.10, 4.42, 4.55 and 5.23.

[0455] $^{13}\text{C-NMR}$ (125 MHz, D_2O): guanidine: δ 157.56; carbonyl carbons: δ 169.69, 169.84 and 173.20.

Example 84

15 $\text{HOOC-CH}_2\text{-(R)Cgl-Pic-Nag} \times 2 \text{ HCl}$

(i) $\text{Boc-(R)Cgl-Pic-Nag(Z)}$

[0456] Prepared from Boc-(R)Cgl-Pic-OH in the same way as described for $\text{Boc-(R)Cha-Pic-Nag(Z)}$ according to method (ic) in Example 65.

[0457] $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.9-1.8 (m, 27H), 2.4 (d, 1H), 3.1-3.3 (m, 5H), 3.9 (d, 1H), 4.2 (t, 1H), 5.1 (s, 2H), 5.2 (bd, 2H), 6.7-7.4 (m, 9H).

(ii) $\text{H-(R)Cgl-Pic-Nag(Z)}$

25

[0458] Gaseous hydrogen chloride was bubbled through a solution of $\text{Boc-(R)Cgl-Pic-Nag(Z)}$ (1.38 g, 2.22 mmol) in ethyl acetate (25 ml). After 10 minutes the solvent was evaporated and the residue was dissolved in ethyl acetate and 10% Na_2CO_3 . The organic phase was separated, washed with brine and dried (MgSO_4). Evaporation of the solvent gave 1.02 g (92%) of the title compound.

30 [0459] $^1\text{H-NMR}$ (300 MHz, MeOD): δ 1.0-1.9 (m, 18H), 2.2-2.3 (m, 1H), 3.2-3.3 (m, 5H), 3.6 (d, 1H), 3.8-3.9 (bd, 1H), 4.2 (t, 1H), 4.7-4.8 (bs, 5H), 5.1 (s, 2H), 5.2 (s, 1H), 7.2-7.3 (m, 5H).

(iii) $\text{BnOOC-CH}_2\text{-(R)Cgl-Pic-Nag(Z)}$

35 [0460] A solution of the triflate ester of benzyl glycolate (291 mg, 0.98 mmol) in CH_2Cl_2 (2 ml) was added at -25°C to a stirred mixture of $\text{H-(R)Cgl-Pic-Nag(Z)}$ (0.52 g, 1.04 mmol) and K_2CO_3 (494 mg, 3.58 mmol) in acetonitrile (5 ml) and CH_2Cl_2 (1 ml). The temperature was allowed to reach room temperature during a couple of hours and after 5 days the reaction mixture was diluted with water and extracted with EtOAc and toluene. Drying of the organic phase (MgSO_4) and concentration of the solution gave 319 mg (47%) of colorless crystals.

40 [0461] $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 1.0-1.1 (m, 1H), 1.1-1.3 (m, 4H), 1.35-1.6 (m, 5H), 1.6-1.85 (m, 8H), 1.8-2.2 (bs, 1H), 2.23-2.5 (m, 2H), 2.9 (t, 1H), 3.1-3.5 (m, 6H), 3.6-3.7 (m, 2H), 5.0-5.1 (m, 4H), 5.2 (s, 1H), 6.5-7.4 (m, 13H).

(iv) $\text{HOOC-CH}_2\text{-(R)Cgl-Pic-Nag} \times 2 \text{ HCl}$

45 [0462] $\text{BnOOC-CH}_2\text{-(R)Cgl-Pic-Nag(Z)}$ (319 mg, 0.49 mmol) was dissolved by heating in isopropanol (50 ml) and water (5 ml) and hydrogenated for 24 h over 10% Pd/C (228 mg). After filtration and evaporation of the solvent and subsequent dissolution in dilute hydrochloric acid followed by freeze drying, the peptide (223 mg, 91%) was isolated as a white powder.

50 [0463] $^1\text{H-NMR}$ (500 MHz, D_2O): δ 1.1-2.1 (m, 18H) 2.3 (d, 1H), 3.3 (t, 2H), 3.4 (t, 3H), 3.85-4.05 (m, 3H), 4.6 (d, 1H), 5.15 (s, 1H).

[0464] $^{13}\text{C-NMR}$ (75 MHz, D_2O): guanidine: δ 157.43; carbonyl carbons: δ 169.2, 172.94.

55

Example 85**H-(R)Hoc-Pro-Nag x 2 TFA**

5 (i) Boc-(R)Hoc-Pro-Nag(Z)

[0465] Prepared from Boc-(R)Hoc-Pro-OH in the same way as described for Boc-(R)Cha-Pic-Nag(Z) according to Example 65 (ic).

10 (ii) H-(R)Hoc-Pro-Nag(Z)

[0466] Prepared in the same way as described for H-(R)Cha-Pro-Agm(Z) (See Example 3).

(iii) H-(R)Hoc-Pro-Nag x TFA

15

[0467] Prepared by using the deprotection procedure (a) on The product (ii) above.

[0468] ¹H-NMR (300 MHz, D₂O): δ 0.90-1.05 (m, 2H), 1.16-1.48 (m, 6H), 1.48-1.84 (m, 6H), 1.84-2.24 (m, 6H), 2.40 (m, 1H), 3.25-3.45 (m, 4H), 3.74 (m, 1H), 3.85 (m, 1H), 4.42 (m, 1H), 4.51 (m, 1H).

20 Example 86

HOOC-CH₂-(R)Hoc-Pro-Nag x HOAc

(i) BnOOC-CH₂-(R)Hoc-Pro-Nag(Z)

25

[0469] Prepared from H-(R)Hoc-Pro-Nag(Z) (See Example 85) according to the procedure described in Example 4.

(ii) HOOC-CH₂-(R)Hoc-Pro-Nag x HOAc

30 [0470] Prepared by using the deprotection procedure (a) on the product (i) above.

[0471] ¹H-NMR (300 MHz, D₂O): δ 0.76-0.97 (m, 2H), 1.00-1.37 (m, 6H), 1.50-2.12 (m, 12H) 1.89 (s, acetate), 2.27 (m, 1H), 3.10-3.33 (m, 4H), 3.41 (bs, 2H), 3.61 (m, 1H), 3.77 (m, 1H), 4.12 (m, 1H), 4.37 (m, 1H).

[0472] ¹³C-NMR (75 MHz, D₂O): guanidine: δ 157.4; carbonyl carbons: δ 170.8, 173.9, 174.5.

35 Example 87

HOOC-CH₂-(R)Hoc-Pic-Nag x HOAc

(i) Boc-(R)Hoc-Pic-Nag(Z)

40

[0473] Prepared from Boc-(R)Hoc-Pic-OH in the same way as described for Boc-(R)Cha-Pic-Nag(Z) according to method (ic) in Example 65.

(ii) H-(R)Hoc-Pic-Nag(Z)

45

[0474] Prepared in the same way as described for H-(R)Cha-Pro-Agm(Z) (See Example 3).

(iii) BnOOC-CH₂-(R)Hoc-Pic-Nag(Z)

50 [0475] Prepared according to the procedure described in Example 4.

(iv) HOOC-CH₂-(R)Hoc-Pic-Nag x HOAc

[0476] Prepared by using the deprotection procedure (a) on the product (iii) above.

55 [0477] ¹H-NMR (300 MHz, D₂O): δ 0.75-0.95 (m, 2H), 1.00-1.30 (m, 6H), 1.30-1.50 (m, 2H), 1.50-1.82 (m, 12H), 1.82-1.95 (bs, acetate), 2.23 (bd, 1H), 3.08-3.32 (m, 6H), 3.52 (bs, 2H), 3.77 (bd, 1H), 4.50 (bs, 1H), 5.00 (bs, 1H).

Example 88HOOC-CH₂-(R)Dph-Pic-Nag x 2 HCl

5 (i) Boc-(R)Dph-Pic-Nag(Z)

[0478] Prepared from Boc-(R)Dph-Pic-OH in the same way as described for Boc-(R)Cha-Pic-Nag(Z) (See Example 65 (ic)).

10 (ii) H-(R)Dph-Pic-Nag(Z)

[0479] Prepared in the same way as described for H-(R)Cgl-Pic-Nag(Z) (See Example 84 (ii)).

(iii) BnOOC-CH₂-(R)Dph-Pic-Nag(Z)

15

[0480] Prepared from H-(R)Dph-Pic-Nag(Z) according to the procedure described in Example 4.

(iv) HOOC-CH₂-(R)Dph-Pic-Nag x 2 HCl

20 [0481] Prepared by using the deprotection procedure (d) on the product (iii) above.

[0482] ¹H-NMR (500 MHz, D₂O): δ 0.46 (m, 1H), 1.2-1.35 (m, 2H), 1.45 (m, 1H), 1.53 (m, 1H), 1.89 (pentet, 2H), 2.03 (bd, 1H), 3.24 (bt, 1H), 3.29 (t, 2H), 3.38 (t, 2H), 3.72 (d, 1H), 3.78 (d, 1H), 3.79 (m, 1H), 4.68 (d, 1H), 4.89 (m, 1H), 5.73 (d, 1H), 7.4-7.6 (m, 6H), 7.65 (t, 2H), 7.81 (d, 2H).25 Example 89HOOC-CH₂-(R)Dch-Pic-Nag x HOAc

(i) Boc-(R)Dch-Pic-Nag(Z)

30

[0483] Prepared from Boc-(R)Dch-Pic-OH in the same way as described for Boc-(R)Cha-Pic-Nag(Z) (in Example 65 (ic)).

(ii) H-(R)Dch-Pic-Nag(Z)

35

[0484] Prepared in the same way as described for H-(R)Cgl-Pic-Nag(Z) (in Example 84 (ii)).

(iii) BnOOC-CH₂-(R)Dch-Pic-Nag(Z)

40 [0485] Prepared from H-(R)Dch-Pic-Nag(Z) according to the procedure described in Example 4.

(iv) HOOC-CH₂-(R)Dch-Pic-Nag x HOAc

[0486] Prepared by using the deprotection procedure (a) on the product (iii) above.

45 [0487] ¹H-NMR (500 MHz, D₂O): δ 1.2-2.0 (m, 30H), 2.09 (s, acetate), 2.30 (bd, 1H), 3.32 (t, 2H), 3.4-3.5 (m, 3H), 3.65 (d, 1H), 3.70 (d, 1H), 3.86 (bd, 1H), 4.86 (m, 1H), 5.09 (m, 1H).[0488] ¹³C-NMR (125 MHz, D₂O): guanidine: δ 159.4, carbonyl carbons: δ 172.5, 173.3, 174.9.Example P1

50

Solution for parenteral administration

[0489] A solution is prepared from the following ingredients:

55

HOOC-CH ₂ -(R)Cha-Pic-Nag x 2HBr	5 g
Sodium chloride for injection	9 g
Acetic acid	3 g
Water for inj. up to 1000 ml	

[0490] The active constituent, the sodium chloride and the acetic acid are dissolved in the water. The pH is adjusted with 2 M NaOH to pH 3-7. The solution is filtered through a sterile 0.2 µm filter and is aseptically filled into sterile ampoules.

Example P2

Tablets for oral administration

[0491] 1000 tablets are prepared from the following ingredients:

Thrombin inhibitor	100 g
Lactose	200 g
Polyvinyl pyrrolidone	30 g
Microcrystalline cellulose	30 g
Magnesium stearate	6 g

[0492] The active constituent and lactose are mixed with an aqueous solution of polyvinyl pyrrolidone. The mixture is dried and milled to form granules. The microcrystalline cellulose and then the magnesium stearate are then admixed. The mixture is then compressed in a tablet machine giving 1000 tablets, each containing 100 mg of active constituent.

Biology

Determination of thrombin clotting time and IC₅₀TT:

[0493] Human thrombin (T 6769, Sigma Chem Co) in buffer solution, pH 7.4, 100 µl, and inhibitor solution, 100 µl, were incubated for one min. Pooled normal citrated human plasma, 100 µl, was then added and the clotting time measured in an automatic device (KC 10, Amelung).

[0494] The clotting time in seconds was plotted against the inhibitor concentration, and the IC₅₀TT was determined by interpolation.

[0495] IC₅₀TT is the concentration of inhibitor that doubles the thrombin clotting time for human plasma. pIC₅₀TT is the -log 10 of IC₅₀TT in mol/l. The preferred compounds of the invention have an pIC₅₀TT in the range 6.6 - 8.2.

Determination of Activated Partial Thromboplastin Time (APTT)

[0496] APTT was determined in pooled normal human citrated plasma with the reagent PTT Automated 5 manufactured by Stago. The inhibitors were added to the plasma (10 µl inhibitor solution to 90 µl plasma) and APTT was determined in the mixture by use of the coagulation analyser KC10 (Amelung) according to the instructions of the reagent producer. The clotting time in seconds was plotted against the inhibitor concentration in plasma and the IC₅₀APTT was determined by interpolation.

[0497] IC₅₀APTT is defined as the concentration of inhibitor in plasma that doubled the Activated Partial Thromboplastin Time. pIC₅₀APTT is the -log 10 of IC₅₀APTT in mol/l. Those of the preferred compounds of the invention that were tested showed a pIC₅₀APTT of 5.1 - 6.4.

ABBREVIATIONS

[0498]

5	Agm =	Agmatine
	Agm(Z) =	ω -N-benzyloxycarbonyl agmatine
	AA ₁ =	Amino acid 1
	AA ₂ =	Amino acid 2
	Aze =	(S)-Azetidin-2-carboxylic acid
10	Bla =	α -substituted butyrolactone
	Boc =	tertiary butoxy carbonyl
	Brine =	saturated water/NaCl solution
	Bu =	butyl
	Bn =	benzyl
15	Cgl =	(S)-Cyclohexyl glycine
	Ch =	cyclohexyl
	Cha =	(S)- β -cyclohexyl alanine
	CME-CDI =	1-Cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-p-toluenesulfonate
	DCC =	dicyclohexyl carbodiimide
20	Dch =	(S)-Dicyclohexyl alanine
	DMAP =	N,N-dimethyl amino pyridine
	DMF =	dimethyl formamide
	DMSO =	dimethyl sulphoxide
	Dph =	(S)-Diphenyl alanine
25	EDC =	1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
	Et =	ethyl
	EtOAc =	ethyl acetate
	HOAc =	acetic acid
	HOBt =	N-hydroxy benzotriazole
30	Hoc =	(S)-Homocyclohexyl alanine
	Hop =	(S)-Homophenyl alanine
	HOSu =	N-hydroxysuccinimide
	Mag =	miniagmatine
	Me =	methyl
35	Mor =	(S)-morpholine-2-carboxylic acid
	Mpa =	mega pascal
	Nag =	noragmatine
	Nag(Z) =	δ -N-benzyloxycarbonyl-noragmatine
	NMM =	N-methyl morpholine
40	Pgl =	(S)-phenyl glycine
	Ph =	phenyl
	Phe =	(S)-phenyl alanine
	Pic =	(S)-pipecolinic acid
	Pr =	propyl
45	Pro =	(S)-proline
	RPLC =	reverse phase high- performance liquid chromatography
	Tf =	trifluoromethyl sulphonyl
	TFA =	trifluoroacetic acid
	THF =	tetrahydrofuran
50	p-TsOH =	para-toluenesulfonic acid
	Val =	(S)-valine
	Z =	benzyloxy carbonyl

Prefixes n, s, i and t have their usual meanings: normal, iso, sec and tertiary.

55

Scheme I (Exempl 3-18,20-21,24-28,30-34,36-40,43-49,
51-53,57-64 and 67-93)

5

10

15

20

25

30


35

40

45

50

55



AA₁ = H-(R)Cha-OH, Me-(R)Cha-OH, H-(R,S)Pro(3-(trans)Ph)-OH,
H-(R)Hoc-OH, H-(R)Cgl-OH, H-(R)Dph-OH, H-(R)Dch-OH

AA₂ = H-Pro-OH, H-Pic-OH, H-Mor-OH, H-Aze-OH, H-Pic(4-(S)Me)-OH
H-Pic(4-(R)Me)-OH, H-(R,S)Pic(4,5-dehydro)-OH,
H-(R)Pic(4-(R)Me)-OH, H-Pro(5-(R,S)Me)-OH,
H-Pro(5-(S)Me)-OH, H-Pic(6-(S)Me)-OH

The N terminal group in the final compound =

H, HO-(CH₂)₃-, ⁿBu-, HOOC-CH₂-, MeOOC-CH₂-, ⁱPrOOC-CH₂-, ^tBuOOC-CH₂-,
HOOC-CH(Me)-, HOOC-CH(ⁿPr)-, HOOC-CH(Ph)-, HOOC-CH(CH₂CH₂Ph)-
HOOC-CH₂CH₂-, HOOC-CH₂CH₂CH₂-, EtOOC-CH₂CH₂CH₂-, Bla,
HOOC-CH₂-OOC-CH₂-, EtOOC-CO-, MeOOC-CO-, HOOC-CO-, H₂NOC-CH₂-,
HOOC-CH(CH₂COOH)-, MeOOC-CH(CH₂COOMe)-, HOOC-CH₂-NH-CO-CH₂-,
HOOC-CH(CH₂OH)-, (HO)₂P(O)-CH₂-, EtO(HO)P(O)-CH₂-,
(EtO)₂P(O)-CH₂-.

Scheme II (Example 55,56,65 and 66)

5

Boc-(R,S)Pro(3-Ph)-OH

10

1. H-Pro-OBn, HOBT, NMM, DMF
2. H₂, Pd/C
3. HOSu, CME-CDI, CH₃CN

15

Boc-(R,S)Pro(3-Ph)-Pro-OSu

H-Agm(Z), NMM

DMF, r.t.

Boc-(R,S)Pro(3-Ph)-Pro-Agm(Z)

20

1. TFA, CH₂Cl₂
2. H₂, Pd/C

H-(R,S)Pro(3-Ph)-Pro-Agm

Example 55

25

Boc-(R,S)Pro(3-(trans)Ph)-OH

Rh/Al₂O₃, H₂

HOAc, MeOH

Boc-(R,S)Pro(3-(trans)Ch)-OH

30

Boc-(R)Cha-OH

See Example 55
(above)

H-(R,S)Pro(3-(trans)Ch)-Pro-Agm

Example 56

35

1. HOBT, CME-CDI, CH₂Cl₂
2. HClxH-Pic-OEt, NMM, DMF
3. LiOH, THF, H₂O
4. HOSu, DCC, DMF

Boc-(R)Cha-Pic-OSu

40

or
Boc-(Me)(R)Cha-(R,S)Pic-OSu

H-Nag(Z), NMM,

DMF, r.t.

Boc-(R)Cha-Pic-Nag(Z)

or
Boc-(Me)(R)Cha-(R,S)Pic-Nag(Z)

45

1. HOBT, CME-CDI, CH₂Cl₂
2. HClxH-Pic-OEt, NMM, DMF
3. LiOH, THF, H₂O
4. HOSu, DCC, DMF

Boc-(Me)(R)Cha-OH

50

1. TFA
2. H₂, Pd/C


H-(R)Cha-Pic-Nag (Example 65)

or


Me-(R)Cha-(R,S)Pic-Nag
Example 66

55


Scheme III (Example 1 and 2)




Scheme IV (Example 19)



Scheme V (Example 54)




Scheme VI (Example 22,23,29,35,41,42 and 50)



Claims

1. A compound of the general formula



Formula I

wherein:

A represents a methylene group, or

A represents an ethylene group and the resulting 5-membered ring may or may not carry one or two fluorine atoms, a hydroxy group or an oxo group in position 4, or may or may not be unsaturated, or

A represents $-\text{CH}_2\text{-O-}$, $-\text{CH}_2\text{-S-}$, $-\text{CH}_2\text{-SO-}$, with the heteroatom functionality in position 4, or

A represents a *n*-propylene group and the resulting 6-membered ring may or may not carry in position 5 one fluorine atom, a hydroxy group or an oxo group, carry two fluorine atoms in one of positions 4 or 5 or be unsaturated in position 4 and 5, or carry in position 4 an alkyl group with 1 to 4 carbon atoms, or

A represents $-\text{CH}_2\text{-O-CH}_2-$, $-\text{CH}_2\text{-S-CH}_2-$, $-\text{CH}_2\text{-SO-CH}_2-$;

R^1 represents H, an alkyl group having 1 to 4 carbon atoms, a hydroxyalkyl group having 2-3 carbon atoms or $\text{R}^{11}\text{OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and R^{11} is H or an alkyl group having 1 to 4 carbon atoms or an alkylene group having 2-3 carbon atoms intramolecularly bound alpha to the carbonyl group in R^1 , or

R^1 represents $\text{R}^{12}\text{OOC-1,4-phenyl-CH}_2-$, where R^{12} is H or an alkyl group having 1 to 4 carbon atoms, or

R^1 represents $\text{R}^{13}\text{-NH-CO-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R^{13} is H or an alkyl group having 1 to 4 carbon atoms or $-\text{CH}_2\text{COOR}^{12}$, where R^{12} is as defined above, or

R^1 represents $\text{R}^{12}\text{OOC-CH}_2\text{-OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R^{12} is as defined above, or

R^1 represents CH_3SO_2- , or

R^1 represents $\text{R}^{12}\text{OCOCO-}$ where R^{12} is as defined above, or

R^1 represents $-\text{CH}_2\text{PO}(\text{OR}^{14})_2$, $-\text{CH}_2\text{SO}_3\text{H}$ or $-\text{CH}_2-(5-(1\text{H})\text{-tetrazolyl})$ where R^{14} is, individually at each occurrence, H, methyl or ethyl;

R^2 represents H or an alkyl group having 1 to 4 carbon atoms or $R^{21}\text{OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted in the position which is alpha to the carbonyl group, and the alpha substituent is a group $R^{22}-(\text{CH}_2)_p-$, wherein $p = 0-2$ and R^{22} is methyl, phenyl, OH, COOR^{21} , and R^{21} is H or an alkyl group having 1 to 4 carbon atoms.

m is 0, 1 or 2, R^3 represents a cyclohexyl group and R^4 represents H, or

m is 1 and R^3 represents a cyclohexyl or phenyl group and R^4 forms an ethylene bridge together with R^1 , or

m is 1 and R^3 and R^4 each represents a cyclohexyl or phenyl group;

R^5 represents H or an alkyl group having 1 to 4 carbon atoms;

n is an integer 2 to 6; and

B represents $-\text{N}(\text{R}^6)-\text{C}(\text{NH})-\text{NH}_2$, wherein R^6 is H or a methyl group, or

B represents $-\text{S}-\text{C}(\text{NH})-\text{NH}_2$, or $-\text{C}(\text{NH})-\text{NH}_2$.

either the compound as such or in the form of a physiologically acceptable salt and including stereoisomers.

2. A compound according to claim 1 wherein R^1 represents $R^{11}\text{OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and R^{11} is H.
3. A compound according to claim 2 wherein A is ethylene and R^5 is H or an alkyl group having 1 to 4 carbon atoms.
4. A compound according to claim 2 wherein A is n-propylene and the resulting 6-membered ring may or may not carry in position 4 on alkyl group with 1 to 4 carbon atoms, and R^5 is H or an alkyl group having 1 to 4 carbon atoms.
5. A compound according to one or more of the preceding claims wherein R^3 is cyclohexyl, m is 1, 2 and R^4 is H.
6. A compound according to one or more of the preceding claims wherein n is 3.
7. A compound according to one or more of the preceding claims having S-configuration on the α -amino acid in the P2 position.
8. A compound according to claim 7 having R-configuration on the α -amino acid in the P3 position.
9. A compound selected from

H-(R)Cha-Pro-Agm
 Me-(R)Cha-Pro-Agm
 $\text{HO}-(\text{CH}_2)_3-(\text{R})\text{Cha-Pro-Agm}$
 $^i\text{PrOOC-CH}_2-(\text{R})\text{Cha-Pro-Agm}$
 $\text{HOOC}-(\text{R},\text{S})\text{CH}(\text{Me})-(\text{R})\text{Cha-Pro-Agm}$
 $\text{HOOC}-(\text{RorS})\text{CH}(\text{Me})-(\text{R})\text{Cha-Pro-Agm/a}$
 $\text{HOOC}-(\text{RorS})\text{CH}(^n\text{Pr})-(\text{R})\text{Cha-Pro-Agm/a}$
 $\text{HOOC}-(\text{RorS})\text{CH}(^n\text{Pr})-(\text{R})\text{Cha-Pro-Agm/b}$
 $\text{HOOC}-(\text{RorS})\text{CH}(\text{Ph})-(\text{R})\text{Cha-Pro-Agm/b}$
 $\text{HOOC}-(\text{R},\text{S})\text{CH}(\text{CH}_2\text{CH}_2\text{Ph})-(\text{R})\text{Cha-Pro-Agm}$
 $\text{HOOC}-(\text{RorS})\text{CH}(\text{CH}_2\text{CH}_2\text{Ph})-(\text{R})\text{Cha-Pro-Agm/a}$
 $\text{HOOC-CH}_2\text{-CH}_2-(\text{R})\text{Cha-Pro-Agm}$
 $\text{EtOOC-CO}-(\text{R})\text{Cha-Pro-Agm}$
 $(\text{R},\text{S})\text{Bla}-(\text{R})\text{Cha-Pro-Agm}$
 $\text{HOOC}-(\text{RorS})\text{CH}(\text{CH}_2\text{CH}_2\text{Ph})-(\text{R})\text{Cha-Pro-Agm/b}$

H-(R)Cha-Pro-Nag
ⁿBu-(R)Cha-Pro-Nag
 HO-(CH₂)₃-(R)Cha-Pro-Nag
 EtOOC-CH₂-(R)Cha-Pro-Nag
 5 ⁱPrOOC-CH₂-(R)Cha-Pro-Nag
 ^tBuOOC-CH₂-(R)Cha-Pro-Nag
 HOOC-CH₂-OOC-CH₂-(R)Cha-Pro-Nag
 H₂N-CO-OH₂-(R)Cha-Pro-Nag
 HOOC-CH₂-NH-CO-OH₂-(R)Cha-Pro-Nag
 10 (HOOC-CH₂)₂-(R)Cha-Pro-Nag
 HOOC-CH₂-(nBu)(R)Cha-Pro-Nag
 HOOC-(R,S)CH(Me)-(R)Cha-Pro-Nag
 HOOC-(RorS)CH(Me)-(R)Cha-Pro-Nag/a
 EtOOC-(R,S)CH(Me)-(R)Cha-Pro-Nag
 15 HOOC-(RorS)CH(ⁿPr)-(R)Cha-Pro-Nag/a
 HOOC-(R)CH(CH₂-OH)-(R)Cha-Pro-Nag
 HOOC-(R,S)CH(Ph)-(R)Cha-Pro-Nag
 HOOC-(S)CH(CH₂CH₂Ph)-(R)Cha-Pro-Nag
 HOOC-(R)CH(CH₂CH₂Ph)-(R)Cha-Pro-Nag
 20 HOOC-CH₂-CH₂-(R)Cha-Pro-Nag
 EtOOC-CH₂-OH₂-(R)Cha-Pro-Nag
 HOOC-(CH₂)₃-(R)Cha-Pro-Nag
 EtOOC-(CH₂)₃-(R)Cha-Pro-Nag
 HOOC-CO-(R)Cha-Pro-Nag
 25 MeOOC-CO-(R)Cha-Pro-Nag
 (R,S)Bla-(R)Cha-Pro-Nag
 HOOC-(R,S)CH(CH₂COOH)-(R)Cha-Pro-Nag
 MeOOC-(R,S)CH(CH₂COOMe)-(R)Cha-Pro-Nag
 HOOC-Ph-4-CH₂-(R)Cha-Pro-Nag
 30 (HO)₂P(O)-CH₂-(R)Cha-Pro-Nag
 EtO(HO)P(O)-CH₂-(R)Cha-Pro-Nag
 (EtO)₂P(O)-CH₂-(R)Cha-Pro-Nag
 HOOC-CH₂-(R)Cha-Pro-Mag
 H-(R,S)Pro(3-Ph)-Pro-Agm
 35 H-(R,S)Pro(3-(trans)Ch)-Pro-Agm
 HOOC-CH₂-(R,S)Pro(3-(trans)Ph)-Pro-Agm
 HOOC-CH₂-(R,S)Pro(3-(trans)Ph)-Pro-Nag
 HOOC-CH₂-(Me)(R)Cha-(R,S)Pic-Agm
 HOOC-(R,S)CH(Me)-(R)Cha-Pic-Agm
 40 HOOC-(RorS)CH(Me)-(R)Cha-Pic-Agm/a
 HOOC-CH₂-CH₂-(R)Cha-Pic-Agm
 H-(R)Cha-Pic-Nag
 Me-(R)Cha-(R,S)Pic-Nag
 MeOOC-CH₂-(R)Cha-Pic-Nag
 45 ⁱPrOOC-CH₂-(R)Cha-Pic-Nag
 HOOC-CH₂-(Me)(R)Cha-(RorS)Pic-Nag/b
 HOOC-(R,S)CH(Me)-(R)Cha-(R,S)Pic-Nag
 HOOC-(RorS)CH(Me)-(R)Cha-(RorS)Pic-Nag/c
 HOOC-CH₂-CH₂-(R)Cha-Pic-Nag
 50 HOOC-CH₂-(R)Cha-(R,S)Mor-Agm
 HOOC-CH₂-(R)Cha-(RorS)Mor-Nag
 H-(R)Cha-Aze-Nag
 HOOC-CH₂-(R)Cha-Aze-Nag
 H-(R)Cha-Pro(5-(S)Me)-Nag
 55 HOOC-CH₂-(R)Cha-(RorS)Pic(4,5-dehydro)-Nag/b
 HOOC-CH₂-(R)Cha-(R)Plc(4-(R)Me)-Nag
 HOOC-CH₂-(R)Cgl-Pic-Nag
 H-(R)Hoc-Pro-Nag

HOOC-CH₂-(R)Hoc-Pro-Nag
 HOOC-CH₂-(R)Hoc-Pic-Nag
 HOOC-CH₂-(R)Dph-Pic-Nag
 HOOC-CH₂-(R)Dch-Pic-Nag
 5 HOOC-CH₂-(R)Cha-Pro(5-(R,S)Me)-Nag
 HOOC-CH₂-(R)Cha-Pic(4-(R)Me)-Nag
 H-(R)Cha-Pic(4-(R)Me)-Nag
 HOOC-CH₂-(R)Cha-Pic(6-(S)Me)-Nag

10 either as such or in the form of a physiologically acceptable salt and including stereoisomers.

10. A compound selected from

HOOC-CH₂-(R)Cha-Pro-Agm
 15 HOOC-CH₂-(Me)(R)Cha-Pro-Agm
 HOOC-(RorS)CH(Me)-(R)Cha-Pro-Agm/b
 HOOC-CH₂-(R)Cha-Pro-Nag
 HOOC-CH₂-(R)Cha-Pic-Agm
 HOOC-(RorS)CH(Me)-(R)Cha-Pic-Agm/b
 20 HOOC-(RorS)CH(Me)-(R)Cha-(RorS)Pic-Nag/d
 HOOC-CH₂-(R)Cha-Pro(5-(S)Me)-Nag
 HOOC-CH₂-(R)Cha-Pic(4-(S)Me)-Nag

either as such or in the form of a physiologically acceptable salt and including stereoisomers.

25 11. The compound

HOOC-CH₂-(Me)(R)Cha-Pro-Nag,

30 either as such or in the form of a physiologically acceptable salt and including stereoisomers.

12. The compound

HOOC-(RorS)CH(Me)-(R)Cha-Pro-Nag/b,

35 either as such or in the form of a physiologically acceptable salt and including stereoisomers.

13. The compound

40 HOOC-CH₂-(R)Cha-Pic-Nag

either as such or in the form of a physiologically acceptable salt and including stereoisomers.

45 14. A process for preparing a compound according to any of claims 1-13, which process comprises coupling of an N-terminally protected amino acid or dipeptide or a preformed, N-terminally alkylated protected dipeptide to a compound


H₂N-(CH₂)_n-X

50 wherein n is an interger 2 to 6 and X is an unprotected or protected guanidino group or a protected amino group, or a group transferable into an amino group, where the amino group is subsequently transferred into a guanidino group,

and if desired forming a physiologically acceptable salt, and in those cases where the reaction results in a mixture of stereoisomers, these are optionally separated by standard chromatographic or re-crystallisation techniques, and
 55 if desired a single stereoisomer is isolated.

15. A process according to claim 14 for preparing a compound according to any of claims 1-13, which process comprises:


a) (Method I) Coupling of an N-terminally protected dipeptide with either a protected- or unprotected amino guanidine or a straight chain alkylamine carrying a protected or masked amino group at the terminal end of the alkyl chain, using standard peptide coupling, as shown in the formula:



wherein R^3 , R^4 , R^5 , n , m and A are as defined in Formula I, R^6 is H or alkyl, W_1 is an amino protecting group such as tertiarybutoxy carbonyl and benzyloxy carbonyl and X is $-NH-C(NH)NH_2$, $-NH-C(NH)NH-W_2$, $-N(W_2)-C(NH)NH-W_2$,


$-NH-C(NW_2)-NH-W_2$ or $-NH-W_2$, where W_2 is an amine protecting group such as tertiarybutoxy carbonyl or benzyloxy carbonyl, or X is a masked amino group such as azide, giving the protected peptide, or

b) (Method II) Coupling of an N-terminally protected amino acid, with either a protected- or unprotected amino guanidine or a straight chain alkylamine carrying a protected or masked amino group at the terminal end of the alkyl chain, using standard peptide coupling, as shown in the formula




wherein W_1 , A, R^5 and X are as defined above followed by deprotection of the W_1 -group and coupling with the N-terminal amino acid, in a protected form, or

40 c) (Method III) Coupling of a preformed N-terminally alkylated and protected dipeptide, prepared by standard peptide coupling, with either a protected or unprotected amino guanidine or a straight chain alkylamine carrying a protected or masked aminogroup at the terminal end of the alkyl chain, using standard peptide coupling, as shown in the formula



wherein R^2 , R^3 , R^4 , R^5 , n , m , A and X are defined as above provided that R^2 is other than H and W_3 is an acyl protecting group such as trifluoroacetyl, whereupon the final compounds are made in any of the following ways, depending on the nature of the X -group used: Removal of the protecting group(s) (when $X = -\text{NH}-\text{C}(\text{NH})\text{NH}_2$, $\text{NH}-\text{C}(\text{NH})\text{NH}-W_2$, $-\text{N}(W_2)-\text{C}(\text{NH})\text{NH}-W_2$, $-\text{NH}-\text{C}(\text{NW}_2)\text{NH}-W_2$) or a selective deprotection of the W_1 -group (e.g. when $X = -\text{NH}-\text{C}(\text{NH})\text{NH}-W_2$, $-\text{N}(W_2)-\text{C}(\text{NH})\text{NH}-W_2$, $-\text{NH}-\text{C}(\text{NW}_2)\text{NH}-W_2$, W_2 in this case must be orthogonal to W_1) followed by alkylation of the N-terminal nitrogen and deprotection or a selective deprotection/unmasking of the terminal alkylamino function ($X = \text{NH}-W_2$, W_2 in this case must be orthogonal to W_1 and W_3 , respectively, or X = a masked aminogroup, such as azide) followed by a guanidation reaction, using standard methods, of the free amine and deprotection of the W_1 - or W_3 -group, respectively, and if desired forming a physiologically acceptable salt, and in those cases where the reaction results in a mixture of stereoisomers, these are optionally separated by standard chromatographic or re-crystallisation techniques, and if desired a single stereoisomer is isolated.

16. Use of a compound of the formula:



either as such or in the form of a salt, and as such or having the guanidino group either mono protected at the δ -nitrogen or diprotected at the δ -nitrogens or the γ , δ -nitrogens, as a starting material in synthesis of a serine protease inhibitor, and in particular in synthesis of a thrombin inhibitor.

17. Use according to claim 16, where the serine protease inhibitor is a peptidic compound.

18. A compound according to any of claims 1-13 for use in therapy.

19. A compound according to claim 18 for use as an anticoagulant or antithrombotic agent.

20. A pharmaceutical preparation comprising an effective amount of a compound as outlined in claims 1-13 in conjunction with one or more pharmaceutical carriers.

21. A pharmaceutical preparation according to claim 20 for use as an anticoagulant or antithrombotic agent.

22. Use of compound according to any of claims 1-13 as an active ingredient for manufacture of a pharmaceutical preparation for inhibition of thrombin in a human or animal organism.

23. Use according to claim 16 where the compound is δ -N-benzyloxycarbonyl-noragmatine either as such or in the form of a salt, or having protection at the δ -nitrogen or γ -nitrogen.

24. Use according to claim 23 where the compound is α -N-tert.butyloxycarbonyl- δ -N-benzyloxycarbonyl-noragmatine either as such or in the form of a salt, or having protection at the δ -nitrogen or γ -nitrogen.

25. A compound δ -N-benzyloxycarbonyl-noragmatine either as such or in the form of a salt, or having further protection at the δ -nitrogen or γ -nitrogen.


26. A compound according to claim 25 which is δ -N-benzyloxycarbonyl-noragmatine.

27. A compound α -N-tert.butyloxy carbonyl- δ -N-benzyloxycarbonyl-noragmatine either as such or in the form of a salt, or having protection at the δ -nitrogen or γ -nitrogen.

28. A compound according to claim 27 which is α -N-tert.butyloxycarbonyl- δ -N-benzyloxycarbonyl-noragmatine.

Patentansprüche

1. Verbindung der allgemeinen Formel



Formel I

worin:

A für eine Methylengruppe steht, oder

A für eine Ethylengruppe steht und der sich ergebende 5-gliedrige Ring gegebenenfalls ein oder zwei Fluor-
atome, eine Hydroxylgruppe oder eine Oxogruppe in Position 4 trägt oder gegebenenfalls ungesättigt ist, oder

A für -CH₂-O-, -CH₂-S- oder -CH₂-SO- steht, wobei sich die Heteroatomfunktionalität in Position 4 befindet,
oder

A für eine n-Propylengruppe steht und der sich ergebende 6-gliedrige Ring gegebenenfalls in Position 5 ein
Fluoratom, eine Hydroxylgruppe oder eine Oxogruppe trägt, in einer der Positionen 4 oder 5 zwei Fluoratom-
e trägt oder in Position 4 und 5 ungesättigt ist oder in Position 4 eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen
trägt, oder

A für -CH₂-O-CH₂-, -CH₂-S-CH₂- oder -CH₂-SO-CH₂- steht;

R¹ für H, eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen, eine Hydroxyalkylgruppe mit 2-3 Kohlenstoffatomen
oder R¹¹OOC-Alkyl-, worin die Alkylgruppe 1 bis 4 Kohlenstoffatome aufweist und R¹¹ H oder eine Alkylgruppe
mit 1 bis 4 Kohlenstoffatomen oder eine in alpha-Stellung zur Carbonylgruppe in R¹ intramolekular gebundene
Alkylengruppe mit 2-3 Kohlenstoffatomen darstellt, steht, oder

R¹ für R¹²OOC-1,4-Phenyl-CH₂-, worin R¹² H oder eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen darstellt,
steht, oder

R¹ für R¹³-NH-CO-Alkyl-, worin die Alkylgruppe 1 bis 4 Kohlenstoffatome aufweist und gegebenenfalls in
alpha-Stellung zur Carbonylgruppe mit einer Alkylgruppe mit 1 bis 4 Kohlenstoffatomen substituiert ist und R¹³
H, eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen oder -CH₂COOR¹², worin R¹² die oben angegebene Bedeu-
tung hat, darstellt, steht, oder

R¹ für R¹²OOC-CH₂-OOC-Alkyl-, worin die Alkylgruppe 1 bis 4 Kohlenstoffatome aufweist und gegebenenfalls
in alpha-Stellung zur Carbonylgruppe mit einer Alkylgruppe mit 1 bis 4 Kohlenstoffatomen substituiert ist und
R¹² die oben angegebene Bedeutung hat, steht, oder

R¹ für CH₃SO₂- steht, oder

R¹ für R¹²OCOCO-, worin R¹² die oben angegebene Bedeutung hat, steht, oder

R¹ für -CH₂PO(OR¹⁴)₂-, -CH₂SO₃H oder -CH₂-(5-(1H)-Tetrazolyl) steht, wobei R¹⁴ unabhängig voneinander
jeweils für H, Methyl oder Ethyl steht;

R² für H, eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen oder R²¹OOC-Alkyl-, worin die Alkylgruppe 1 bis 4

Kohlenstoffatome aufweist und gegebenenfalls in alpha-Stellung zur Carbonylgruppe mit einer Gruppe R^{22} - $(CH_2)_p$ -, worin $p = 0-2$ ist und R^{22} für Methyl, Phenyl, OH oder $COOR^{21}$ steht, substituiert ist und R^{21} H oder eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen darstellt, steht;

m für 0, 1 oder 2, R^3 für eine Cyclohexylgruppe und R^4 für H steht, oder

m für 1 und R^3 für eine Cyclohexyl- oder Phenylgruppe steht und R^4 gemeinsam mit R^1 eine Ethylenbrücke bildet, oder

m für 1 steht und R^3 und R^4 jeweils für eine Cyclohexyl- oder Phenylgruppe stehen;

R^5 für H oder eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen steht;

n für eine ganze Zahl von 2 bis 6 steht und

B für $-N(R^6)-C(NH)-NH_2$, worin R^6 H oder eine Methylgruppe darstellt, steht, oder

B für $-S-C(NH)-NH_2$ oder $-C(NH)-NH_2$ steht,

entweder als solche oder in Form eines physiologisch unbedenklichen Salzes und einschließlich Stereoisomeren.

2. Verbindung nach Anspruch 1, in der R^1 für $R^{11}OOC$ -Alkyl-, worin die Alkylgruppe 1 bis 4 Kohlenstoffatome aufweist und R^{11} H darstellt, steht.

3. Verbindung nach Anspruch 2, in der A für Ethylen und R^5 für H oder eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen steht.

4. Verbindung nach Anspruch 2, in der A für n-Propylen steht und der sich ergebende 6-gliedrige Ring gegebenenfalls in Position 4 eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen trägt und R^5 für H oder eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen steht.

5. Verbindung nach einem oder mehreren der vorhergehenden Ansprüche, in der R^3 für Cyclohexyl, m für 1 oder 2 und R^4 für H steht.

6. Verbindung nach einem oder mehreren der vorhergehenden Ansprüche, in der n für 3 steht.

7. Verbindung nach einem oder mehreren der vorhergehenden Ansprüche, die an der α -Aminosäure in P2-Position S-Konfiguration aufweist.

8. Verbindung nach Anspruch 7, die an der α -Aminosäure in P3-Position R-Konfiguration aufweist.

9. Verbindung, ausgewählt unter

H-(R)Cha-Pro-Agm

Me-(R)Cha-Pro-Agm

HO-(CH₂)₃-(R)Cha-Pro-Agm

ⁱPrOOC-CH₂-(R)Cha-Pro-Agm

HOOC-(R,S)CH(Me)-(R)Cha-Pro-Agm

HOOC-(R oder S)CH(Me)-(R)Cha-Pro-Agm/a

HOOC-(R oder S)CH(ⁿPr)-(R)Cha-Pro-Agm/a

HOOC-(R oder S)CH(ⁿPr)-(R)Cha-Pro-Agm/b

HOOC-(R oder S)CH(Ph)-(R)Cha-Pro-Agm/b

HOOC-(R,S)CH(CH₂CH₂Ph)-(R)Cha-Pro-Agm

HOOC-(R oder S)CH(CH₂CH₂Ph)-(R)Cha-Pro-Agm/a

HOOC-CH₂-CH₂-(R)Cha-Pro-Agm

EtOOC-CO-(R)Cha-Pro-Agm

(R,S)Bla-(R)Cha-Pro-Agm

HOOC-(R oder S)CH(CH₂CH₂Ph)-(R)Cha-Pro-Agm/b


H-(R)Cha-Pro-Nag
ⁿBu-(R)Cha-Pro-Nag
 HO-(CH₂)₃-(R)Cha-Pro-Nag
 EtOOC-CH₂-(R)Cha-Pro-Nag
 5 ⁱPrOOC-CH₂-(R)Cha-Pro-Nag
 ^tBuOOC-CH₂-(R)Cha-Pro-Nag
 HOOC-CH₂-OOC-CH₂-(R)Cha-Pro-Nag
 H₂N-CO-CH₂-(R)Cha-Pro-Nag
 HOOC-CH₂-NH-CO-CH₂-(R)Cha-Pro-Nag
 10 (HOOC-CH₂)₂-(R)Cha-Pro-Nag
 HOOC-CH₂-(nBu)(R)Cha-Pro-Nag
 HOOC-(R,S)CH(Me)-(R)Cha-Pro-Nag
 HOOC-(R oder S)CH(Me)-(R)Cha-Pro-Nag/a
 EtOOC-(R,S)CH(Me)-(R)Cha-Pro-Nag
 15 HOOC-(R oder S)CH(ⁿPr)-(R)Cha-Pro-Nag/a
 HOOC-(R)CH(CH₂-OH)-(R)Cha-Pro-Nag
 HOOC-(R,S)CH(Ph)-(R)Cha-Pro-Nag
 HOOC-(S)CH(CH₂CH₂Ph)-(R)Cha-Pro-Nag
 HOOC-(R)CH(CH₂CH₂Ph)-(R)Cha-Pro-Nag
 20 HOOC-CH₂-CH₂-(R)Cha-Pro-Nag
 EtOOC-CH₂-CH₂-(R)Cha-Pro-Nag
 HOOC-(CH₂)₃-(R)Cha-Pro-Nag
 EtOOC-(CH₂)₃-(R)Cha-Pro-Nag
 HOOC-CO-(R)Cha-Pro-Nag
 25 MeOOC-CO-(R)Cha-Pro-Nag
 (R,S)Bla-(R)Cha-Pro-Nag
 HOOC-(R,S)CH(CH₂COOH)-(R)Cha-Pro-Nag
 MeOOC-(R,S)CH(CH₂COOMe)-(R)Cha-Pro-Nag
 HOOC-Ph-4-CH₂-(R)Cha-Pro-Nag
 30 (HO)₂P(O)-CH₂-(R)Cha-Pro-Nag
 EtO(HO)P(O)-CH-(R)Cha-Pro-Nag
 (EtO)₂P(O)-CH₂-(R)Cha-Pro-Nag
 HOOC-CH₂-(R)Cha-Pro-Mag
 H-(R,S)Pro(3-Ph)-Pro-Agm
 35 H-(R,S)Pro(3-(trans)Ch)-Pro-Agm
 HOOC-CH₂-(R,S)Pro(3-(trans)Ph)-Pro-Agm
 HOOC-CH₂-(R,S)Pro(3-(trans)Ph)-Pro-Nag
 HOOC-CH₂-(Me)(R)Cha-(R,S)Pic-Agm
 HOOC-(R,S)CH(Me)-(R)Cha-Pic-Agm
 40 HOOC-(R oder S)CH(Me)-(R)Cha-Pic-Agm/a
 HOOC-CH₂-CH₂-(R)Cha-Pic-Agm
 H-(R)Cha-Pic-Nag
 Me-(R)Cha-(R,S)Pic-Nag
 MeOOC-CH₂-(R)Cha-Pic-Nag
 45 H₂N-CO-CH₂-(R)Cha-Pro-Nag
 HOOC-CH₂-NH-CO-CH₂-(R)Cha-Pro-Nag
 (HOOC-CH₂)₂-(R)Cha-Pro-Nag
 HOOC-CH₂-(nBu)(R)Cha-Pro-Nag
 HOOC-(R,S)CH(Me)-(R)Cha-Pro-Nag
 50 HOOC-(R oder S)CH(Me)-(R)Cha-Pro-Nag/a
 EtOOC-(R,S)CH(Me)-(R)Cha-Pro-Nag
 HOOC-(R oder S)CH(ⁿPr)-(R)Cha-Pro-Nag/a
 HOOC-(R)CH(CH₂-OH)-(R)Cha-Pro-Nag
 HOOC-(R,S)CH(Ph)-(R)Cha-Pro-Nag
 55 HOOC-(S)CH(CH₂CH₂Ph)-(R)Cha-Pro-Nag
 HOOC-(R)CH(CH₂CH₂Ph)-(R)Cha-Pro-Nag
 HOOC-CH₂-CH₂-(R)Cha-Pro-Nag
 EtOOC-CH₂-CH₂-(R)Cha-Pro-Nag

HOOC-(CH₂)₃-(R)Cha-Pro-Nag
 EtOOC-(CH₂)₃-(R)Cha-Pro-Nag
 HOOC-CO-(R)Cha-Pro-Nag
 MeOOC-CO-(R)Cha-Pro-Nag
 5 (R,S)Bla-(R)Cha-Pro-Nag
 HOOC-(R,S)CH(CH₂COOH)-(R)Cha-Pro-Nag
 MeOOC-(R,S)CH(CH₂COOMe)-(R)Cha-Pro-Nag
 HOOC-Ph-4-CH₂-(R)Cha-Pro-Nag
 (HO)₂P(O)-CH₂-(R)Cha-Pro-Nag
 10 EtO(HO)P(O)-CH₂-(R)Cha-Pro-Nag
 (EtO)₂P(O)-CH₂-(R)Cha-Pro-Nag
 HOOC-CH₂-(R)Cha-Pro-Mag
 H-(R,S)Pro(3-Ph)-Pro-Agm
 H-(R,S)Pro(3-(trans)Ch)-Pro-Agm
 15 HOOC-CH₂-(R,S)Pro(3-(trans)Ph)-Pro-Agm
 HOOC-CH₂-(R,S)Pro(3-(trans)Ph)-Pro-Nag
 HOOC-CH₂-(Me)(R)Cha-(R,S)Pic-Agm
 HOOC-(R,S)CH(Me)-(R)Cha-Pic-Agm
 HOOC-(R oder S)CH(Me)-(R)Cha-Pic-Agm/a
 20 HOOC-CH₂-CH₂-(R)Cha-Pic-Agm
 H-(R)Cha-Pic-Nag
 Me-(R)Cha-(R,S)Pic-Nag
 MeOOC-CH₂-(R)Cha-Pic-Nag
ⁱPrOOC-CH₂-(R)Cha-Pic-Nag
 25 HOOC-CH₂-(Me)(R)Cha-(R oder S)Pic-Nag/b
 HOOC-(R,S)CH(Me)-(R)Cha-(R,S)Pic-Nag
 HOOC-(R oder S)CH(Me)-(R)Cha-(R oder S)Pic-Nag/c
 HOOC-CH₂CH₂-(R)Cha-Pic-Nag
 HOOC-CH₂-(R)Cha-(R,S)Mor-Agm
 30 HOOC-CH₂-(R)Cha-(R oder S)Mor-Nag
 H-(R)Cha-Aze-Nag
 HOOC-CH₂-(R)Cha-Aze-Nag
 H-(R)Cha-Pro(5-(S)Me)-Nag
 HOOC-CH₂-(R)Cha-(R oder S)Pic(4,5-dehydro)-Nag/b
 35 HOOC-CH₂-(R)Cha-(R)Pic(4-(R)Me)-Nag
 HOOC-CH₂-(R)Cgl-Pic-Nag
 H-(R)Hoc-Pro-Nag
 HOOC-CH₂-(R)Hoc-Pro-Nag
 HOOC-CH₂-(R)Hoc-Pic-Nag
 40 HOOC-CH₂-(R)Dph-Pic-Nag
 HOOC-CH₂-(R)Dch-Pic-Nag
 HOOC-CH₂-(R)Cha-Pro(5-(R,S)Me)-Nag
 HOOC-CH₂-(R)Cha-Pic(4-(R)Me)-Nag
 H-(R)Cha-Pic(4-(R)Me)-Nag
 45 HOOC-CH₂-(R)Cha-Pic(6-(S)Me)-Nag

entweder als solche oder in Form eines physiologisch unbedenklichen Salzes und einschließlich Stereoisomeren.


10. Verbindung, ausgewählt unter

50 HOOC-CH₂-(R)Cha-Pro-Agm
 HOOC-CH₂-(Me)(R)Cha-Pro-Agm
 HOOC-(R oder S)CH(Me)-(R)Cha-Pro-Agm/b
 HOOC-CH₂-(R)Cha-Pro-Nag
 55 HOOC-CH₂-(R)Cha-Pic-Agm
 HOOC-(R oder S)CH(Me)-(R)Cha-Pic-Agm/b
 HOOC-(R oder S)CH(Me)-(R)Cha-(R oder S)Pic-Nag/d
 HOOC-CH₂-(R)Cha-Pro(5-(S)Me)-Nag



entweder als solche oder in Form eines physiologisch unbedenklichen Salzes und einschließlich Stereoisomeren.

5 11. Verbindung



entweder als solche oder in Form eines physiologisch unbedenklichen Salzes und einschließlich Stereoisomeren.

10

12. Verbindung



15 entweder als solche oder in Form eines physiologisch unbedenklichen Salzes und einschließlich Stereoisomeren.

13. Verbindung




20

entweder als solche oder in Form eines physiologisch unbedenklichen Salzes und einschließlich Stereoisomeren.

14. Verfahren zur Herstellung einer Verbindung nach einem der Ansprüche 1-13, bei dem man eine N-terminal geschützte Aminosäure, ein N-terminal geschütztes Dipeptid oder ein vorher hergestelltes N-terminal alkyliertes geschütztes Dipeptid zu einer Verbindung

25



30

kuppelt, worin n für eine ganze Zahl von 2 bis 6 und X für eine ungeschützte oder geschützte Guanidinogruppe oder eine geschützte Aminogruppe oder eine in eine Aminogruppe überführbare Gruppe steht, wobei man die Aminogruppe anschließend in eine Guanidinogruppe überführt, und gegebenenfalls ein physiologisch unbedenkliches Salz herstellt und in den Fällen, in denen bei der Umsetzung ein Stereoisomerengemisch anfällt, dieses Gemisch gegebenenfalls nach Standardmethoden der Chromatographie oder Umkristallisation trennt und gegebenenfalls ein einzelnes Stereoisomer isoliert.

35

15. Verfahren nach Anspruch 14 zur Herstellung einer Verbindung nach einem der Ansprüche 1-13, bei dem man:


40

a) (Methode I) ein N-terminal geschütztes Dipeptid entweder mit einem geschützten oder ungeschützten Aminoguanidin oder einem geradkettigen Alkylamin mit einer geschützten oder maskierten Aminogruppe am terminalen Ende der Alkylkette nach Standardpeptidkupplungsmethoden kuppelt, wie es in der Formel gezeigt ist:

45


50

55



worin R^3 , R^4 , R^5 , n , m und A die in Formel I angegebenen Bedeutungen haben und R^6 für H oder Alkyl, W_1 für eine Aminoschutzgruppe wie tert.-Butoxycarbonyl und Benzyloxycarbonyl und X für $-NH-C(NH)NH_2$, $-NH-C(NH)NH-W_2$, $-N(W_2)-C(NH)NH-W_2$, $-NH-C(NW_2)NH-W_2$ oder $-NH-W_2$, worin W_2 eine Aminoschutzgruppe wie tert.-Butoxycarbonyl oder Benzyloxycarbonyl darstellt, oder für eine maskierte Aminogruppe wie Azid steht, wobei man das geschützte Peptid erhält, oder


b) (Methode II) eine N-terminal geschützte Aminosäure entweder mit einem geschützten oder ungeschützten Aminoguanidin oder einem geradkettigen Alkylamin mit einer geschützten oder maskierten Aminogruppe am terminalen Ende der Alkylkette nach Standardpeptidkupplungsmethoden kuppelt, wie es in der Formel gezeigt ist:



worin W_1 , A , R^5 und X die oben angegebenen Bedeutungen haben, und danach die Gruppe W_1 entschützt und mit der N-terminalen Aminosäure in geschützter Form kuppelt, oder


c) (Methode III) ein nach Standardpeptidkupplungsmethoden vorher hergestelltes N-terminal alkyliertes und

geschütztes Dipeptid entweder mit einem geschützten oder ungeschützten Aminoguanidin oder einem geradkettigen Alkylamin mit einer geschützten oder maskierten Aminogruppe am terminalen End der Alkylkette nach Standardpeptidkupplungsmethoden kuppelt, wie es in der Formel gezeigt ist:



worin R^2 , R^3 , R^4 , R^5 , n , m , A und X die oben angegebenen Bedeutungen haben mit der Maßgabe, daß R^2 nicht für H steht und W_3 eine Acylschutzgruppe wie Trifluoracyl darstellt, wonach man die Endverbindungen je nach Art der verwendeten Gruppe X auf eine der folgenden Arten herstellt: Abspaltung der Schutzgruppe(n) (wenn $X = -NH-C(NH)NH_2$, $NH-C(NH)NH-W_2$, $-N(W_2)-C(NH)NH-W_2$, $-NH-C(NW_2)NH-W_2$) oder selektive Entschützung der Gruppe W_1 (z.B. wenn $X = -NH-C(NH)NH-W_2$, $-N(W_2)-C(NH)NH-W_2$, $-NH-C(NW_2)NH-W_2$, in diesem Fall muß W_2 zu W_1 orthogonal sein) und anschließende Alkylierung des N-terminalen Stickstoffs und Entschützung oder selektive Entschützung/Demaskierung der terminalen Alkylaminofunktion ($X = NH-W_2$, in diesem Fall muß W_2 zu W_1 bzw. W_3 orthogonal sein, oder $X =$ maskierte Aminogruppe wie Azid) und anschließende Guanidierungsreaktion des freien Amins nach Standardmethoden und Entschützung der Gruppe W_1 bzw. W_3 , und gegebenenfalls ein physiologisch unbedenkliches Salz herstellt und in den Fällen, in denen bei der Umsetzung ein Stereoisomerengemisch anfällt, dieses Gemisch gegebenenfalls nach Standardmethoden der Chromatographie oder Umkristallisation trennt und gegebenenfalls ein einzelnes Stereoisomer isoliert.

16. Verwendung einer Verbindung der Formel



entweder als solche oder in Form eines Salzes und als solche oder mit am δ -Stickstoffatom monogeschützter oder an den δ -Stickstoffatomen oder den γ, δ -Stickstoffatomen bisgeschützter Guanidinogruppe als Edukt bei der Synthese eines Serinprotease-Inhibitors und insbesondere bei der Synthese eines Thrombininhibitors.


17. Verwendung nach Anspruch 16, wobei der Serinprotease-Inhibitor eine peptidische Verbindung ist.

18. Verbindung nach einem der Ansprüche 1-13 zur Verwendung bei der Therapie.

19. Verbindung nach Anspruch 18 zur Verwendung als Antikoagulans oder Antithrombotikum.
20. Pharmazeutische Zubereitung, enthaltend eine wirksame Menge einer Verbindung gemäß den Ansprüchen 1-13 in Verbindung mit einem oder mehreren pharmazeutischen Trägern.
21. Pharmazeutische Zubereitung nach Anspruch 20 zur Verwendung als Antikoagulans oder Antithrombotikum.
22. Verwendung einer Verbindung nach einem der Ansprüche 1-13 als Wirkstoff zur Herstellung einer pharmazeutischen Zubereitung zur Thrombininhibierung in einem menschlichen oder tierischen Organismus.
23. Verwendung nach Anspruch 16, wobei es sich bei der Verbindung um δ -N-Benzoyloxycarbonyl-noragmatin entweder als solches oder in Form eines Salzes oder mit Schutz am δ - oder γ -Stickstoffatom handelt.
24. Verwendung nach Anspruch 23, wobei es sich bei der Verbindung um α -N-tert.-Butyloxycarbonyl- δ -N-benzyloxycarbonyl-noragmatin entweder als solches oder in Form eines Salzes oder mit Schutz am δ - oder γ -Stickstoffatom handelt.
25. Verbindung δ -N-Benzoyloxycarbonyl-noragmatin entweder als solche oder in Form eines Salzes oder mit weiterem Schutz am δ - oder γ -Stickstoffatom.
26. Verbindung nach Anspruch 25, bei der es sich um δ -N-Benzoyloxycarbonyl-noragmatin handelt.
27. Verbindung α -N-tert.-Butyloxycarbonyl- δ -N-benzyloxycarbonyl-noragmatin entweder als solche oder in Form eines Salzes oder mit weiterem Schutz am δ - oder γ -Stickstoffatom.
28. Verbindung nach Anspruch 27, bei der es sich um α -N-tert.-Butyloxycarbonyl- δ -N-benzyloxycarbonyl-noragmatin handelt.

Revendications

1. Composé de formule générale



Formula I

dans laquelle :

- A représente un groupement méthylène, ou
- A représente un groupement éthylène et le cycle à 5 membres obtenu peut ou peut ne pas porter un ou deux atomes de fluor, un groupement hydroxy ou un groupement oxo en position 4, ou peut ou peut ne pas être insaturé, ou
- A représente -CH₂-O-, -CH₂-S-, -CH₂-SO-, avec la fonctionnalité hétéroatomique en position 4, ou
- A représente un groupement n-propylène et le cycle à 6 membres obtenu peut ou peut ne pas porter en position 5 un atome de fluor, un groupement hydroxy ou un groupement oxo, porter deux atomes de fluor en l'une des positions 4 ou 5, ou être insaturé en position 4 et 5, ou porter en position 4 un groupement alkyle avec 1

à 4 atomes de carbone, ou

A représente $-\text{CH}_2-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{S}-\text{CH}_2-$, $-\text{CH}_2-\text{SO}-\text{CH}_2-$;

R^1 représente H, un groupement alkyle possédant 1 à 4 atomes de carbone, un groupement hydroxyalkyle possédant 2-3 atomes de carbone ou $\text{R}^{11}\text{OOC-alkyl-}$, le groupement alkyle possédant 1 à 4 atomes de carbone et R^{11} étant H ou un groupement alkyle possédant 1 à 4 atomes de carbone ou un groupement alkylène possédant 2-3 atomes de carbone liés de manière intramoléculaire en alpha au groupement carbonyle dans R^1 , ou

R^1 représente $\text{R}^{12}\text{OOC-1,4-phényl-CH}_2-$, R^{12} étant H ou un groupement alkyle possédant 1 à 4 atomes de carbone, ou

R^1 représente $\text{R}^{13}\text{-NH-CO-alkyl-}$, le groupement alkyle possédant 1 à 4 atomes de carbone et pouvant être substitué en alpha au carbonyle avec un groupement alkyle possédant 1 à 4 atomes de carbone, et R^{13} étant H ou un groupement alkyle possédant 1 à 4 atomes de carbone ou $-\text{CH}_2\text{COOR}^{12}$, R^{12} étant comme défini ci-dessus, ou

R^1 représente $\text{R}^{12}\text{OOC-CH}_2\text{-OOC-alkyl-}$, le groupement alkyle possédant 1 à 4 atomes de carbone et pouvant être substitué en alpha au carbonyle avec un groupement alkyle possédant 1 à 4 atomes de carbone, et R^{12} étant comme défini ci-dessus, ou

R^1 représente CH_3SO_2- , ou

R^1 représente $\text{R}^{12}\text{OCOCO-}$, R^{12} étant comme défini ci-dessus, ou

R^1 représente $-\text{CH}_2\text{PO(OR}^{14})_2$, $-\text{CH}_2\text{SO}_3\text{H}$ ou $-\text{CH}_2\text{-(5-(1H)tétrazolylo)}$, R^{14} étant, individuellement à chaque occurrence, H, méthyle ou éthyle;

R^2 représente H ou un groupement alkyle possédant 1 à 4 atomes de carbone ou $\text{R}^{21}\text{OOC-alkyl-}$, le groupement alkyle possédant 1 à 4 atomes de carbone et pouvant être substitué en la position qui est en alpha du groupement carbonyle, et le substituant en alpha étant un groupement $\text{R}^{22}\text{-(CH}_2)_p-$, dans lequel $p = 0-2$ et R^{22} est méthyle, phényle, OH, COOR^{21} , et R^{21} est H ou un groupement alkyle possédant 1 à 4 atomes de carbone;

m est 0, 1 ou 2, R^3 représente un groupement cyclohexyle et R^4 représente H, ou

m est 1 et R^3 représente un groupement cyclohexyle ou phényle et R^4 forme un pont éthylène ensemble avec R^1 , ou

m est 1 et R^3 et R^4 représentent chacun un groupement cyclohexyle ou phényle;

R^5 représente H ou un groupement alkyle possédant 1 à 4 atomes de carbone;

n est un nombre entier de 2 à 6; et

B représente $-\text{N(R}^6)\text{-C(NH)-NH}_2$, dans lequel R^6 est H ou un groupement méthyle, ou

B représente $-\text{S-C(NH)-NH}_2$, ou $-\text{C(NH)-NH}_2$.

le composé étant soit tel quel soit sous la forme d'un sel physiologiquement acceptable et comprenant des stéréoisomères.

2. Composé suivant la revendication 1, dans lequel R^1 représente $\text{R}^{11}\text{OOC-alkyl-}$, le groupement alkyle possédant 1 à 4 atomes de carbone et R^{11} étant H.

3. Composé suivant la revendication 2, dans lequel A est un éthylène et R^5 est H ou un groupement alkyle possédant 1 à 4 atomes de carbone.

4. Composé suivant la revendication 2, dans lequel A est un n-propylène et le cycle à 6 membres obtenu peut ou peut ne pas porter en position 4 un groupement alkyle avec 1 à 4 atomes de carbone, et R^5 est H ou un groupement alkyle possédant 1 à 4 atomes de carbone.

5. Composé suivant une ou plusieurs des revendications précédentes, dans lequel R^3 est un cyclohexyle, m est 1, 2 et R^4 est H.

6. Composé suivant une ou plusieurs des revendications précédentes, dans lequel n est 3.

7. Composé suivant une ou plusieurs des revendications précédentes, ayant une configuration S sur l'acide -aminé en position P2.

8. Composé suivant la revendication 7, ayant une configuration R sur l'acide -aminé en position P3.

9. Composé sélectionné parmi

H-(R)Cha-Pro-Agm
 Me-(R)Cha-Pro-Agm
 HO-(CH₂)₃-(R)Cha-Pro-Agm
ⁱPrOOC-CH₂-(R)Cha-Pro-Agm
 5 HOOC-(R,S)CH(Me)-(R)Cha-Pro-Agm
 HOOC-(RorS)CH(Me)-(R)Cha-Pro-Agm/a
 HOOC-(RorS)CH(ⁿPr)-(R)Cha-Pro-Agm/a
 HOOC-(RorS)CH(ⁿPr)-(R)Cha-Pro-Agm/b
 HOOC-(RorS)CH(Ph)-(R)Cha-Pro-Agm/b
 10 HOOC-(R,S)CH(CH₂CH₂Ph)-(R)Cha-Pro-Agm
 HOOC-(RorS)CH(CH₂CH₂Ph)-(R)Cha-Pro-Agm/a
 HOOC-CH₂-CH₂-(R)Cha-Pro-Agm
 EtOOC-CO-(R)Cha-Pro-Agm
 (R,S)Bla-(R)Cha-Pro-Agm
 15 HOOC-(RorS)CH(CH₂CH₂Ph)-(R)Cha-Pro-Agm/b
 H-(R)Cha-Pro-Nag
ⁿBu-(R)Cha-Pro-Nag
 HO-(CH₂)₃-(R)Cha-Pro-Nag
 EtOOC-CH₂-(R)Cha-Pro-Nag
 20 ⁱPrOOC-CH₂-(R)Cha-Pro-Nag
^tBuOOC-CH₂-(R)Cha-Pro-Nag
 HOOC-CH₂-OOC-CH₂-(R)Cha-Pro-Nag
 H₂N-CO-CH₂-(R)Cha-Pro-Nag
 HOOC-CH₂-NH-CO-CH₂-(R)Cha-Pro-Nag
 25 (HOOC-CH₂)₂-(R)Cha-Pro-Nag
 HOOC-CH₂-(nBu)-(R)Cha-Pro-Nag
 HOOC-(R,S)CH(Me)-(R)Cha-Pro-Nag
 HOOC-(RorS)CH(Me)-(R)Cha-Pro-Nag/a
 EtOOC-(R,S)CH(Me)-(R)Cha-Pro-Nag
 30 HOOC-(RorS)CH(ⁿPr)-(R)Cha-Pro-Nag/a
 HOOC-(R)CH(CH₂-OH)-(R)Cha-Pro-Nag
 HOOC-(R,S)CH(Ph)-(R)Cha-Pro-Nag
 HOOC-(S)CH(CH₂CH₂Ph)-(R)Cha-Pro-Nag
 HOOC-(R)CH(CH₂CH₂Ph)-(R)Cha-Pro-Nag
 35 HOOC-CH₂-CH₂-(R)Cha-Pro-Nag
 EtOOC-CH₂-CH₂-(R)Cha-Pro-Nag
 HOOC-(CH₂)₃-(R)Cha-Pro-Nag
 EtOOC-(CH₂)₃-(R)Cha-Pro-Nag
 HOOC-CO-(R)Cha-Pro-Nag
 40 MeOOC-CO-(R)Cha-Pro-Nag
 (R,S)Bla-(R)Cha-Pro-Nag
 HOOC-(R,S)CH(CH₂COOH)-(R)Cha-Pro-Nag
 MeOOC-(R,S)CH(CH₂COOMe)-(R)Cha-Pro-Nag
 HOOC-Ph-4-CH₂-(R)Cha-Pro-Nag
 45 (HO)₂P(O)-CH₂-(R)Cha-Pro-Nag
 EtO(HO)P(O)-CH₂-(R)Cha-Pro-Nag
 (EtO)₂P(O)-CH₂-(R)Cha-Pro-Nag
 HOOC-CH₂-(R)Cha-Pro-Mag
 H-(R,S)Pro(3-Ph)-Pro-Agm
 50 H-(R,S)Pro(3-(trans)Ch)-Pro-Agm
 HOOC-CH₂-(R,S)Pro(3-(trans)Ph)-Pro-Agm
 HOOC-CH₂-(R,S)Pro(3-(trans)Ph)-Pro-Nag
 HOOC-CH₂-(Me)(R)Cha-(R,S)Pic-Agm
 HOOC-(R,S)CH(Me)-(R)Cha-Pic-Agm
 55 HOOC-(RorS)CH(Me)-(R)Cha-Pic-Agm/a
 HOOC-CH₂-CH₂-(R)Cha-Pic-Agm
 H-(R)Cha-Pic-Nag
 Me-(R)Cha-(R,S)Pic-Nag

MeOOC-CH₂-(R)Cha-Pic-Nag
¹PrOOC-CH₂-(R)Cha-Pic-Nag
 HOOC-CH₂-(Me)(R)Cha-(RorS)Pic-Nag/b
 HOOC-(R,S)CH(Me)-(R)Cha-(R,S)Pic-Nag
 5 HOOC-(RorS)CH(Me)-(R)Cha-(RorS)Pic-Nag/c
 HOOC-CH₂-CH₂-(R)Cha-Pic-Nag
 HOOC-CH₂-(R)Cha-(R,S)Mor-Agm
 HOOC-CH₂-(R)Cha-(RouS)Mor-Nag
 H-(R)Cha-Aze-Nag
 10 HOOC-CH₂-(R)Cha-Aze-Nag
 H-(R)Cha-Pro(5-(S)Me)-Nag
 HOOC-CH₂-(R)Cha-(RouS)Pic(4,5-déshydro)-Nag/b
 HOOC-CH₂-(R)Cha-(R)Pic(4-(R)Me)-Nag
 HOOC-CH₂-(R)Cgl-Pic-Nag
 15 H-(R)Hoc-Pro-Nag
 HOOC-CH₂-(R)Hoc-Pro-Nag
 HOOC-CH₂-(R)Hoc-Pic-Nag
 HOOC-CH₂-(R)Dph-Pic-Nag
 HOOC-CH₂-(R)Dch-Pic-Nag
 20 HOOC-CH₂-(R)Cha-Pro(5-(R,S)Me)-Nag
 HOOC-CH₂-(R)Cha-Pic(4-(R)Me)-Nag
 H-(R)Cha-Pic(4-(R)Me)-Nag
 HOOC-CH₂-(R)Cha-Pic(6-(S)Me)-Nag

25 soit tel quel soit sous la forme d'un sel physiologiquement acceptable et comprenant des stéréoisomères.

10. Composé sélectionné parmi

HOOC-CH₂-(R)Cha-Pro-Agm
 30 HOOC-CH₂-(Me)(R)Cha-Pro-Agm
 HOOC-(RouS)CH(Me)-(R)Cha-Pro-Agm/b
 HOOC-CH₂-(R)Cha-Pro-Nag
 HOOC-CH₂-(R)Cha-Pic-Agm
 HOOC-(RorS)CH(Me)-(R)Cha-Pic-Agm/b
 35 HOOC-(RorS)CH(Me)-(R)Cha-(RouS)Pic-Nag/d
 HOOC-CH₂-(R)Cha-Pro(5-(S)Me)-Nag
 HOOC-CH₂-(R)Cha-Pic(4-(S)Me)-Nag

40 soit tel quel soit sous la forme d'un sel physiologiquement acceptable et comprenant des stéréoisomères.

11. Composé

HOOC-CH₂-(Me)(R)Cha-Pro-Nag,

45 soit tel quel soit sous la forme d'un sel physiologiquement acceptable et comprenant des stéréoisomères.

12. Composé

HOOC-(RouS)CH(Me)-(R)Cha-Pro-Nag/b,


50 soit tel quel soit sous la forme d'un sel physiologiquement acceptable et comprenant des stéréoisomères.

13. Composé

55 HOOC-CH₂-(R)Cha-Pic-Nag,

soit tel quel soit sous la forme d'un sel physiologiquement acceptable et comprenant des stéréoisomères.

14. Procédé de préparation d'un composé suivant l'une quelconque des revendications 1-13, ledit procédé comprenant le couplage d'un acide aminé ou dipeptide protégé au niveau N terminal ou d'un dipeptide préformé alkylé protégé au niveau N terminal, avec un composé




dans lequel n est un nombre entier de 2 à 6 et X est un groupement guanidino non protégé ou protégé ou un groupement amino protégé, ou un groupement transférable en un groupement amino, le groupement amino étant ensuite transféré en un groupement guanidino,

et, si on le souhaite, la formation d'un sel physiologiquement acceptable et, au cas où la réaction donne un mélange de stéréoisomères, ceux-ci sont facultativement séparés par des techniques chromatographiques ou de recristallisation standard et, si on le souhaite, on isole un stéréoisomère unique.

15. Procédé suivant la revendication 14 pour la préparation d'un composé suivant l'une quelconque des revendications 1-13, ledit procédé comprenant :


a) (Procédé I) le couplage d'un dipeptide protégé au niveau N terminal, avec soit une guanidine à amino protégé ou non protégé, soit une alkylamine à chaîne linéaire portant un groupement amino protégé ou masqué à l'extrémité de la chaîne alkyle, en utilisant un couplage de peptides standard, comme le montre la formule :



dans laquelle R^3 , R^4 , R^5 , n, m et A sont comme défini dans la formule I, R^6 est H ou un alkyle, W_1 est un groupement protecteur d'amino tel qu'un butoxycarbonyle tertiaire et un benzyloxycarbonyle et X est $-\text{NH}-\text{C}(\text{NH})\text{NH}_2$, $-\text{NH}-\text{C}(\text{NH})\text{NH}-\text{W}_2$, $-\text{N}(\text{W}_2)-\text{C}(\text{NH})\text{NH}-\text{W}_2$, $-\text{NH}-\text{C}(\text{NW}_2)-\text{NH}-\text{W}_2$ ou $-\text{NH}-\text{W}_2$, W_2 étant un groupement protecteur d'amine tel qu'un butoxycarbonyle tertiaire ou un benzyloxycarbonyle, ou X est un groupement amino masqué tel qu'un azide, ce qui donne le peptide protégé, ou


b) (Procédé II) le couplage d'un acide aminé protégé au niveau N terminal, avec soit une aminoguanidine protégée ou non protégée, soit une alkylamine à chaîne linéaire portant un groupement amino protégé ou masqué

à l'extrémité de la chaîne alkyle, en utilisant un couplage de peptides standard, comme le montre la formule



dans laquelle W_1 , A , R^5 et X sont comme défini ci-dessus, suivi de la déprotection du groupement W_1 et du couplage avec l'acide aminé N terminal, sous une forme protégée, ou

c) (Procédé III) le couplage d'un dipeptide préformé alkylé au niveau N terminal et protégé, préparé par un couplage de peptides standard avec soit une aminoguanidine protégée ou non protégée, soit une alkylamine à chaîne linéaire portant un groupement amino protégé ou masqué à l'extrémité de la chaîne alkyle, en utilisant un couplage de peptides standard, comme le montre la formule




dans laquelle R^2 , R^3 , R^4 , R^5 , n , m , A et X sont comme défini ci-dessus, étant entendu que R^2 est différent de H et W_3 est un groupement protecteur d'acyle tel qu'un trifluoroacyle,

après quoi les composés finaux sont fabriqués suivant l'une quelconque des voies suivantes, suivant la nature du groupement X - utilise : élimination du ou des groupements protecteurs (lorsque $X = -NH-C(NH)NH_2$, $-NH-C(NH)NH-W_2$, $-N(W_2)-C(NH)NH-W_2$, $-NH-C(NW_2)-NH-W_2$) ou une déprotection sélective du groupement W_1 - (par exemple lorsque $X = -NH-C(NH)NH-W_2$, $-N(W_2)-C(NH)NH-W_2$, $-NH-C(NW_2)-NH-W_2$, W_2 doit dans ce cas être orthogonal par rapport à W_1) suivie d'une alkylation de l'azote N-terminal et d'une déprotection ou d'une déprotection/démasquage sélective de la fonction alkylamino terminale ($X = NH-W_2$, W_2 doit dans ce cas être orthogonal par rapport à W_1 et W_3 , respectivement, ou $X =$ un groupement amino masqué, comme un azide) suivie d'une réaction de guanidation de l'amine libre, en utilisant des procédés standard, et déprotection du groupement W_1 - ou W_3 -, respectivement,

et si on le souhaite, la formation d'un sel physiologiquement acceptable et, au cas où la réaction donne un mélange de stéréoisomères, ceux-ci sont facultativement séparés par des techniques chromatographiques ou de recristallisation standard et, si on le souhaite, on isole un stéréoisomère unique.

16. Utilisation d'un composé de la formule :



soit tel quel soit sous la forme d'un sel, et soit tel quel soit possédant le groupement guanidino, soit mono-protégé au niveau de l'azote soit diprotégé au niveau des azotes ou des azotes , , en tant que matériau de départ dans la synthèse d'un inhibiteur de la sérine protéase, et en particulier dans la synthèse d'un inhibiteur de la thrombine.

17. Utilisation suivant la revendication 16, dans laquelle l'inhibiteur de la sérine protéase est un composé peptidique.
18. Composé suivant l'une quelconque des revendications 1-13, destiné à être utilisé dans un traitement.
19. Composé suivant la revendication 18, destiné à être utilisé en tant qu'agent anticoagulant ou antithrombotique.
20. Préparation pharmaceutique comprenant une quantité efficace d'un composé comme décrit aux revendications 1-13 combinée avec un ou plusieurs supports pharmaceutiques.
21. Préparation pharmaceutique suivant la revendication 20, destinée à être utilisée en tant qu'agent anticoagulant ou antithrombotique.
22. Utilisation d'un composé suivant l'une quelconque des revendications 1-13 en tant qu'ingrédient actif pour la fabrication d'une préparation pharmaceutique pour l'inhibition de la thrombine chez l'homme ou chez l'animal.
23. Utilisation suivant la revendication 16, dans laquelle le composé est la -N-benzyloxycarbonyl-noragmatine, soit telle quelle, soit sous la forme d'un sel, soit possédant une protection au niveau de l'azote ou de l'azote .
24. Utilisation suivant la revendication 23, dans laquelle le composé est la -N-tert-butyloxycarbonyl--N-benzyloxycarbonyl-noragmatine, soit telle quelle, soit sous la forme d'un sel, soit possédant une protection au niveau de l'azote ou de l'azote .
25. Composé -N-benzyloxycarbonyl-noragmatine, soit tel quel, soit sous la forme d'un sel, soit possédant en outre une protection au niveau de l'azote ou de l'azote .
26. Composé suivant la revendication 25, qui est la -N-benzyloxycarbonyl-noragmatine.
27. Composé -N-tert-butyloxycarbonyl- -N-benzyloxycarbonyl-noragmatine, soit tel quel, soit sous la forme d'un sel, soit possédant une protection au niveau de l'azote ou de l'azote .
28. Composé suivant la revendication 27, qui est la -N-tert-butyloxycarbonyl- -N-benzyloxycarbonyl-noragmatine.